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ABSTRACT 
Background  
Overexpression of multidrug efflux transporters at the blood–brain barrier, such 
as P-glycoprotein (Pgp), might contribute to pharmacoresistance by reducing 
target-site concentrations of antiepileptic drugs (AEDs). We assessed Pgp 
activity in vivo in patients with mesial temporal lobe epilepsy (mTLE). 
Methods  
Fourteen pharmacoresistant mTLE patients with unilateral hippocampal 
sclerosis (HS), three patients with pharmacoresistant epilepsy due to focal 
cortical dysplasia (FCD), eight seizure-free mTLE patients and 13 healthy 
controls underwent baseline PET scans with the Pgp substrate (R)-
[¹¹C]verapami (VPM). Pharmacoresistant mTLE patients and healthy controls 
underwent a second VPM PET scan following infusion of the Pgp-inhibitor 
tariquidar (TQD).  The transfer rate constant from plasma to brain, K1, was 
estimated using a single-tissue compartment model with a VPM-in-plasma 
arterial input function. Analysis was performed on the first 10min of dynamic 
data containing limited radiolabeled metabolites. Regions were defined 
automatically using a brain atlas (ROI analysis), and ratios of VPM-K1 values 
were calculated between a reference region (parietal cortex) and target regions. 
Parametric maps of VPM-K1 were also generated using generalised linear least 
squares and was used for SPM voxel-based analysis. For the voxel-based 
analysis at baseline we created VPM PET images corrected for differences in 
whole brain radiotracer uptake. Furthermore, we compared VPM PET scans 
with epileptic tissues removed during epilepsy surgery and measured peripheral 
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markers of Pgp function: PBMC ABCB1 mRNA, ABCB1 polymorphism and 
S100B.  
Findings  
The ROI analysis revealed differences in VPM metabolism between mTLE 
patients and healthy controls which is caused by AED-mediated hepatic 
cytochrome P450 enzyme induction in mTLE patients requiring images to be 
normalised for global brain differences. When using ROI analysis and 
normalised VPM ratios there was no difference in VPM-K1 ratios in 
pharmacoresistant compared to seizure-free mTLE patients or healthy controls. 
The ROI analysis after partial Pgp-inhibition with TQD showed attenuated global 
increases of VPM brain uptake in pharmacoresistant mTLE patients compared 
to healthy controls but there where no regional differences.  
The voxel-based analysis at baseline revealed that pharmacoresistant mTLE 
patients had reduced VPM uptake compared to seizure-free mTLE patients and 
healthy controls in ipsi- and contralateral temporal lobes. Higher Pgp activity 
was associated with higher seizure frequency. After Pgp-inhibition with TQD 
pharmacoresistant mTLE patients had reduced increases of VPM brain uptake 
in the whole brain and ipsilateral hippocampus, implicating Pgp overactivity in 
the epileptogenic hippocampus. The difference in percentage change in VPM 
brain uptake after Pgp-inhibition with TQD inversely correlated with the 
difference in percentage area of Pgp immunopositive labeling in 
pharmacoresistant mTLE patients who underwent epilepsy surgery. 
Pharmacoresistant epilepsy patients with FCD had reduced VPM brain uptake  
in close proximity to the area of FCD but also extending to other ipsilateral 
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regions. There were no differences in peripheral markers of Pgp function 
between the three groups. Our results support the hypothesis of Pgp overactivity 
in pharmacoresistant epilepsy.  
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OUTLINE OF THESIS AND STATEMENT OF PERSONAL 
CONTRIBUTION 
 
This thesis is structured as follows: 
 
SECTION 1: BACKGROUND 
Chapters I-III summarise the background that is important to understand the 
following work and outlines the objective of this thesis. 
 
Chapter I: presents the current understanding of the mechanism of seizure 
generation, classification scheme of seizures and epilepsy, investigation tools 
applied to diagnose seizures and possible treatment options. 
 
Chapter II: summarises the background of pharmacoresistance in epilepsy and 
discusses the different hypotheses of pharmacoresistant epilepsy. It focuses on 
the transporter hypothesis and presents the mechanisms of P-glycoprotein 
(Pgp) overexpression. It outlines preclinical and clinical studies investigating Pgp 
in mesial temporal lobe epilepsy (mTLE) and describes imaging studies 
examining Pgp function. 
 
Chapter III: outlines the objectives and hypothesis of this thesis. 
 
 
SECTION II: EXPERIMENTAL STUDIES 
Chapter IV: describes the common methods used in the most experimental 
studies used in the thesis. 
 
 
Chapters V-XI describe the experimental studies. 
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Chapters V and VI show the results of the region of interest analysis (ROI) of 
(R)-[11C]verapamil (VPM)  PET at baseline and after partial Pgp inhibition 
 
Chapter V: I present my work investigating Pgp function using VPM-PET in 
patients with mTLE. Using ROI analysis I show that there are differences in VPM 
metabolism between mTLE patients and healthy controls which is caused by 
AED-mediated hepatic cytochrome P450 enzyme induction in mTLE patients 
requiring images to be normalised for global brain differences. Additionally I 
show an association between Pgp activity and seizure frequency in mTLE 
patients. When using ROI analysis and normalised VPM images there was no 
difference in VPM-K1 ratios in pharmacoresistant compared to seizure-free 
mTLE patients or healthy controls.  
 
Chapter VI: by using ROI analysis I show attenuated global increases of VPM 
brain uptake after partial Pgp-inhibition by TQD in pharmacoresistant mTLE 
patients compared to healthy controls but there where no regional differences.  
 
Chapters VII and VIII show the results of the voxel-based analysis of the same 
data. We hypothesise that the voxel-based analysis of the same data would 
complement the ROI findings. 
 
Chapter VII: by using voxel-based SPM analysis normalised for global brain 
differences I show that at baseline there is lower focal VPM uptake indicating 
higher Pgp activity in pharmacoresistant compared to seizure-free mTLE 
patients and healthy controls. Furthermore, Pgp overactivity in the ipsilateral 
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hippocampus of pharmacoresistant mTLE patients correlates with seizure 
frequency.   
Chapter VIII: I present the voxel-based SPM analysis after partial Pgp-inhibition 
by TQD showing attenuated increases of VPM uptake with a maximum effect in 
epileptogenic hippocampus. 
 
Chapter IX: I show a correlation of Pgp overexpression revealed in postsurgical 
tissue with the Pgp overactivity demonstrated with voxel-based analysis after 
partial Pgp-inhibition by TQD in pharmacoresistant mTLE patients. Here I would 
like to thank Drs Joan Liu and Maria Thom from the Institute of Neurology, 
University College London, who did the immunohistochemisty study on the 
postsurgical tissue. 
 
Chapter X: I present that there is no differences in peripheral markers of Pgp 
function measured with PBMC ABCB1 mRNA, ABCB1 polymorphism and 
S100B between the three groups. Professor Joan Abbott and colleagues at 
Kings College kindly performed the S100 protein analysis. Drs Joan Liu and 
Maria Thom from the Institute of Neurology, University College London, did the 
genetic analysis and Dr Dickens and Professor Pirmohamed from the University 
of Liverpool helped with the PBMC analysis. 
 
Chapter XI: I extended our study including patients with focal cortical dysplasia 
(FCD) complementing the previous results of mTLE patients showing 
pharmacoresistant epilepsy patients with FCD had reduced VPM brain uptake in 
close proximity to the area of FCD but also extending to other ipsilateral regions.  
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SECTION III DISCUSSION AND CONCLUSION 
Chapter XII in this section, I discuss the limitations, neurobiological and clinical 
applications as well as future research directions in the context of the principal 
experimental findings. 
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CHAPTER I  BACKGROUND 
1.1 EPILEPSY 
1.1.1 Introduction 
Epilepsy is a common neurological disorder with an estimated prevalence in 
Europe of 4.3-7.8 per 1000 (Pugliatti M et al. 2007). Despite advances in 
antiepileptic drug (AED) therapy about one-third of patients with epilepsy are 
resistant to drug treatment (Regesta and Tanganelli 1999). Uncontrolled 
epilepsy can shorten lifespan, lead to bodily injury, neuropsychological and 
psychiatric impairment, and social disability (Kwan and Brodie, 2005). Patients 
who are pharmacoresistant often present with certain features of the epileptic 
condition, such as history of febrile seizures (FS), high frequency of seizures 
prior to treatment, early onset of seizures, structural brain lesions or psychiatric 
comorbidities (Regesta and Tanganelli, 1999). Most patients with refractory 
epilepsy are resistant to several, if not all, AEDs, even though these drugs act 
by diverse mechanisms (Kwan and Brodie, 2005).  
Functional imaging, in particular positron emission tomography (PET) offers new 
hope for the development of better treatments by increasing our understanding 
of mechanisms underlying drug- resistance. 
1.1.2 Definition 
Clinically, epilepsy is characterised by recurrent spontaneous seizures. An 
epileptic seizure is an acute and transient event, which is manifested as a brief 
change in behaviour caused by the disorder, synchronous and rhythmic firing of 
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populations of neurons in the central nervous system (McNamara 1999). A wide 
diversity of epilepsy syndromes have been described based upon several 
characteristics, such as symptoms, seizure types and electroencephalographic 
patterns. 
1.1.3 Classification of seizures 
Classifications are required for the purpose of dividing heterogeneous disease 
patterns into homogeneous classes to understand the biology of the disease. 
They can highlight the causes, pathophysiology and management of the disease 
and it allows communication between physicians, teaching and scientific 
research, epidemiology and pharmacology of the disease (Engel 1998). The 
international league against epilepsy (ILAE) creates and updates the 
classification of epilepsies. The ILAE classification of seizures was first 
published in 1969 (Gastaut 1969; Gastaut 1970) and updated in 1981 for 
seizures (ILAE 1981) and 1989 for epilepsies (ILAE 1989).  Classically two 
seizure types have been recognised: those arising from focal cortical 
disturbances and those characterised by synchronous discharge of both 
hemispheres. These correspond to partial and generalised seizures and can be 
differentiated both clinically and by their electroencephalographic (EEG) 
findings. This division formed the basis of the revised International classification 
of Epileptic Seizures introduced by the ILAE in 1981. In this classification system 
partial seizures are also divided further into “simple” and “complex”, depending 
on whether consciousness is retained or lost. However, the previous ILAE 
classifications were based on concepts that predate modern neuroimaging, 
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genomic technologies and concepts of molecular biology. On this background 
the ILAE released in 2010 (Berg et al. 2010) recommendations for the 
classification of seizures and epilepsies in an attempt to change the old 
terminology, in accordance with the technology and scientific advances that 
have occurred in the last several years (Beghi 2011). Changes to the ILAE’s 
1981 classification of seizures include that neonatal seizures are no longer 
classified separately, absence seizures are simplified into typical, atypical or 
absence with special features which now included myoclonic absence and 
eyelid myoclonica as well as epileptic spasms (Table 1). Additionally the 
distinction between simple partial and complex partial focal seizures was 
eliminated but the concept of impairment of consciousness/awareness is still 
preserved. 
Table 1: International classification of seizures (ILAE 2010) 
Generalised seizures 
Tonic-clonic 
Absence 
Typical 
Atypical 
Absence with special features 
Mycoclonic absences 
Eyelid myoclonia 
Mycloclonic 
Mycloclonic 
Mycloclonic atonic 
Mycloclonic tonic 
Clonic 
Tonic 
Atonic 
Focal seizures 
Unknown 
Epileptic spasms 
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1.1.4 Aetiology 
In the revision of the 1989 ILAE classification, both focal and generalised 
epilepsy and syndromes were divided according to the aetiology into “idiopathic” 
(epilepsies not associated with a structural lesion, neurologic abnormalities or 
cognitive impairment), “symptomatic” (seizures as a consequence of a focal 
abnormality) and “cryptogenic” (symptomatic aetiology suspected but aetiology 
not known). Epilepsy may be caused by brain trauma, infections of the central 
nervous system (CNS), cerebrovascular disease or brain tumours. Other 
neuropathological lesions associated with chronic epilepsy include hippocampal 
sclerosis (HS) and malformations of the brain and will be discussed in the next 
chapter. The aetiology also varies according to age. Children and adolescents 
are more likely to have epilepsy of unknown or genetic origin. Onset of epilepsy 
during adult life is more commonly associated with an underlying neurological 
disorder.  
The new 2010 ILAE classification takes recent understanding and knowledge in 
genomics, neuroimaging and neurophysiology into account. Therefore the new 
classification replaced the term “idiopathic” with the term “genetic”. The epilepsy 
must be a direct result of a known or presumed genetic defect and the seizures 
are a core symptom of the disorder. An example would be Dravet syndrome due 
to a mutation in the sodium channel, voltage gated, type 1, alpha subunit 
(SCN1A). The term “symptomatic” is replaced by the term “structural/metabolic”. 
To be classified in this category the epilepsy has to be associated with a 
structural lesion or metabolic disease that has been shown in previous studies to 
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substantially increase the risk of developing epilepsy. Examples of structural 
lesions include stroke, trauma, infection, tuberous sclerosis and malformations 
of cortical development. The term “cryptogenic” is replaced by the term 
“unknown cause” (Berg et al. 2010).  
A well known issue in epilepsy is the occurrence of pharmacoresistance. The 
importance of this issue is illustrated by the fact that about 20-30% of all people 
with epilepsy have poorly controlled seizures, or their seizures are refractory to 
drug treatment (Regesta and Tanganelli, 1999). Not all forms of epilepsy have 
the same rate of pharmacoresistance. Because of the high risk of therapy 
resistance, together with its relatively high prevalence, most studies on 
pharmacoresistance in epilepsy have involved mesial temporal lobe epilepsy. 
1.2 MESIAL TEMPORAL LOBE EPILEPSY 
1.2.1 Introduction 
Temporal lobe epilepsy (TLE) is the most common focal epilepsy. 60-70% of 
focal epilepsies are believed to originate from the temporal lobe. The seizures 
associated with temporal lobe epilepsy consist of focal seizures with and without 
loss of awareness. The most common cause of TLE in surgical series is 
hippocampal sclerosis (HS), which can be reliably detected in vivo by magnetic 
resonance imaging (MRI) (Lee et al. 1998). Structural damage in TLE 
associated with HS is a condition that characterises mesial temporal lobe 
epilepsy (mTLE). Such damage and dysfunction frequently extends beyond the 
hippocampus into the parahippocampal and entorhinal cortex (Bonilha et al. 
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2004). As reviewed by Engel , patients often have a history of complicated FS or 
other initial precipitating injuries, such as head trauma or intracerebral infections, 
within the first four or five years of their life (Engel 1996). There is also an 
increased prevalence of a family history of epilepsy. In the latter half of the first 
decade of life habitual seizures start to occur, which in most cases initially can 
be brought under control by pharmacotherapy. Subsequently, the seizures often 
remit for several years until adolescence or early childhood. After this latent 
period habitual complex partial seizures develop, which are mostly insensitive to 
medication. At this stage, about 60% of the patients become pharmacoresistant.   
1.2.2 Hippocampal structures and connections 
The hippocampal formation is located in the medial part of the temporal lobe, 
lying on the floor of the temporal horn of the lateral ventricle. The hippocampus 
is one of a group of structures forming the limbic system and is a part of the 
hippocampal formation. This also includes the dentate gyrus, subiculum, and 
entorhinal cortex.  The limbic system has been shown to play a critical role in all 
aspects of emotions, fear, learning and memory (Geinisman 2000; Geinisman, 
Disterhoft et al. 2000; Cardinal, Parkinson et al. 2002). The hippocampus is a 
crescent-shaped structure and its resemblance to a seahorse prompted the use 
of its Greek-derived name. The hippocampus is divided into four Cornu 
Ammonis (CA) zones, labelled CA1 – CA4. Areas CA1 and CA3 are the largest 
and most easily identified (Figure 1).  The principal neurons in the CA are 
pyramidal neurons (90%). The CA1 pyramidal neurons are the main output 
neurons of the hippocampus and their axons are glutamatergic (Sweatt 2009). 
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The axons of the CA1 neurons project predominantly to the ipsilateral and 
contralateral entorhinal cortices and to the contralateral hippocampus via the 
fornix. Secondary efferents of the CA1 pyramidal neurons via the subicular 
neurons also project to subcortical regions, including the ventral striatum and 
mamillary bodies. The major input to the hippocampus arises from the entorhinal 
cortex. This input is termed the perforant path. Axons of the perforant path arise 
principally in layers II and III of the entorhinal cortex, with minor contributions 
from the deeper layers IV and V (Sharma et al. 2007). Axons from layers II/IV 
project to the granule cells of the dentate gyrus and pyramidal cells of the CA3 
region, while those from layers III/V project to the pyramidal cells of the CA1 and 
the subiculum. 
 
Figure 1: Structure of the hippocampus 
The figure is from Mark et al. (Mark et al. 1993). 
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1.2.3 Hippocampal sclerosis 
1.2.3.1 Neuropathology 
Hippocampal sclerosis (HS) is the most common pathological finding in mesial 
temporal lobe epilepsy and found in approximately 70% of temporal lobe 
resections for pharmacoresistant partial seizures (Zentner et al. 1995). The 
presence of sclerosis is a good indicator for a positive outcome to surgery. 
Despite the strong association between HS and temporal lobe epilepsy, it 
remains unclear whether or not the relationship is causal-or if both conditions 
might reflect an underlying developmental abnormality of the hippocampus 
(Thom 2014). Macroscopically the hippocampus is firm and shrunken, 
sometimes with visible collapse of the CA1 subfield (Sommer’s sector (Sommer 
1880)). Microscopic findings include a characteristic pattern of neuronal loss and 
reactive gliosis. Under the general category of HS, several patterns have been 
recognised: 1) classical HS with neuronal loss in CA1 and the hilar region, 2) 
End-folium sclerosis or mesial temporal sclerosis type 3 (MTS type 3) with 
neuronal loss primarily in the hilar region, and 3) loss restricted to CA1 only 
(MTS type 2) (Thom et al 2011). Non-classical or atypical patterns of HS have 
been associated with poorer surgical outcomes than classical HS. Seizure free 
outcomes for MTS type 3 at one year are 25% to 28% compared to 66% to 77% 
for MTS type 2 and 72% to 84% for classical HS (Thom et al. 2010). In addition 
to neuronal loss and gliosis, there is also an associated mossy fibre sprouting, 
by which new axons arise from granular cells and extend upwards into the 
molecular layer of the dentate gyrus. It is thought that they may contribute to 
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epileptogenesis by forming potentially self-excitatory connection within the 
dentate gyrus. Additionally granular cell dispersion can be found with an 
increased width of the granular cell layer which is more than ten cells deep. 
However, these also occur on the opposite side and therefore may be a 
response to generalised seizure activity rather than signifying damage (Thom 
2014). 
1.2.3.2 Aetiology and pathogenesis 
Animal models of limbic status epilepticus demonstrate hat HS can be acquired-
and the pathological features in many cases are similar to those seen in humans 
(Coulter et al. 2002). MRI and post-mortem studies confirm that acute 
hippocampal damage may follow status epilepticus (Provenzale et al. 2008). A 
leading hypothesis suggests that an initial precipitating insult in childhood such 
as febrile convulsion may injure the hippocampus and that this “first hit” at a 
critical period of development may act as a template for progressive neuronal 
loss and gliosis (Thom 2009). The degree of vulnerability of hippocampal cells is 
most probably age dependant and is particularly prone to occur in the first years 
of life. Hippocampus sclerosis may then be seen as part of a scarring process 
which sooner or later leads to epileptic attacks. FS are the most common 
seizure disorders in childhood, occurring in 2-5% of children before the age of 
five years. The incidence of subsequent epilepsy is 2-8% (Baram et al. 2002). 
MRI studies in children with prolonged (>30 minutes) FS performed both in the 
acute stages (<48 hours after seizures) and chronic stages (4-8 months later) 
showed enlarged hippocampal volume and prolonged T2 relaxation time, 
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suggesting acute hippocampal oedema that resolves within several months of 
acute events (Scott et al. 2002). When seizures are prolonged maximum 
damage occurs at the seizure source. Although fever is the commonest 
provocation it is not the only potential stimulus and in both humans and animal 
models several epileptogenic stimuli cause the sequence of hippocampal 
followed by secondarily generalized seizures (Neville and Gindner 2010). 
1.2.4 Clinical features of mTLE 
Seizures take the form of focal seizures without (simple partial) and with loss of 
awareness (complex partial). Focal seizures (complex partial seizures) where 
patients loose awareness typically have gradual onset, slow evolution and last 
longer than most extra-temporal complex partial seizures (2-10 minutes) (Blair 
2012). The typical complex partial seizure consists of three components 
discussed below. 
1.2.4.1 Aura 
Auras occur in approximately 80% of temporal lobe seizures (Ferrari-Marinho et 
al. 2012). They usually precede seizures with loss of awareness but can also 
occur in isolation.  Speech usually ceases or is severely reduced, but repetitive 
vocalization may occur. If a patient has one seizure focus, the seizure semiology 
tends to be stereotyped. The most common aura is some type of visceral 
sensation such as nausea, butterflies, or a rising epigastric sensation (French et 
al. 1993). This may be accompanied by fear, and fear may exist alone as the 
second most common aura. Fear or anxiety is usually associated with seizures 
arising from the amygdala (Gloor et al. 1982). Other less common auras include 
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olfactory and gustatory hallucinations, alteration of visual perceptions 
(micropsia, macropsia), and distortions of memory (déjá vu, jamais vu).  
Olfactory sensations can signal the start of seizures in the Sylvian region or 
entorhinal cortex and visual illusions may be seen with seizures arising from the 
fusiform or the inferior temporal gyrus. Auditory hallucinations can consist of a 
buzzing sound, voices, or muffling of ambient sounds and occur if discharges 
arise from the superior temporal gyrus. Autonomic symptoms include alterations 
in heart rate, blood pressure, skin colour, pupil size, piloerection, and sweating 
(Panayiotopoulos 2005). 
1.2.4.2 Motor arrest 
Following the aura, a temporal lobe complex partial seizure begins with motor 
rest or absence (also called motionless stare). The patient stops ongoing 
activities and looks blank and stares. This is more common in mesial temporal 
lobe than extra-temporal lobe epilepsy (Shorvon 2010) 
1.2.4.3 Automatisms 
Automatisms are semi-purposeful involuntary motor activity occurring either in 
the course of, or after an epileptic seizure. Oroalimentary automatisms (eg, lip 
smacking, chewing, or swallowing), during which the patient is usually, but not 
always, unresponsive may be noted. Gestural automatisms, as well as reactive 
automatisms that can be ictal or postictal (or both), are commonly seen. A 
number of lateralizing features can occur (Kotagal et al. 1989; Williamson et al. 
1998). When dystonic posturing occurs, it is contralateral to the side of seizure 
onset, whereas unilateral automatisms are ipsilateral (often in combination with 
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contralateral dystonic posturing). Head deviation early in the seizure is usually 
ipsilateral to the seizure focus, but head deviation late in the seizure is 
contralateral and often a prelude to generalization. Patients usually experience a 
postictal period of confusion and headache. Postictal aphasia suggests onset in 
the language-dominant temporal lobe.  Post-ictal nose-rubbing is commonly 
seen in temporal lobe epilepsy and in 90% of cases is ipsilateral to the seizure 
focus. Amnesia is the rule for the blank spells and automatism but auras are 
often remembered. By definition, amnesia occurs during a complex partial 
seizure because of bilateral hemispheric involvement. The postictal phase may 
last for a longer period (several minutes). A complex partial seizure may evolve 
to a secondarily generalized tonic-clonic seizure but this is much less common 
(Panayiotopoulos 2005). 
1.2.5 Electrophysiological features of mTLE 
The human electroencephalogram (EEG) was discovered by the German 
psychiatrist, Hans Berger, in 1929. Its potential applications in epilepsy rapidly 
became clear, when Gibbs and colleagues in Boston demonstrated 3 per 
second spike wave discharged in what was then termed petit mal epilepsy. 
Electrical activity recorded by electrodes placed on the scalp or surface of the 
brain mostly reflects summation of excitatory and inhibitory post synaptic 
potentials in apical dendrites of pyramidal neurons in the more superficial layers 
of the cortex. Quite large areas of cortex, in the order of a few square 
centimetres, have to be activated synchronously to generate enough potential 
for changes to be registered at electrodes placed on the scalp. Mesial temporal 
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lobe epilepsy with unilateral hippocampus sclerosis shows anterior/mid temporal 
interictal spikes which are ipsilateral or predominate over the pathological 
temporal lobe (Smith 2005).  In a third of patients the interictal discharges are 
present bilaterally during sleep. Strongly lateralised interictal discharges are 
predictive of side of seizure onset (Chung et al. 1991; Holmes et al. 1996). No 
definite EEG changes are usually seen with auras. Lateralized rhythmic 5-7 Hz 
ictal discharge accompanies a seizure in 80% of patients with mesial temporal 
lobe epilepsy. It typically occurs 10-40 seconds after clinical seizure onset. If 
present this activity correctly lateralises seizure onset in 95% of patients. Focal 
postictal slow activity is present in about 70% of seizures and if present is 
consistent with the side of seizure onset correctly in about 90% of patients 
(Verma and Radtke 2006). 
1.2.6 Neuroimaging features of mTLE 
1.2.6.1 MRI in mTLE 
Modern neuroimaging and in particular MRI has revolutionised epilepsy surgery. 
The principal role of MRI imaging is to reveal cerebral lesions that might cause 
epilepsy as a clear-cut removal of a focal abnormality improves the chances of 
seizure freedom (Duncan 2010). Indeed, 70% of patients which have such 
lesions removed enter remission (Spencer and Huh 2008). High-resolution MRI 
at 1.5 T with tailored protocols might increase the yield of subtle lesions in 
surgical candidates by 30% relative to routine MRI (Wieshmann 2003).The 
ability of higher field magnets (3T) further increases the rate of detection of 
pathology in 20% of patients with refractory epilepsy and previously 
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unremarkable or inconclusive MRI (Duncan 2010). MRI in mTLE reliably detects 
HS with features such as unilateral hippocampal atrophy, decreased signal 
intensity seen on T1 and increased signal intensity on T2 (Jackson et al. 1990; 
Jackson et al. 1993). Hippocampal atrophy ipsilateral to EEG abnormalities is 
the most reliable predictor of seizure control following surgery with a specificity 
of 93% and a sensitivity of 83% (Lee et al. 1998). The presence of bilateral 
hippocampal disease is associated with poorer surgical outcome (Jack et al. 
1992). Manual hippocampal volumetry can identify unilateral and bilateral 
hippocampal damage (Duncan 2010). These capabilities are important in the 
presurgical work up to identify subtle hippocampal damage and to ensure the 
other hippocampus is intact. Furthermore, automated hippocampal volume 
estimations have been developed (Hammers et al. 2007b; Bonilha et al. 2009; 
Chupin et al. 2009; Winston et al. 2013). Anatomic surface modelling of 
hippocampal atrophy also can identify abnormal hippocampal morphology that is 
not evident on conventional analysis (Hogan et al. 2008). The diffusity of water 
increases in the sclerotic hippocampus. Diffusion abnormalities have been found 
in hippocampi ipsilateral to the seizure onset that are normal on conventional 
MRI, suggesting that diffusion MRI might be more sensitive than standard 
structural MRI (Wehner et al. 2007). 
Other quantitative techniques have shown unilateral high T2 relaxometry to be a 
useful identifier of hippocampal histopathology and to correlate with the severity 
of atrophy (Jackson et al. 1993). Abnormal T2 signal is seen in the contralateral 
hippocampus in 30%-40%. T2 relaxometry is also a sensitive measure of 
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amygdala pathology. Single voxel proton magnetic resonance spectroscopy as 
well as magnetic resonance spectroscopic imaging have demonstrated a 
reduction in temporal lobe N-acetylaspartate to choline plus creatine ratios in up 
to 75% of mTLE patients, correctly lateralizing in 55%. Bilateral abnormalities, 
however, have been reported using magnetic resonance spectroscopic imaging 
techniques in 45% of mTLE patients (Cendes et al. 1997; Li et al. 2000; Thom et 
al. 2010). It is unclear whether spectroscopy aids in the prediction of seizure 
freedom following surgery (Kuzniecky et al. 1999; Li et al. 2000). Functional MRI 
is used for language lateralisation and localisation (Binder et al. 1997; Koepp 
2014). 
1.2.6.2 Functional neuroimaging with PET and SPECT in mTLE 
Positron emission tomography (PET) and single photon emission computed 
tomography (SPECT) are imaging techniques that can study CNS function in 
vivo. Thereby a radionuclide is synthetically introduced into a molecule of 
biological relevance and administered to a patient or animal. PET and SPECT 
cameras monitor the distribution of these radiotracers over time. In PET the 
radioisotope undergoes positron decay and emits a positron, which interacts 
with an electron in situ, producing a pair of annihilation photons moving in 
approximately opposite directions which can be detected outside the body by a 
PET camera (Sawle, 1995). In contrast with PET, the radiotracers used in 
SPECT emit a single photon (gamma ray) that is detected directly using 
collimators. By detecting photons "coincident" in time, PET provides more 
radiation event localization information and, thus, higher resolution images than 
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SPECT. Therefore the great advantage of PET over SPECT is a higher 
sensitivity, better temporal and spatial resolution and ability to provide a 
quantitative measure of radioactivity in tissues. 
1.2.6.2.1 PET in mTLE 
PET scanning was first applied to clinical epilepsy in the mid-1970s, the first 
published report was in 1978 (Kuhl et al. 1978). In 1984 Engel reviewed the 
clinical work accrued to that date. PET has the potential in differentiating clinical 
syndromes and elucidating epileptogenic mechanisms (Engel 1984). Initially 
13N-labeled ammonia and fluorine-18 fluorodeoxy-glucose (18FDG) were used, 
and still today 18FDG remains the most common tracer employed in epilepsy 
(Shorvon 2009). 
1.2.6.2.1.1 Glucose metabolism with 18FDG in mTLE 
.18FDG measures glucose metabolism as an indirect marker of neuronal activity. 
Interictal hypometabolism at the ictal focus has been shown to be useful for the 
localisation of the epileptic zone. 18FDG has a sensivity of 70-85% in patients 
with mTLE (Ryvlin et al. 1998; Won et al. 1999). However, in patients with extra-
TLE the diagnostic sensivity is significantly lower: between 30-60% depending 
on the seizure focus (La Fougère et al. 2009). In particular 18FDG is of value in 
selecting patients for temporal lobeectomy and for identifying epileptogenic 
areas in MRI-negative temporal lobe epilepsy, where PET correctly localises the 
lesion in 80% of cases (Won et al. 1999). In mTLE, focal hypometabolism 
ipsilateral to the lobe to be resected is a predictor of a good surgical outcome 
(Willmann et al. 2007). Among patients with mTLE, those who were seizure free 
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after temporal lobe resection were shown to have a greater proportion of the 
hypometabolic area resected than did individuals who continued with seizures 
(Vinton et al. 2007). This finding raises the possibility of tailoring the extent of 
resection according to the area of hypometabolism (Duncan 2010). Additionally 
18FDG often has a wider distribution than that of the seizure focus. For example 
many patients with mTLE present with an additional pronounced 
hypometabolism of the frontal lobe, which may represent inhibitory phenomena 
induced by the epileptogenic focus (La Fougère et al. 2009). Similarly networks 
of hypometabolism had some correlation with patterns of EEG spread of ictal 
activity. Hypometabolism has been noted in the thalamus or in the insular cortex 
and putamen associated with dystonic limb posturing in the ictus (Lee et al. 
2009). 
1.2.6.2.2 SPECT in mTLE 
SPECT scanning was tried in the early 1980s initially using 123I isopropyl 
amphetamine or 133XE (Shorvon 2009). Soon iodine isotopes were replaced by 
radioactive technetium 99mTC-HMPAO administered by intravenous injection. 
99mTc-HMPAO SPECT is used to image directly the regional increase in 
cerebral blood flow that occurs during an epileptic seizure, and thus to directly 
image the epileptic focus. The injection can be given during the seizure and the 
scan recorded in the subsequent three hours. This is a major advantage, as it 
does not require the patient to have a seizure in the scanner and the ictal image 
can be acquired at some time after the seizure is resolved. SPECT is a 
complementary rather than competing technology to PET. Ictal SPECT is 
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superior to interictal SPECT for the identification of the location or the 
lateralisation of epileptic seizures in mTLE, indicating sensitivities between 73-
97% for ictal and only 50% for interictal SPECT (Devous, Thisted et al. 1998; 
Spanaki, Spencer et al. 1999; Zaknun, Bal et al. 2008). Cortical and subcortical 
changes in regional cerebral blood flow during seizures may begin with 
hyperperfusion in the epileptic zone follow by rapid extension to other regions 
through seizure spread and generalisation. If ictal injection is made within the 
first 30s of temporal lobe seizures onset, it reportedly shows diffuse temporal 
lobe hyperperfusion in 100% of patients but the longer the delay the lower the 
sensitivity (Van Paesschen 2004). A great advance of SPECT to improve the 
ability to detect and define the extent of epileptogenic lesions is the subtraction 
of ictal and interictal SPECT which should preferably be co-registered to MRI 
(O'Brien et al. 1999). 
1.2.7 Epilepsy surgery in mTLE 
Epilepsy is resistant to treatment in one third of patients. The effects of chronic 
uncontrolled epilepsy and multidrug therapy include progressive cognitive and 
behavioural decline as well as increased accident and death rates (Cascino 
1990; Silfvenius 1999). In carefully selected patients, epilepsy surgery can 
control seizures, improve quality of life, and reduce the costs of medical care 
(Kuzniecky and Devinsky 2007). Surgical intervention is an appropriate 
consideration for 3% of people who develop epilepsy (Duncan 2011). Every 
year, for every 50 million people in the developed world 1000 individuals with 
refractory epilepsy are estimated to require evaluation for epilepsy surgery, with 
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50% of such patients proceeding to surgery (Lhatoo et al. 2003). Furthermore 
for each 50 million people a backlog exists of 5000 patients who would benefit 
from surgery (Lhatoo et al. 2003; Cascino 2008 ). Localisation-related seizures 
of temporal lobe origin have been considered to most likely benefit from surgery. 
In a randomised, controlled intention-to-treat trial including 80 patients, the 40 
patients who had temporal lobe epilepsy surgery had a 58% chance of freedom 
form disabling seizures compared with 8% of patients who continued medical 
therapy (p<0.001) (Wiebe et al. 2001). The goal of epilepsy surgery is complete 
removal of the epileptogenic area without causing a permanent neurological 
deficit. Several different diagnostic techniques can be used to determine the ictal 
generator and epileptogenic zone. Structural and functional imaging, 
neurophysiological techniques and psychological testing help to identify the 
seizure focus and will be discussed in the paragraphs below. Even though there 
might be a high chance of seizure freedom, the risks and benefit of epilepsy 
surgery vary for each individual patient.  Epilepsy surgery may be divided into 
two major categories: resective and functional. In adults, the most common 
surgical procedure for mTLE involves the medial temporal lobe—either an 
amygdalohippocampectomy (resection of the amygdala, hippocampal head and 
body, and adjacent parahippocampal gyrus) or an anteromedial temporal 
resection that also includes resection of the anterior, inferior, and middle 
temporal gyri (3-4 cm from the temporal tip) (Al-Otaibi et al. 2012).  
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1.2.7.1 Presurgical evaluation 
A key aim of pre-surgical evaluation is to determine the epileptogenic zone and 
the relationship of this zone to eloquent areas of the brain. No single pre-
operative investigation can determine the epileptogenic zone with complete 
reliability and when various investigation modalities are combined there may be 
variable degree of congruence (Rosenow and Lüders 2001). 
1.2.7.2 Clinical history and seizure pattern 
Neurological history and examination are carried out to identify any underlying 
disorder and to localise dysfunctional areas. Examination can also provide 
localizing features. Patients’ history can also give information that may inform 
the odds of success, including patient age, age of epilepsy onset, epilepsy 
duration, the occurrence of secondary generalised seizures and status 
epilepticus and antecedent history, including the presence of head injuries, 
meningitis or FS. 
1.2.7.3 Electrophysiology 
Interictal and ictal scalp EEG recordings are critical determinants of surgical 
candidacy. Recordings of multiple seizures are required in some patients, 
especially when functional (e.g. interictal EEG) or imaging (e.g. MRI) data 
suggest more than one seizure focus (Kuzniecky and Devinsky 2007). Focal 
interictal abnormalities and concordant ictal EEG and behavioural changes 
during seizures can provide sufficient localisation for surgical intervention. 
However, identification of a structural abnormality consistent with 
electrophysiological data is desirable before surgery. An intracranial EEG 
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recording with seizure monitoring may be useful when the exact localisation of 
the epileptogenic zone is not conclusive enough from non-invasive evaluation 
(Zumsteg and Wieser 2000). The type of intracranial recording depends on the 
suspected pathophysiological substrate of the epilepsy and its location. 
1.2.7.4 Neuroimaging 
Modern neuroimaging and in particular MRI has revolutionised epilepsy surgery. 
The principal role of imaging is to reveal cerebral lesions that might cause 
epilepsy as a clear-cut removal of a focal abnormality improves the chances of 
seizure freedom (Duncan 2010). Indeed, 70% of patients which have such 
lesions removed enter remission (Spencer and Huh 2008). High-resolution MRI 
at 1.5 T with tailored protocols might increase the yield of subtle lesions in 
surgical candidates by 30% relative to routine MRI (Wieshmann 2003). The 
ability of higher field magnets (3T) further increases the rate of detection of 
pathology in 20% of patients with refractory epilepsy and previously 
unremarkable or inconclusive MRI (Duncan 2010). Nuclear medicine studies 
with 18FDG-PET is highly sensitive for mTLE but its yield is low in extra-temporal 
TLE. It is in particular valuable when MRI is normal. Interictal SPECT has lower 
sensivity for localisation than does 18FDG-PET (Rathore et al. 2014). But ictal 
SPECT can provide unique localisation data in patients with normal MRI or 
multiple lesions. Functional MRI is used for language lateralisation and 
localisation (Wehner and Lüders 2008). Magnetoenephalography can localise 
interictal epileptiform discharge and has a high correlation with intracranial ictal 
localisation (Knowlton et al. 1997). 
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1.2.7.5 Neuropsychology testing  
Neuropsychological tests traditionally assess function in five cognitive domains, 
all of which can dissociate in the pathological brain. These are intelligence, 
language, memory, perception and executive or frontal lobe functions. In 
conjunction with MRI and other presurgical investigations, neuropsychological 
scores are used to asses s the suitability of patients for epilepsy surgery and 
can be used to predict post-operative outcome, in terms of cognitive change and 
seizure control (Baxendale and Thompson 2010). Neuropsychological 
assessment has an important role in evaluating candidates for temporal lobe 
surgery since the temporal lobe has long been implicated in memory function. 
Bilateral hippocampal excision is associated with profound anterograde 
amnesia. Unilateral resections are traditionally associated with material-specific 
memory dysfunction. The traditional view is that the dominant temporal lobe 
(usually left) is important for verbal memory processing and the non-dominant 
temporal lobe (usually the right) for non-verbal or visual processing (McAndrews 
and Cohn 2012). Neuropsychological performance has been related to surgical 
outcome. Patients with more focal neuropsychological deficits and less overall 
cognitive impairment should be expected to have better outcomes with respect 
to seizure frequency, given the absence of evidence of dysfunction extending 
beyond the resection zone (Wendling et al. 2013; Jutila et al. 2014). Patients at 
high risk of significant memory decline can be counselled pre-operatively and 
can be trained in compensatory strategies prior to the surgery when appropriate 
(Baxendale and Thompson 2010).  
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1.2.7.6 Outcome of surgery 
The outcome of surgery should be measured not only in terms of seizure 
freedom, but also in terms of neuropsychology, neurological deficits, 
psychosocial adjustments and quality of life. The fraction of epileptogenic tissue 
removed is a major determinate of seizure outcome. Temporal lobe surgery 
results in approximately 70% of patients becoming seizure –free in the first two 
to three years after surgery, and a further 20% are improved. The overall 
mortality of temporal lobectomy is less than 0.5% and the risk of permanent 
hemiparesis is less than 1%. A transient hemiparesis can occur in up to 5% 
(Téllez-Zenteno et al. 2005). Memory problems and visual field defects that 
prevent driving can occur in up to 5% of those undergoing mesial temporal lobe 
resection (Georgiadis et al. 2013). Psychosis and depression are not uncommon 
following temporal lobe resection and most patients should be warned of the 
possibility of these following the surgery (Cleary et al. 2013a; Cleary et al. 
2013b). In comparison, best medical therapies over a similar period yield a 5% 
chance of becoming seizure free and a 0.5 to 1.0% chance of death per a year 
from epilepsy (Wiebe et al. 2001). Hence surgery is a highly effective treatment 
for patients with medically refractory mTLE (Thom et al. 2010). 
On the other hand one third of patients continue with seizures after surgical 
therapy. At the moment it is not clear why some patients fail to become or 
remain seizure-free after surgery. Recurrence of seizures in the first year 
following surgery is a predictor of poor outcome and may suggest that the 
epileptogenic zone has not completely been removed. There is an association 
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between the volume of tissue removed and seizure freedom following surgery 
(Siegel et al. 1990). Reports of patients who failed the first mesial temporal 
resection have shown significant improvement in outcome with an extension of 
the amount of mesial temporal tissue removed (Germano et al. 1994). The 
extent of the hippocampal resection itself has been shown to influence seizure 
free outcome with the resection that extends more posteriorly having a 
significantly greater proportion of patients who become seizure free (Wyler et al. 
1995). Observations suggest that, despite early seizure control after surgery, 
tissue beyond the hippocampus and parahippocampal complex may be capable 
of generating seizures and that the seizure onset zone may involve the entire 
mesial temporal lobe (Thom et al. 2010). 
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CHAPTER II   PHARMACORESISTANCE IN EPILEPSY 
2.1 PHARMACORESISTANT EPILEPSY 
2.1.1 Definition of pharmacoresistant epilepsy 
The concept of pharmacoresistant epilepsy seems to be self-explanatory, but for 
some years a universally agreed definition remained elusive. In 2010 the 
International League against Epilepsy suggested that  pharmacoresistant 
epilepsy  be defined as failure of adequate response to two tolerated and 
appropriately prescribed  AED schedules (whether as monotherapies or in 
combination) to achieve sustained seizure freedom (Kwan et al., 2010). 
2.1.2 Seizure-freedom  
The International League Against Epilepsy defined seizure freedom as absence 
of seizures for at least three times the longest preintervention interseizure 
interval in the previous year (Kwan et al., 2010). 
2.1.3 Remitting-relapsing epilepsy 
There is an intermediate pattern of pharmacoresistance, although there is no 
universally agreed definition for this condition.  Bilevicus et al. (Bilevicius et al. 
2010) define the intermediate seizure pattern as present if a patient still 
experiences occasional seizures despite adequate AED regimen, which had led 
to at least two periods of at least one  year of being seizure free. On the other 
hand Neligan et al. (Neligan et al. 2011) defined seizures as intermittent when 
there was at least one previous period of remission of two years or more since 
seizure onset had occurred. 
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2.1.4 Neurobiological hypotheses for pharmacoresistance in 
epilepsy 
There are several hypotheses that explain the mechanisms associated with 
pharmacoresistance in epilepsy. Current theories on the causes of drug 
resistance in epilepsy include the transporter hypothesis, the target hypothesis, 
the network hypothesis, the gene variant/methylation hypothesis and the intrin-
sic severity hypothesis. However, none of these hypotheses is currently a stand-
alone theory that is able to convincingly explain how drug resistance arises in 
human epilepsy (Löscher et al. 2013). 
2.1.4.1 The transporter hypothesis 
The drug transporter hypothesis proposes that pharmacoresistance is related to 
increased expression of multidrug efflux transporter proteins such as Pgp. 
These proteins are thought to prevent AED entry by actively extruding AEDs 
from their target site (Sisodiya et al., 2002). Multidrug efflux transporters are 
highly expressed in capillary endothelial cells and astrocytic foot processes that 
form the BBB. They limit intracellular concentration of substrates by pumping 
them out of the cell through an active energy-dependant mechanism. Pgp 
(encoded by the adenosine triphosphate (ATP)-binding cassette subfamily B 
member 1 gene (ABCB1) was discovered more than thirty years ago (Juliano 
and Ling, 1976) and it is the multidrug efflux transporter protein we know most 
about in terms of its structure and mechanism. Epilepsy was the first CNS 
disorder for which pharmacoresistance was associated with enhanced 
expression of Pgp in the brain (Tishler et al., 1995). Pathologically elevated 
expression of Pgp has been found in resected brain tissue of patients with 
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pharmacoresistant mTLE undergoing surgery (Sisodiya et al., 2002) as well as 
in limbic brain regions of mouse and rat models of mTLE (Löscher and 
Potschka, 2005). It is currently not clear whether the endothelial and 
parenchymal overexpression of Pgp is a consequence of epilepsy, of 
uncontrolled seizures, of chronic treatment with AEDs, or is constitutive, i.e. 
present before the onset of epilepsy (Löscher and Potschka, 2005).  
2.1.4.2 The target hypothesis 
According to the target hypothesis, epilepsy pharmacoresistance occurs when 
intrinsic (genetic) or acquired (disease related) changes in drug targets make 
them less sensitive to AEDs (Schmidt and Löscher 2009). Two studies have 
provided evidence of reduced sensivity to carbamazepine in brain tissue from 
patients who were pharmacoresistant to carbamazepine and underwent 
resective surgery (Remy et al. 2003; Jandová et al. 2006). Since the 
carbamazepine was applied directly to the brain slices in these experiments 
circumventing the BBB and any transporter effects, reduced sensivity is 
presumably due to altered target sensivity. Both studies are restricted to 
carbamazepine only and it is unknown whether pharmacodynamic insensitivity 
in these tissues extended to AEDs with different mechanisms of action. The 
acquired version of the target hypothesis proposes that the pharmacodynamic 
sensivity of the AED target is modified by the disease state. For example there 
is a loss in benzodiazepine sensivity in a rat model of mTLE resulting from 
alterations in the subunit composition of the neurotransmitter gamma-
aminobutyric acid (GABA)A receptors, which are the molecular target of 
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benzodiazepines (Brooks-Kayal et al. 1998). The GABAA receptor subunit 
composition can change in response to prolonged seizure activity, and 
pronounced inter-individual differences have been reported in human epileptic 
tissue (Loup et al. 2009). In addition, the consequences of GABAA receptor 
activation depend largely on chloride homeostasis and its modulation by chloride 
transporters. Changes in the expression rate of chloride transporters described 
in the epileptic brain can result in outward chloride fluxes mediating 
depolarization and excitation instead of hyperpolarization and inhibition (Deisz 
2002). AEDs promoting GABAA -receptor mediated neurotransmission might 
lose their efficacy under these circumstances (Potschka 2013). 
2.1.4.3 The inherent severity model of epilepsy 
The inherent severity model of epilepsy suggests that there is a continuum in 
severity of the disease, which determines its relative response to medication 
(Rogawski and Johnson, 2008). Prospective studies of outcome in populations 
of patients with newly treated epilepsy have consistently shown that the single 
most important factor associated with the chance of remission of seizures is the 
frequency of seizures in the early phase of epilepsy, with an association 
between increased number of seizures in this period and poorer outcome. In a 
hospital-based, prospective cohort, patients with eleven or more seizures before 
treatment were more than twice as likely to be pharmacoresistant to their AEDs 
than patients with two or fewer seizures pre-treatment, independent of the time 
from the first seizure to starting treatment (Mohanraj and Brodie, 2006). 
Interestingly the same observation has been made in a chronic rodent model 
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where epilepsy with spontaneous recurrent seizures was induced by status 
epilepticus. Frequency of spontaneous recurrent seizures was determined by 
video-electroencephalography in a total of 33 epileptic rats before onset of 
treatment with phenobarbital. Thirteen (39%) rats did not respond to treatment 
with phenobarbital. Before treatment, average seizure frequency in non-
responders was significantly higher than seizure frequency in responders, 
which, however, was due to six non-responders that exhibited more than three 
seizures per day. Such high seizure frequency was not observed in responders, 
demonstrating that high seizure frequency predicts pharmacoresistance in this 
model, but does not occur in all non-responders (Löscher and Brandt 2010).  
2.1.4.4 The network hypothesis 
According to this hypothesis, structural brain alterations and/or network changes 
(for example, hippocampal sclerosis) are involved in resistance to AEDs. The 
network hypothesis suggests that recurring episodes of excessive neuronal 
activity (i.e. seizures) induce structural changes and alterations of brain plasticity 
including axonal sprouting, synaptic reorganization, neurogenesis, and gliosis 
which contribute to the formation of abnormal neural networks. This in turn leads 
to loss of the inhibitory effect of the endogenous antiepileptic system and 
prevents AEDs from entering their targets, eventually leading to 
pharmacoresistance (Banerjee et al. 2014). Intractability to currently available 
AEDs may reveal the fact that there are many mechanisms for seizure 
generation in a given patient, and if one is inhibited other mechanisms still exist. 
The alterations of brain plasticity including axonal sprouting, synaptic 
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reorganization, neurogenesis and gliosis would not be the etiological factors, but 
rather adaptive changes in response to seizures. However, poorly controlled 
seizures may induce progressive alterations of brain plasticity, eventually 
forming aberrant neural network and causing pharmacoresistance. Thus, the 
formation of aberrant neural network may be a potential contributing and 
etiological factor for pharmacoresistant epilepsy (Fang et al. 2011). 
2.1.4.5 The gene variant hypothesis/methylation hypothesis 
The fifth hypothesis is the gene variant or methylation hypothesis, which 
suggests that there is an inherent resistance that is governed by genetic variants 
of proteins that are involved in the pharmacokinetics and pharmacodynamics of 
AED activity. The methylation hypothesis indicates that seizures are associated 
to long-lasting epigenetic mechanisms such as acetylation, methylation, 
phosphorylation, ubiquitination of DNA and alterations in multidrug transporter 
molecules that contribute to the development of pharmacoresistance in epilepsy 
Recently Kobow et al. (Kobow et al. 2013)  discussed the potential role of 
epigenetic alterations as an underlying pathogenic process of 
pharmacoresistance in epilepsy. Epigenetic regulation is a key mechanism to 
define the versatile activity states of a gene, whereby a set of chromatin-
modifying actions leads to a change in genetic activity, without affecting DNA 
sequence itself. These biochemical cascades and signals have been shown to 
play a major role in various pathologic conditions, including cancer and cancer-
related drug resistance.  It has also been shown that seizures induce epigenetic 
changes in the hippocampus in experimental TLE models (Huang et al. 2002) 
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and in human TLE specimens compared to controls (Kobow et al. 2009) 
suggesting a pathophysiological impact of promoter methylation in human 
epilepsies. Additionally, it has been demonstrated that targeting a single 
molecular entity that modulates multiple molecular pathways by transcriptional 
repressors, such as neuron-restrictive silencer factor (NRSF; also known as 
REST), or via epigenetic mechanisms, offers new strategies for epilepsy 
therapies (McClelland et al. 2011; Kobow et al. 2013; Kullmann et al. 2014). 
 
Still, none of the prevailing pharmacological hypotheses is able to fully explain 
the neurobiological basis for pharmacoresistance and most of the experimental 
data suggest that multifactorial rather than single alterations underlie 
pharmacoresistance (Schmidt and Löscher 2009). 
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2.2 BACKGROUND TRANSPORTER HYPOTHESIS 
The discussion regarding a putative contribution of efflux transporters to drug 
resistance has been initiated by a study reporting overexpression of the BBB 
transporter Pgp in human epileptic tissue from patients with pharmacoresistant 
epilepsy (Tishler et al., 1995). The transporter hypothesis has gained interest in 
recent years, because if true, it would allow overcoming drug resistance by 
either inhibiting or bypassing Pgp or other involved efflux transporters (Hughes 
2008; Löscher and Langer 2010).  
2.2.1 Blood-brain barrier  
The blood-brain barrier (BBB) is a physical and metabolic barrier between the 
brain and the systemic circulation (Pardridge 1999). The BBB is composed of a 
monolayer of brain capillary endothelial cells. Unlike capillaries in other parts of 
the body, the cerebral capillaries are joined by tight junctions, which restrict 
solute flux between the blood and the brain. The brain capillary endothelial cells 
are surrounded by extracellular matrix, pericytes, and astrocyte foot processes 
(Loescher and Potschka 2005). Circulating molecules gain access to the brain 
via one of two processes: 1) lipid-mediated transport of small nonpolar 
molecules through the BBB by free (passive) diffusion, or 2) catalyzed transport 
(Pardridge 1999; Loescher and Potschka 2005).  
The endothelial cells of the BBB contain numerous membrane transporters 
involved in the influx and efflux of essential substrates (Lee et al. 2001). ABC 
efflux transporters, such as Pgp, at the BBB limit the brain uptake of a variety of 
therapeutic agents, including compounds that are relatively lipophilic and would 
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be predicted to permeate the endothelial lining of the brain microvasculature 
(Golden and Pollack 2003). Pgp is located at the luminal (apical = blood-facing 
side) membrane of endothelial cells (Beaulieu et al. 1997; Schinkel and Jonker 
2003). Thus, Pgp substrates entering the endothelial cells from the blood are 
immediately pumped back into the blood. As a consequence, the net penetration 
of substrate compounds from the blood into the brain tissue can be dramatically 
decreased. In the absence of Pgp in the BBB, the brain penetration of Pgp 
substrate drugs can increase up to ten - to 100-fold, with sometimes dramatic 
consequences for the toxicity of compounds (Schinkel and Jonker 2003). 
Furthermore, blockade of BBB Pgp by cerebral application of Pgp inhibitors 
significantly increases the brain concentration of various drugs, again being in 
line with Pgp functioning as an efflux transporter in the BBB (Löscher and 
Potschka 2005a). 
Clear expression of Pgp in astrocytes is especially seen in certain pathological 
states such as epilepsy (Sisodiya 2003).   
In contrast to Pgp, data on the other ABC transporters in the BBB are much 
more limited (Schinkel and Jonker 2003). At least six multidrug resistant proteins 
(MRP) (MRP1-6) are expressed at the BBB of different species (Begley 2004). 
However, the exact subcelluar localization (apical vs basolateral) of most of 
these MRPs in brain capillary endothelial cells remains to be determined 
(Löscher and Potschka 2005).  
 
69 
 
2.2.2 Blood-cerebrospinal-fluid barrier  
There is a shift in the appreciation of the contribution of the blood-cerebrospinal-
fluid (CSF) barrier to the drug transport between blood and brain. Several drug 
efflux transporters are present in epithelial cells of the blood-CSF barrier. 
However, in contrast to the BBB, the exact functional role of efflux transporters 
in these other brain barrier is less well understood (Löscher and Potschka 
2005a). The blood-CSF barrier is located at the choroid plexus (CP) and the 
outer arachnoid membrane. The blood- CSF barrier plays a vital role in the 
selectivity and permeability of the CP membrane to various nutrients and 
xenobiotics (Lee et al. 2001). The CP, which is the main source for CSF 
production, is a leaf-like highly vascular organ that projects into the ventricles of 
the brain and functions as a highly regulated solute- and drug-permeability 
barrier. The apical surface area has a same size range as the luminal surface 
area of the endothelial cells of the BBB, thereby providing a similarly large 
surface for solute exchange (Löscher and Potschka 2005a). The CP is 
comprised of fenestrated, highly permeable capillaries at the blood side that are 
surrounded by stroma and a monolayer of epithelial cells that face the CSF and 
are joined together by tight junctions (Lee et al. 2001). Once a solute or drug 
has crossed the capillary wall, it must penetrate the epithelial cells before 
entering the CSF (Löscher and Potschka 2005a).  
The molecular identity and localization of the proteins responsible for the influx 
and efflux of drugs and metabolites at the CP are currently explored. Transport 
of drugs and metabolites involves mainly the solute carrier and ABC transporters 
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(Lee et al. 2001; Ghersi-Egea and Strazielle 2002; De Lange 2004). Rao et al. 
(Rao et al. 1999) first described the expression of Pgp and MRP1 in the epithelia 
of the CP and their contribution in a bipolar permeation barrier for selected drugs 
crossing the blood-CSF barrier (Löscher and Potschka 2005a). It was concluded 
that Pgp localizes sub-apically at the CP with transport into the direction of CSF, 
whereas MRP1 localizes basolaterally, conferring transport to the blood side of 
epithelial cells (Rao et al. 1999). Thus, in the choroidal epithelium, Pgp and 
MRP1 seem to have opposing drug-transport functions. The basolateral 
localization of MRP1 at the CP epithelium was subsequently confirmed by other 
groups (Wijnholds et al. 2000). However, in general, the role of these and other 
drug transporters in blood-CSF barrier function is only incompletely understood 
and more studies need to be done (Löscher and Potschka 2005a). 
2.2.3 ABC transporters: function and role in pharmacoresistance 
Active drug efflux transporters of the ATP binding cassette (ABC)-containing 
family of proteins have a major impact on the pharmacological behaviour of 
most of the drugs in use today. The penetration of drugs into a range of 
important pharmacological sanctuaries, such as brain, testis, and fetus, and the 
penetration into specific cell- and tissue compartments can be extensively 
limited by ABC transporters (Schinkel 1999; Schinkel and Jonker 2003). ABC 
transporters are expressed in many tissues including the intestine, liver, kidney, 
brain and they maintain chemical homeostasis by mediating the transport of 
molecules across a membrane irrespective of concentration gradient. These 
transporters are encoded by 49 genes in the human genome and have been 
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grouped into seven subfamilies (designated ABCA-ABCG) based on sequence 
homology  (Dean et al. 2001; Gottesman et al. 2002; Szakacs et al. 2006). ABC 
transporters in their functional form comprise a minimum of four core domains 
that form the permeation pathway for transport of substrates, and two nucleotide 
binding domains that hydrolyze adenosine triphosphate (ATP) to power this 
process. Resistance to treatment by multiple drugs has been associated with the 
expression of ABC transporters in the target tissue. Three ABC proteins appear 
to account for most observed multidrug resistance (MDR) in humans and 
rodents (Sharom 2008); P-glycoprotein (Pgp/MDR1/ABCB1), MDR-associated 
protein (MRP)1 (ABCC1) and breast cancer resistance protein ABCG2 
(variously known as BCRP, ABCP for its high expression in placenta or MXR for 
mitoxantrone resistance) (Litman et al. 2001). I will focus on these three most 
important multidrug transporters; however the family of mammalian ABC 
transporters is far more extensive and functionally highly diverse (Jones and 
George 2004). 
2.2.3.1 P-glycoprotein 
Pgp was discovered more than 30 years ago (Juliano and Ling 1976) and it is 
the ABC protein we know most about in terms of its structure and mechanism. 
Pgp is generally expressed at higher levels in epithelial cell surfaces throughout 
the body. It is found exclusively at the apical surface of cells in the kidney 
proximal tubule, canalicular membrane of hepatocytes, pancreas, the villous 
membrane of the small and large intestine and the adrenal gland (Thiebaut et al. 
1987; Croop et al. 1989). Pgp is also located in blood-tissue barriers, including 
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the placenta and endometrium, blood-inner ear barrier, blood-mammary tissue 
barrier, blood-testis barrier, blood-nerve barrier, blood- brain barrier (where it is 
exclusively oriented to transport substrates toward blood) and epithelial cells of 
the blood-CSF barrier (Rao et al. 1999; Eckford and Sharom 2009). Pgp either 
restricts drug-entry to the body via the gastrointestinal tract and excretes 
metabolites into the urine or gastrointestinal tract or prevents their access from 
the blood to the fetus and sensitive organs such as the brain and testis (Eckford 
and Sharom 2009).  
Pgp is a phosphorylated glycoprotein with an apparent molecular weight of 
170kDA (Löscher and Potschka 2005a). There are two types of human Pgp: 
type I, encoded by the MDR 1 gene (ABCB1), which confers the drug resistance 
phenotype and promotes drug efflux at the blood-brain barrier, and type II, 
encoded by (ABCB2), present in the canalicular membrane of hepatocytes and 
functioning as phosphatidylcholine translocase (Demeule et al. 2002). The 
MDR1 gene in humans is located on chromosome seven and has 28 exons 
(Fromm 2004). Structurally the transporter consists of two interwoven 
transmembrane regions, each containing six transmembrane helices and an 
ATP-binding site located intracellularly. The transmembrane helices of Pgp allow 
it to bind and induce efflux of a broad range of substrates with varying affinities 
(Ambudkar et al. 1999). Although substrates for Pgp tend to be hydrophobic or 
weak base molecules with a planar ring system, Pgp is considered polyspecific 
because it can recognize a wide range of substrates including antiarrhythmics, 
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antihistamines, cholesterol-lowering statins and human immunodeficiency virus 
protease inhibitors ((Gottesman et al. 2002), Figure 2).  
2.2.3.2 Multidrug resistance protein 
The multidrug resistance protein (MRP) 1 was discovered in 1992 by Cole (Cole 
et al. 1992) and co-workers and the MRP family of proteins comprised nine 
characterized members (MRP1-9) also named ABCC1-6 and 10-12, 
respectively. Among MRP proteins, MRP1 is the most studied and like Pgp, 
MRP1 is an ATP-dependent transporter. It is expressed at low levels throughout 
many normal tissues and cell types in the body, but it is more highly expressed 
in the adrenal gland, bladder, CP, colon, erythrocytes, kidney, lung, placenta, 
spleen, stomach, testis, helper T-cells and muscle (both skeletal and cardiac) 
(Eckford and Sharom 2009). In contrast to Pgp and MRP2, it is localized on the 
basolateral membranes in polarized cells (Evers et al. 1996). The basolateral 
localization of MRP1 serves to protect sensitive tissues. For example, 
basolateral expression of MRP1 in the CP allows the protein to transport drugs 
from the cerebrospinal fluid to the blood to protect sensitive nervous tissues 
(Rao et al. 1999). MRP1 is a 190-kDa protein containing 1531 amino acids and 
its cognate gene is located on chromosome 16p13.11 (Conseil et al. 2005). 
MRP1 functions mainly as a co-transporter of amphipathic organic anions. It can 
transport hydrophobic drugs or other compounds that are conjugated or 
complexed to the anionic tripeptide glutathione, glucuronic acid, or to sulfate 
(Schinkel and Jonker 2003), Figure 2).  
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2.2.3.3 Breast cancer resistance protein  
In the early 1990s several groups began reporting non-Pgp, non-MRP1-
mediated pharmacoresistance in a variety of drug selected cell lines (Nakagawa 
et al. 1992 ; Kellner et al. 1997). The gene responsible for the novel phenotype 
was first cloned by Doyle and colleagues from a breast cancer cell line and was 
therefore called BCRP for breast cancer resistance protein (Doyle et al. 1998). 
Like Pgp, the breast cancer resistance protein (BCRP) is also localized to the 
apical face of polarized membranes. It is found in epithelial cells of the intestine, 
human placenta syncytiotrophoblasts, liver bile canaliculi, prostate, brain, 
lobules and lactiferous ducts of the mammary gland, and renal tubules, as well 
as the endothelium of veins and capillaries, including those at the blood-brain 
barrier and the placenta (Doyle et al. 1998; Eckford and Sharom 2009). Based 
on messenger ribonucleic acid (mRNA) analysis ABCG2 was more strongly 
expressed at the BBB than Pgp or MRP1 (Eisenblätter et al. 2003). 
The tissue distribution of BCRP shows extensive overlap with that of Pgp, 
suggesting that it might have a similar role as Pgp in the pharmacological 
handling of substrate drugs. It appears to transport both positively and 
negatively charged drugs, including sulfate conjugates and the list of its 
substrates is rapidly expanding, highlighting the importance of this protein 
(Sharom 2008), Figure 2). 
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Figure 2:  Multidrug transporter localisation in brain 
Pgp, P-glycoprotein; BCRP, breast cancer resistance protein, MRP, multidrug 
resistance protein. ABCA, ATP-Binding Cassette, Sub-Family A (ABC). Figure is from 
Wolf et al. (Wolf et al. 2012). 
 
2.3 MECHANISMS OF PGP OVEREXPRESSION IN 
PHARMACORESISTANT MTLE 
An important question is whether the overexpression of efflux transporters in 
epileptic brain tissue is constitutive or acquired/induced, or both mechanisms 
may be at play. A constitutive overexpression could occur as a result of a 
genetic predisposition, or it could be intrinsic to the development of the specific 
pathology. It is also conceivable that overexpression is acquired such as 
induction by recurrent seizures or even the AEDs intended to prevent them 
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(Kwan and Brodie 2005). I will discuss the evidence for the possible various 
mechanisms in the following paragraphs. 
2.3.1 Seizures induce Pgp overexpression 
In rats and mice, experimentally induced seizures have been shown to increase 
the expression of Pgp in brain capillary endothelial cells (BCECs), astrocytes 
and neurons (Löscher and Potschka 2005a). Zhang et al. (Zhang et al. 1999) 
reported increased Pgp expression in the hippocampus following 
intracerebroventricular injection of kainate in rats, causing neuronal injury. This 
increase in Pgp expression was observed in reactive astrocytes as early as one 
day after injection, peaked at two weeks but was still visible at ten weeks. 
Seeger et al. (Seegers et al. 2002) studied Pgp expression at 24 hours and ten 
days after status epilepticus (SE) (to differentiate between seizure related 
changes and changes developing during epileptogenis). Pgp increased 
significantly 24 hours after kainate-induced SE in BCECs at the dentate gyrus, 
amygdala, piriform and parietal gyrus. Additionally in the brain parenchyma of 
rats 24 hours after SE, a significant increase in Pgp expression was observed in 
the piriform and parietal cortex, dentate gyrus and hippocampus. However, the 
alterations in Pgp expression were only transient and disappeared ten days after 
the SE, except for the dentate hilus and the CA1 sector of the hippocampus, in 
which a significant increase in parenchymal Pgp was observed ten days after 
the status. Following systemic injection of kainate in mice, expression of mdr-1, 
the gene encoding Pgp, was found to be increased in the hippocampus for 
three-24 hours after the seizures but returned to control level by 72 hours (Rizzi 
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et al. 2002). Recently Pekcec et al. (Pekcec 2009) studied Pgp expression in 
brain tissue sampled from epileptic dogs following spontaneous status 
epilepticus or seizure clusters to avoid a putative bias of status epilepticus 
induction. They demonstrated a significant upregulation of Pgp in the 
hippocampal hilus (82% above control), the dentate gyrus granule cell layer 
(132% above control) and parietal cortex of canines (123% above control) one-
seven days following a seizure. In further support of the temporal increase of 
Pgp after seizures is the study by Bankstahl and co-workers in two rat SE 
models. Immunohistochemical staining of Pgp did not indicate any increase of 
Pgp expression in brain capillary endothelial cells during SE, whereas significant 
overexpression was determined in both models 48 hours after SE. Seven days 
after SE, Pgp expression had returned to control levels (Bankstahl and Löscher 
2008).  Löscher and Potschka (Löscher and Potschka 2005b) suggested that 
the excitatory neurotransmitter glutamate, which is excessively released by 
seizures, is involved in the seizure-induced over-expression of Pgp in the brain. 
This suggestion was based on a report by Zhu and Liu (Zhu and Liu 2004), 
showing that glutamate up regulates the expression and functional activity of 
Pgp in rat BCECs in vitro. They suggested that glutamate upregulates Pgp 
expression in BCECs by an N-methyl-D-aspartate (NMDA) receptor-mediated 
mechanism, which could play a role during ischemic and anoxic injury. 
Bankstahl et al. (Bankstahl et al. 2008a) recently examined this hypothesis and 
evaluated whether glutamate is involved in seizure-induced upregulation of Pgp 
in brain capillaries after systemic-administration of pilocarpine, a model of 
mTLE. Their data shows that the administration of the glutamate receptor 
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antagonist MK-801 after convulsive SE prevents the upregulation of Pgp in brain 
microvessels in the hippocampus, indicating that SE-induced glutamate release 
is involved in the regulation of Pgp expression after seizures. Additionally MK-
801 reduces the neuronal damage after prolonged seizures which may offer a 
therapeutic option. The activation of the NMDA receptor by glutamate is known 
to generate reactive oxygen species (ROS) and Zhu and Liu (Zhu and Liu 2004) 
suggested that ROS may mediate the effect of glutamate on Pgp expression. 
Generation of free radicals such as ROS has been suggested to play a key role 
in neuronal damage developing after SE. It is generally believed that excitotoxic 
cell death is due to excessive activation of NMDA receptors by glutamate, 
leading to excessive activation of calcium ion influx through the receptor’s 
associated ion channels and subsequent free radical production, including ROS. 
Based on this hypothesis, ROS is likely to be the link between seizures induced 
glutamate release and over-expression of Pgp. The data from these animal 
studies indicate that Pgp overexpression is a result of sustained seizure activity 
but not of the processes underlying development of epilepsy. 
2.3.2 Brain inflammation and epilepsy 
It is widely accepted that neurons are the cause of seizures and targeting of 
neuronal ion channels, GABA, and glutamate receptors has been, for decades, 
the mainstream pharmacological approach to eradicate seizures. Although the 
ultimate effectors of seizures are neurons, recent advances in experimental 
neurology have revealed that inflammation can precipitate seizures or sustain 
seizure activity (Marchi et al. 2014). Two distinct inflammatory processes have 
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been linked to seizures. Neuroinflammation is present in epileptic brain where it 
exacerbates seizures or increases their frequency (Vezzani et al. 2011). By 
contrast, systemic inflammation can cause epileptiform neuronal discharge via 
loss of ionic (e.g., potassium (Traynelis and Dingledine 1988) and 
neurotransmitter (e.g., glutamate (Heinemann et al. 2012; Marchi et al. 2014) 
homeostasis. Although neuroinflammation directly affects neurovascular and 
glial function, the effects of systemic inflammation are mediated or facilitated by 
loss of BBB function (Rivest 2010). BBB disruption can be triggered by a direct 
insult to the endothelium (Marchi et al. 2007) or by systemic factors, including 
activation of circulating leukocytes and release of molecular mediators that 
increase vascular permeability (Librizzi et al. 2012; Marchi et al. 2014). Pro-
inflammatory and anti-inflammatory cytokines, chemokines, and prostaglandins 
are responsible for the production of an early immune response. Numerous 
studies have confirmed enhanced inflammatory signalling in chronic rodent 
models and in tissue from patients with TLE (Aronica and Crino 2011; Vezzani 
et al. 2013). Genetic and pharmacological modulation of the synthesis and 
secretion of inflammatory mediators and of their receptors can influence seizure 
thresholds, severity and duration in mouse and rat TLE models (Vezzani et al. 
2013). Anti-inflammatory drugs, such as steroids and intravenous 
immunoglobulins, are useful in selected pharmacoresistant epileptic syndromes, 
whereas fever, immunization, and trivial infection can precipitate seizures, 
providing a solid link between inflammation and seizures (Vezzani and Granata 
2005). In addition, inflammatory mediators seem to contribute to disease-
associated alterations, which can exert an effect on antiepileptic drug 
80 
 
responses. For instance, cytokines can modulate the expression, sub-unit 
composition and functional state of antiepileptic drug targets (Balosso et al. 
2009; Vezzani et al. 2013).  
2.3.2.1 Pgp overexpression and brain inflammation 
Experimental data indicate that seizure activity is one of the main factors up-
regulating Pgp in the epileptic brain (Rizzi et al. 2002; Seegers et al. 2002; Volk 
and Loescher 2005) and glutamate can affect Pgp expression (Zhu and Liu 
2004). Further downstream events in the signalling cascade have been 
identified and Bauer et al (Bauer 2008) have shown that cyclooxygenase-2 
(COX-2) is a central factor of a cascade that drives the transcriptional activation 
of the Pgp-encoding gene in the epileptic brain.  COX is an enzyme that is 
responsible for the formation of prostanoids, including prostaglandins, 
prostacyclin and thromboxane. These lipid mediators play important roles in 
inflammation and pain and in normal physiological functions.  Pharmacological 
inhibition of COX can provide relief from the symptoms of inflammation and pain. 
It has been proven that COX-2 mediates Pgp regulation in response to excess 
glutamate concentrations such as those occurring during epileptic seizures 
(Bauer et al. 2008). It is known that glutaminergic signaling increases COX-2 
expression and that at least in rat mesangial cells COX-2 activation leads to 
increased Pgp (Sorokin 2004). Furthermore, both the nonselective COX inhibitor 
indomethacin as well as the selective COX-2 inhibitor celecoxib counteracted 
Pgp increase by glutamate exposure of isolated rat brain capillaries. Van Vliet et 
al. tested the efficacy of COX-2 inhibitors in a chronic rodent model, 
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overexpressing Pgp (Van Vliet et al. 2004; van Vliet et al. 2007). A sub-chronic 
2-week treatment with the highly selective cyclooxygenase-2 inhibitor SC-58236 
in the chronic epileptic state kept Pgp expression at control levels (Van Vliet et 
al. 2010). These data substantiate that COX-2 inhibition can block repeated 
induction of Pgp by ongoing seizure activity, thereby allowing Pgp to return to 
control levels. Furthermore, enhanced Pgp expression in chronic epileptic rats 
was associated with a significant reduction in the brain penetration of the 
antiepileptic drug phenytoin. Importantly, the brain delivery of phenytoin was 
significantly enhanced by subchronic COX-2 inhibition in rats with recurrent 
seizure activity (Van Vliet et al. 2010). These data provided evidence that COX-
2 inhibition may help to increase concentrations of AEDs at the target sites and 
that COX-2 inhibition could be a novel therapeutic concept to overcome 
pharmacoresistance in epilepsies (Potschka 2010).  
2.3.3 Genetic polymorphism and Pgp expression 
Several studies have tested for an association between Pgp expression in 
patients with epilepsy and polymorphism in drug transporter genes (Löscher and 
Langer 2010). One of these, a single nucleotide polymorphism in exon 26 
(C3435T) of the MDR1 gene is associated with altered expression, functionality 
and substrate specificity of the MDR1 product Pgp. Based on an initial report by 
Siddiqui (Siddiqui et al. 2003), a series of studies supported the hypothesis that 
the C3435T polymorphism is associated with resistance to multiple AEDs 
(Löscher et al. 2009). Several recent genetic association studies have also 
indicated an association of the 3435CC genotype with increased Pgp expression 
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and drug resistant epilepsy (Löscher et al. 2009). In contrast however are other 
studies which did not find a link between ABCB1 and response to AEDs 
(Löscher et al. 2009). Two metaanalyses including 11 studies up to September 
2007 involving 3371 patients and including 22 studies up to February 2010 
involving 6755 patients respectively provided no support for an association 
between pharmacoresistance and ABCB1 (Bournissen et al. 2009; Haerian et al. 
2010).  The inconsistency between the studies might be caused by different 
inclusion criteria (definition of pharmacoresistance, co-morbidities, co-
medication and population structure). A recent study pointed out the importance 
of stratification by patient age and aetiology of epilepsy (Sanchez et al. 2010). 
Another issue are the selection of AEDs included in the studies as the inclusion 
of drugs which have not been confirmed as Pgp substrates will bias the data 
(Potschka 2010). Another factor complicating genetic association studies is 
related to data indicating that the C3435T polymorphism might have contrasting 
consequences on Pgp expression in different ethnic subgroups. This is in line 
with the observation that an association in the opposite directions has been 
described in studies in Asian patients as compared to studies reporting an 
association in a Caucasian patient population (Kasperaviciute and Sisodiya 
2009). 
2.3.4 The effect of Pgp and gender 
Pgp expression is known to differ between men and women; for example, 
hepatic Pgp expression is 2.4-fold lower in females, although there are large 
interindividual differences in Pgp levels (Schuetz et al. 1995). However, little is 
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known about gender differences in Pgp function at the BBB and in patients with 
epilepsy which again may be under gender specific hormonal influences 
(Bebawy and Chetty 2009). Assema et al. (van Assema et al. 2012) examined 
the effect of gender and age at the BBB in 35 healthy men and women in three 
different age groups using VPM PET scans. They found increased volume of 
distribution (VT) of VPM with aging in several large brain regions in men. Young 
and elderly women showed comparable VT values. Young women had higher 
VT compared with young men (van Assema et al. 2012). It is known that (both 
endogenous and synthetic) progesterone/progestins and estrogens can have an 
effect on Pgp function (Bebawy and Chetty 2009). To date no studies have 
investigated the relationship between VPM PET measurements and actual 
hormone levels. Interestingly, a preclinical study has found differences in brain 
uptake of verapamil comparing female mice to male mice, which suggested a 
modest increase in Pgp expression and/or function in female animals (Dagenais 
et al. 2001). But this is in contrast to the findings of the clinical study in humans, 
in which a higher VT was found in young women than in young men, suggesting 
reduced Pgp function in young women (van Assema et al. 2012). Further studies 
are needed to assess whether this discrepancy is due to differences in hormonal 
status or species differences in transporter expression and/or activity at the 
BBB. 
2.3.5 Are antiepileptic drugs Pgp substrates? 
A central question of the transporter hypothesis is whether AEDs are substrates 
for Pgp. Only then, could overexpression of Pgp crucially contribute to 
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pharmacoresistance in epilepsy. So far evidence has been reported that 
phenytoin, phenobarbital, lamotrigine, levetiracetam, topiramate, and 
carbamazepine and oxcarbazepine metabolite are substrates of human Pgp 
(Luna-Tortes et al. 2008; Luna-Tortós et al. 2009). On the other hand data argue 
against a transport of valproic acid and carbamazepine (Baltes et al. 2007a; 
Luna-Tortos et al. 2008). In addition, transport of AEDs has been evaluated in a 
human colon carcinoma cell line. In these in vitro assays no evidence was 
obtained that carbamazepine, vigabatrine, gabapentin, phenobarbital, or 
lamotrigine are substrate of Pgp (Owen et al. 2001; Crowe and Teoh 2006). 
Moreover, Rivers et al. reported that carbamazepine, valproic acid, phenytoin, 
lamotrigin, and primidone are not likely to be substrates of Pgp based on their 
investigations in breast and cancer cell lines (Rivers et al. 2008). Although in 
vitro and in vivo transport assays have indicated that several antiepileptic drugs 
are substrates of Pgp, and that some AEDs are transported by ABC 
transporters, the data however is controversial. Although apparently a simple 
question, obvious difficulties exist in research evaluating the transporter 
substrate characteristics of AEDs. AEDs can pass the BBB efficaciously when 
efflux transporters such as Pgp are expressed at basal level. However, their 
brain penetration is limited once a relevant over expression occurs. Highly 
lipophilic compounds can rapidly diffuse through membranes of endothelial cells 
and might be less sensitive to an impact of active transports. Furthermore 
differences in the affinity to the transporter molecule might exist. Respective 
differences need to be taken into consideration when choosing an in vitro assay 
to explore the substrate specificities of AEDs. It has also been recently 
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demonstrated that the transport of AEDs depends on concentration and it is 
therefore of particular relevance to test potential Pgp substrates at clinically 
relevant concentrations (Zhang et al. 2010). Additionally, recent data also 
suggests that the substrate recognition or transport efficacy by Pgp differs 
between human and mouse for certain AEDs (Baltes et al. 2007b; Sills 2008). 
Such differences might explain in part the controversial data which have been 
reported for AED transport by Pgp from different species (Kwan and Brodie 
2005). 
2.3.6 Antiepileptic drugs induce Pgp overexpression 
Some studies have indicated that antiepileptic drugs might contribute to the 
induction of Pgp overexpression (Potschka 2010). Lombardo et al. (Lombardo et 
al. 2008) reported that carbamazepine, phenobarbital, and phenytoin induce 
Pgp and other transporters in rat brain endothelial cell lines via and interaction 
with the pregnane x receptor and the constitutive androstane receptor. In 
contrast Ambroziak el al. (Ambroziak et al. 2010) did not observe effects of 
these AEDs on expression and functionality of Pgp. Therefore definite 
conclusions regarding the impact of AEDs require further future efforts 
(Potschka 2010). 
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2.4 NEUROIMAGING OF PGP WITH PET   
Although increased transporter expression has been demonstrated in animal 
models of pharmacoresistant epilepsy and in human tissue that had been 
resected in surgery it may not be functionally relevant (Rogawski and Johnson, 
2008). Non invasive brain imaging of multidrug efflux transporter function in 
pharmacoresistant and seizure-free epilepsy patients is a strategy to evaluate 
whether the overexpression of multidrug efflux transporters at the BBB as 
postulated in the transporter hypothesis has any functional consequences that 
underlie pharmacoresistance in epilepsy. Additionally, PET tracers for multidrug 
efflux transporters could be useful to identify epilepsy patients with increased 
multidrug efflux transporter activity who will benefit from treatment with multidrug 
efflux transporter modulation drugs and therefore hold great promises for 
individualized medicine (Sisodiya and Bates 2006). 
Almost all efforts to develop multidrug efflux transporters ligands have focused 
on Pgp expressed at the BBB or in tumours. To date three different categories of 
imaging probes have been described to measure multidrug efflux transporters in 
vivo (Mairinger et al., 2011). 1) Radiolabeled transporter substrates usually 
developed from drugs known to be substrates for Pgp. More recently 2) 
radiolabeled transporter inhibitors as well as 3) radiolabeled prodrugs. 
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2.4.1 Radiolabeled transporter substrates 
2.4.1.1 [11C]verapamil  
[11C]verapamil (VPM) is the best validated PET tracer to image Pgp function to 
date. Verapamil, a calcium channel blocker, has been found to be a substrate 
for Pgp at low concentrations (which are used in PET) but also inhibits the Pgp 
transporter ATP hydrolysis (which initiates substrate extrusion) at high 
concentrations (Ambudkar et al., 1999). As it is well characterised both 
pharmacologically and with regards to its metabolic pathways it was thought to 
be a suitable candidate for a PET tracer to quantify Pgp function in vivo non-
invasively. In 1996 Elsinga et al. were the first to use PET to study multidrug 
resistance and to measure Pgp function. They developed a method using 
racemic (±) verapamil as a PET radiotracer and studied its tissue distribution in 
vivo in rats and in vitro with seizure-free and pharmacoresistant human ovarian 
carcinoma cell lines (Elsinga et al. 1996). The racemic (±) verapamil consists of 
two enantiomers, the (S) - and (R)- verapamil.  In vivo pharmacokinetics and 
pharmacodynamics of both enantiomers in animals and humans are different 
and the (S)-verapamil is more actively metabolised than the R-form, resulting in 
a 2.5 higher concentration of the (R)-enantiomer in plasma (Vogelgesang et al. 
1984). Furthermore (R)-verapamil exerts only 5-10% of the calcium channel 
blocking activity of the (S)-enantiomer and (S)-verapamil is ten times more 
potent in prolonging PR-intervals in humans (Echizen et al. 1985). As the 
enantiomers of verapamil have different pharmacokinetics, the quantification of 
racemic (11C)verapamil may be difficult. For this reason Luurtsema et al. 
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developed a synthesis of (R)-[11C]verapamil and they found that the metabolism 
was slower than that of the racemic verapamil. (Luurtsema et al. 2002; 
Luurtsema et al. 2005). (R)-[11C]verapamil is a high-affinity substrate of Pgp and 
is therefore very effectively transported by Pgp at the BBB. This results in low 
brain uptake of this radiotracer thus making it difficult to elicit regional 
differences in cerebral Pgp function. A possible strategy to overcome the 
limitation of the low brain uptake of Pgp substrate radiotracer is to perform PET 
scans after partial blockade by Pgp modulating drugs such as cyclosporine A 
(CsA) or tariquidar (TQD) (Löscher and Langer, 2010). The third-generation Pgp 
inhibitor TQD is safer than the non-selective CsA for use in human subjects and 
was shown to lack interaction with metabolism and plasma protein binding of 
(R)-[11C]verapamil (Bankstahl et al., 2008;Wagner et al., 2009). Blocking Pgp 
with an inhibitor allows the radiotracer to enter the BBB and hence increase its 
uptake and signal in the brain.  
2.4.1.2 [11C]-N-desmethyl-loperamide 
The radiotracer [11C]-N-desmethyl-loperamide has the advantage that it is 
metabolised to a lesser extent than (R)-[11C]verapamil. It has been used in rats 
(Farwell et al. 2013) as well as monkeys (Liow et al. 2009) and the first human 
studies using PET with [11C]-N-desmethyl-loperamide at baseline (Seneca et al. 
2009) and after  Pgp inhibition with TQD (Kreisl et al. 2010) have been recently 
carried out. At baseline there is virtually no uptake of this radiotracer in the brain. 
After 2 mg/kg of TQD the brain uptake of radioactivity increased only slightly 
(approximately 30%). In contrast, 4 and 6 mg/kg of TQD increased brain uptake 
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two- and four-fold, respectively. Until now, [11C]-N-desmethyl-loperamide has 
not been used clinically to study disease in patients. On the other hand, [11C]-N-
desmethyl-loperamide is a high affinity Pgp substrate that virtually shows no 
brain uptake which makes it unsuitable to map regional differences in Pgp 
function at baseline.  
2.4.2 Radiolabeled Antiepileptic drugs 
It is also possible to label AEDs with a positron emitter. [11C]phenobarbital and 
[11C]phenytoin have been shown to be weak substrates for Pgp and are 
expected to  have higher brain uptake than the high-affinity Pgp  substrate 
[11C]verapamil (Stavchansky et al. 1978; Luna-Tortos et al. 2008). They could 
therefore be better suited to assess regional differences in Pgp function 
(Mairinger et al., 2011), in particular Pgp overexpression. A study in eight 
patients with pharmacoresistant partial epilepsy and two patients without 
epilepsy showed that [11C]phenytoin concentration ratios were lower in the 
visual cortex in epilepsy patients who had an average value of 1.32 (range 1.05-
1.66) compared to 1.61 (1.34-1.87) in nonepileptic patients (Baron et al. 1983). 
But whether phenytoin concentrations are lower within the epileptic focus was 
not addressed in this study (Baron et al. 1983). 
2.4.3 Other radiolabeled Pgp substrates 
Several more radiolabeled drugs and radioligands have been investigated as 
PET tracers for Pgp. The radioligand [18F]MPPF has been developed as an 
alternative to short lived (11C)-labelled tracers for PET studies of  serotonin 5-
HT1A receptors. In microPET studies, treatment with CsA globally increases the 
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uptake of [18F]MPPF in rat brain indicating that [18F]MPPF must be a Pgp 
substrate (Laćan et al. 2008). So far [18F]MPPF has been used in animal studies 
together with the third generation Pgp inhibitor TQD to study Pgp activity 
(Bartmann et al. 2010; La Fougère et al. 2010). By using [18F]MPPF with TQD 
Bartmann et al. (Bartmann et al. 2010) revealed differences in Pgp function 
between pharmacoresistant and seizure-free epileptic rats. Tariquidar pre-
treatment increased the magnitude of [18F] MPPF K1 in the hippocampus by a 
mean of 142% in the non-responders, which significantly exceeded the 92% 
increase observed in the responder group.  The same treatment decreased the 
mean magnitude of [18F] MPPF in the hippocampus by 27% in non-responders, 
without comparable effects in the responder group (Bartmann et al. 2010). 
Additionally, Bartmann et al. (Bartmann et al. 2010) demonstrated that the 
impact of TQD on the brain kinetics of [18F]MPPF correlates with the 
pharmacosensitivity toward phenobarbital in a rodent model of chronic 
pharmacoresistant epilepsy, in which pharmacoresistance proved to be 
associated with Pg overexpression (Potschka 2010). Moreover, preliminary 
results obtained in a clinical study with ten mTLE patients showed that the Pgp 
inhibitor CsA significantly increased the [18F]MPPF binding potential by 14% in 
most brain regions, regardless of their involvement in seizure generation or 
propagation (Hammers et al. 2010). On the other hand, a recent study using 
[18F]MPPF PET in mice and non-human primates together with CsA (Tournier et 
al. 2012) revealed discrepancies in the Pgp-mediated transport of [18F]MPPF 
between mice and non-human primates. Their in vitro data indicates that 
[18F]MPPF is not a substrate of human P-gp and that the effect of the Pgp 
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inhibitor CsA on the brain transport of [18F]MPPF in non-human primate is 
related to an increase in the free fraction of tracer in the plasma, concluding that 
it is unlikely that the kinetics of [18F]MPPF brain transport and distribution are 
affected by Pgp activity in humans. In contrast in situ brain perfusion showed 
that Pgp restricted the permeability of the mouse BBB to 3H-MPPF (Tournier et 
al. 2012). 
The PET radioligand [11C]flumazenil which is clinically used for the assessment 
of GABAA receptor mediated inhibition in epilepsy and to localize epileptic foci 
prior to epilepsy surgery has also been suggested to be a Pgp substrate 
(Ishiwata et al. 2007; Froklage et al. 2012). [11C]flumazenil was recently used to 
detect regional differences in Pgp functionality in five different brain regions of 
control and kainate-treated rats, a model for TLE, before and after TQD 
administration.  The study showed that the GABAA receptor density (Bmax) was 
reduced in kainate-treated rats, compared with controls and that there were 
region-specific Pgp differences, with the hippocampus showing the highest 
Bmax (Syvänen et al. 2012). 
Furthermore, [11C]colchicine (Mehta et al., 1994), [11C]daunorubicin (Elsinga et 
al., 1996), [11C]carvedilol (Bart et al., 2005), [11C]-GR218231 (de Vries et al., 
2005), [18F]paclitaxel (Kurdziel et al., 2003), various 64Cu-labeled copper 
complexes (Packard et al., 2002), 67Ga/68Ga radiopharmaceuticals (Sharma et 
al., 2005), [11C]TMSX, [11C]MPDX, 11C]donepezil (Ishiwata et al. 2007), 
[11C]carazolol and [18F]fluorocarazolol (Doze et al., 2000) have been used to 
study Pgp. However, only limited in vivo data have been reported so far and it is 
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not yet clear if these radiotracers are useful for PET studies to image Pgp 
function in human. 
2.4.4 Radiolabeled transporter inhibitors 
Another complementary approach to assess the Pgp system with PET is the use 
of radiotracers which bind to Pgp without being transported. Such radiotracers 
would asses the transporter distribution and give a signal increase rather than a 
decrease (as will Pgp substrates) in brain regions that overexpress Pgp 
(Löscher and Langer, 2010). Several PET radiotracers based on the Pgp 
inhibitors have been reported to date: [11C]laniquidar, [11C]MC-18, [11C]quinidine 
[11C]elacridar and [11C]tariquidar (Bauer et al. 2010; Mairinger et al. 2012; Bauer 
et al. 2013; Syvänen et al. 2013). These new radiotracers have so far only been 
tested in animal models of naïve, transporter knock-out and epileptic rodents 
with rather surprising results. The cerebral uptake was lower than expected at 
baseline and increased several-fold rather than decreased after administration 
of unlabelled inhibitors (Bauer et al. 2010; Bauer et al. 2013; Syvänen et al. 
2013). These radioligands were administered at very low (tracer) concentrations 
and could behave differently than at high concentrations. It is hypothesized that 
the low brain uptake, i.e. the rather substrate-like behaviour of these 
radiotracers, could be caused by other multidrug efflux transporters (such as 
BCRP) at the BBB transporting the radiotracers out of the brain (Mairinger et al. 
2011).  
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2.5 NEUROIMAGING OF PGP WITH SPECT 
[99mTc]sestamibi was originally developed as a K+ analog for imaging 
myocardial ischemia. It has been shown to be a substrate for Pgp (Luker et al., 
1997). In humans, [99mTC]sestamibi was reported to image Pgp efflux transport 
in multidrug resistant  cancers (Luker et al., 1997). However, it was found not to 
be an ideal substrate radioligand as it is not a selective substrate for Pgp  but 
also for other multidrug efflux transporters (such as MRP1) (Hendrikse et al., 
1998). Furthermore in contrast to PET, SPECT does not enable quantitative 
measurements of uptake and efflux kinetics of Pgp substrates and thus has only 
limited use in studying Pgp function in the BBB (Löscher and Langer, 2010). 
2.6 PRECLINICAL STUDIES OF PGP IN MTLE 
2.6.1 Preclinical epilepsy models 
2.6.1.1 Knockout mice and natural mutants 
Investigations in genetically deficient animals, which lack a functional form of 
one or more drug efflux transporter, have contributed to a significant extend to 
the current knowledge about the physiological and pharmacological function of 
these transporters. Genetically deficient mice have been generated by knockout 
technologies with the purpose of studying the role of specific transporters. 
Furthermore, subpopulations of animals with spontaneous mutations in 
multidrug transporter genes have been identified for different species. The in 
vivo impact of Pgp in the BBB has been intensely studied in knockout mice 
lacking the Pgp isoform mdr1a (mdr1a (-/-)mice) or mdr1a and mdr1b Pgp 
(md1a/1b (-/-) mice). Mdr1a knockout mice lack the mdr1a isoform of Pgp all 
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over the body and in the brain capillary endothelial cells. The animals are viable 
and fertile but are more susceptible to developing a severe, spontaneous 
intestinal inflammation (Löscher and Potschka 2005). 
2.6.1.2 Animal models of epilepsy 
Animal models of epilepsy are a valuable tool to study models of seizure onset, 
neurologic changes during seizures, and new pharmacologic tools for seizure 
propagation or pharmacoresistance. For epilepsy research various animal 
models are available, each with their specific characteristics. Globally, these 
models are categorized into models of seizures and those of epilepsy (Sarkisian 
2001). Examples of seizure, or acute, models are the cortical stimulation model 
and the maximal electroshock model. The amygdala kindling model is also an 
acute model, as most animals do not develop spontaneous epilepsy. The 
models of epilepsy, chronic models, can be subdivided into models of genetic 
epilepsy and models of acquired (symptomatic) epilepsy (Löscher 2011). The 
first category includes both animals with spontaneous mutations and animals 
with induced mutations, resulting in epileptic symptoms and behavior. In animals 
of the acquired or symptomatic epilepsy models, status epilepticus (SE) is 
induced by electrical stimulation (amygdala, perforant path, and hippocampus) 
or through the administration of chemical convulsants (pilocarpine or kainic acid) 
in previously non-epileptic rats, which results in the development of spontaneous 
seizures after a latent period of days to weeks.  
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2.6.1.2.1 Kindling model 
Since its introduction by Goddard in 1967 (Goddard 1967), the kindling model 
has been used extensively as an animal model of epilepsy. Kindling can be 
induced by the repeated administration of a mild electric stimulus to the rat brain 
via an implanted electrode into a limbic structure such as the amygdala, 
hippocampus, entorhinal cortex or other brain areas. Over a period of several 
stimulations session the rat reliably displays stage five seizures, according to the 
Racine scales (Racine 1972). The pathophysiology of kindling is very similar to 
that of human mTLE. For example, kindling leads to structural and functional 
changes characterized by neuronal cell loss, gliosis, neurogenesis and mossy 
fiber spouting (Arida et al. 2009). 
2.6.1.2.2 Pilocarpine model 
The pilocarpine and the kainic acid model are probably the most commonly 
studied chemical-inductive models for mTLE. Pilocarpine, a potent muscarinic 
cholinergic agonist, is administered as a single high dose (300-380mg/kg) to rats 
or mice. It acutely induces sequential behavioral and electrographic changes, 
indicative of sustained epileptic activity, resulting in widespread damage to the 
forebrain in (Arida et al. 2009). After 15-25 minutes this results in motorlimbic 
seizures and leads to SE within 50-60 minutes after pilocarpine administration 
that last for up to 12 hours. After a silent period of a few days animals start 
exhibiting spontaneous recurrent seizures. Morphological analysis of the brain 
after pilocarpine-indcued SE demonstrates cell loss in the hippocampal subfields 
CA1 and CA3 and in the hilus of the dentate gyurs, in the septum, olfactory 
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tubercle, amygdala, piriform cortex, neocortex and thalamic nuclei (Arida et al. 
2009). 
2.6.1.2.3 Kainic acid model 
The excitotoxic glutamate analogue kainite can be systemically or intracerebrally 
injected into an animal and rapidly produce acute seizures. In rodents, large 
doses of the drug induce severe acute seizures with subsequent SE, which is 
followed by a quiescent period of usually several weeks (Arida et al. 2009). This 
latent period is followed by the development of spontaneous recurrent seizures. 
Injections of kainic acid were shown to lead to cell death in the hippocampus, 
amygdala, entorhinal cortex and medial thalamic nuclei (Ben-Ari et al. 1980). 
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2.6.2 Preclinical studies of Pgp in epileptic rats 
In animals, models of temporal lobe epilepsy, such as the kindling and kainate 
models, have been used to study the molecular mechanisms of 
pharmacoresistance. In these models a large group of kindled or epileptic rats is 
treated with AEDs. Subsequently subgroups of animals that either respond 
(pharmacosensitive/seizure-free) or do not respond (pharmacoresistant) to 
AEDs are selected.  Pgp is overexpressed in endothelial cells and ectopically in 
astrocytes, after induction of sustained limbic seizures in rodents (Volk and 
Loescher 2005). Upregulation of the mRNA of the MDR1 gene was detected in 
rat brain during both acute and spontaneous seizures caused by status 
epilepticus. Because limbic seizures were induced in these studies in otherwise 
normal rodent brain, these experimental findings indicate epileptic activity per se 
can increase the expression of Pgp. More recently Volk and Löscher (Volk and 
Löscher 2005) used a rat model of temporal lobe epilepsy to examine whether 
Pgp expression differs in AED responders from non-responders rats. In this 
model, spontaneous recurrent seizures develop after status epilepticus induced 
by amygdala kindling. They showed that phenobarbital-resistant epileptic rats 
exhibit significantly higher endothelial expression of Pgp in limbic brain regions 
compared to drug-responsive rates providing further support for the hypothesis 
of Pgp overexpression in pharmacoresistant epilepsy. Furthermore in another 
study with amygdala epileptic kindled rats significant upregulation of Pgp was 
reported in brain capillary endothelial cells of limbic brain regions. In these rats, 
brain-to-plasma concentration ratios of phenytoin in the hippocampus were 
about 30% lower than those measured in control rats (Potschka and Löscher 
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2002). When kindled rats were divided into phenytoin responders and non 
responders, non responders exhibited a significantly higher expression of Pgp in 
capillary endothelial cells in the epileptogenic focus (Potschka et al. 2004).  
Moreover, no differences in Pgp expression were observed in the adjacent 
piriform cortex indicating that the Pgp expression between non-responders and 
responders are restricted to the kindled focus (Potschka et al. 2004). Rizzi et al. 
(Rizzi, et al. 2002) reported that mdr1 mRNA is overexpressed in mouse 
hippocampus after the induction of limbic seizures. Then phenytoin was 
systemically administered to the mice, its brain-to-plasma ratio was 30% less 
than in mice not subjected to seizures thus indicating reduced drug-
concentrations on brain. 
Moreover, targeting Pgp by modulators can enhance the efficacy of AEDs. The 
co-administration of the unselective inhibitor verapamil proved to potentiate the 
anticonvulsant efficacy of the AED oxcarbazepine (Clinckers et al. 2005). The 
third generation selective modulator tariquidar (TQD) increased the efficacy of 
phenytoin in a chronic rat model where spontaneous recurrent seizures where 
induced by amygdala kindling (Brandt, et al. 2006). However, putative species 
differences in the substrate spectrum of the transporters need to be taken into 
account when extrapolating from rodent data to the clinical situation. 
2.6.3 Preclinical imaging of Pgp function  
PET analysis with [11C]-verapamil to assess Pgp function at the BBB within the 
intact CNS was first validated using mdr1a knockout mice and showed lower 
[11C]-verapamil uptake in the wildtype mice compared to those in the mdr1a 
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knockout mice (Hendrikse, et al. 1998). In addition it was possible to prove that 
the reversal of Pgp function can be monitored by PET. The unselective Pgp 
inhibitor CsA increased the  [11C]-verapamil accumulation to levels comparable 
to this in mdr1a knockout mice (Hendrikse et al. 1998). This concept was 
subsequently replicated in two further studies using the racemic [11C]-verapamil 
and the unselective inhibitor CsA at different doses resulting in dose dependent 
increases of [11C]verapamil by Pgp modulation after CsA (Bart et al. 2003; 
Syvaenen et al. 2006). Furthermore Bankstahl et al. (Bankstahl et al. 2008b) 
performed paired (R)-[11C]verapamil PET scans in a group of 7 healthy Wistar 
rats before and after administration of the new third-generation Pgp inhibitor 
TQD (15 mg/kg). After TQD administration, the distribution volume of (R)-
[11C]verapamil was 12-fold higher than baseline and the influx rate constant K1 
of (R)-[11C]verapamil into the brain, was about eight-fold higher after tariquidar 
hereby, demonstrating that (R)-[11C]verapamil PET combined with TQD 
administration is a promising approach to measure Pgp function at the BBB. 
Recently Kuntner et al. used (R)-[11C]verapamil PET in rats before and after the 
administration of different doses of the selective Pgp inhibitors TQD  and 
elacridar (Kuntner et al.).  They demonstrated that the median effective dose 
(the dose required to achieve 50% of the desired response in 50% of the 
population=ED 50) for TQD is 3.0 +/- 0.2 mg/kg. Furthermore, PET scans after 3 
mg/kg TQD resulted in regionally different enhancement of brain activity 
distribution, with lowest distribution volume in cerebellum and highest 
distribution volume in thalamus pointing to regional differences in cerebral Pgp 
function and expression in rat brain. 
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2.6.4 Preclinical imaging of Pgp function in pharmacoresistant 
epilepsy 
Following the promising results of (R)-[11C]verapamil in healthy Wistar rats a 
proof of concept study was performed in rats 48 hours after pilocarpine-induced 
SE. Both control and post-SE rats underwent (R)-[11C]verapamil PET scans 
after administration of tariquidar at 3mg/kg (Bankstahl et al., 2011). Regional 
PET data was analyzed and Pgp expression was independently quantified in the 
same brain regions using immunohistochemical staining (Bankstahl et al., 2011). 
In brain regions with increased Pgp expression (cerebellum, thalamus, 
hippocampus) in SE rats the influx rate constants from blood to brain, K1, of (R)-
[11C]verapamil were significantly decreased relative to control animals, thereby 
supporting the hypothesis of regionally increased cerebral Pgp function in 
epilepsy. A further PET study with another Pgp substrate radiotracer [18F]MPPF  
confirmed the hypothesis of Pgp overexpression in pharmacoresistant epilepsy. 
Bartmann et al. (Bartmann et al., 2010) evaluated BBB Pgp function in rats with 
seizure-free and pharmacoresistant mTLE. The authors showed that TQD (5 
mg/kg) pre-treatment increased the magnitude of [18F]MPPF K1 in the 
hippocampus by a mean of 142% in AED non-responders, which significantly 
exceeded the 92% observed in the AED responder group. Therefore PET 
imaging approach with combined use of a Pgp substrate radiotracer and a Pgp 
modulator seems to be appropriate to non-invasively determine Pgp efflux 
function at the BBB. 
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2.7 CLINICAL STUDIES OF PGP IN MTLE  
Evidence for increased expression of Pgp has mainly been derived from 
epileptic tissues removed during epilepsy surgery from patients with 
pharmacoresistant epilepsy (Kwan and Brodie 2005). Tishler et al. (Tishler et al., 
1995) were the first to measure MDR1 expression in 19 patients undergoing 
resective epilepsy surgery, 15 of whom had mTLE receiving temporal 
lobeectomy for a mixture of pathologies (mostly hippocampus sclerosis). MDR1 
mRNA level was found to be >ten times higher in 11 of the 19 resected samples 
compared with controls. In addition Pgp was detected by immunohistochemical 
staining in astrocytes where it is not normally present, suggesting novel 
expression. Following Tishler and colleagues’ report multiple follow-up studies 
have confirmed this initial finding in patients with different types of epilepsy and 
different pathologies. Dombrowski et al. (Dombrowski, Desai et al. 2001) applied 
cDNA array and found overexpression of MDR1, MRP2 and MRP5 in 
endothelial cells isolated from temporal lobe blood vessels of brain specimens 
from five pharmacoresistant patients undergoing temporal lobeectomy. Sisodiya 
et al. demonstrated both Pgp and MRP1 in astrocytic cells, but not in capillary 
endothelial cells, in the hippocampus in cases of hippocampal sclerosis 
(Sisodiya, Lin et al. 2002). More recently Aronica et al. (Aronica, Özbas-
Gerçeker et al. 2004) performed detailed immunostaining studies in brain 
sections from 16 patients with hippocampal sclerosis and found upregulation for 
Pgp and MRP2 in capillary endothelium consistent with an enhanced barrier 
function. MRP1 was detected in glial foot processes around blood vessels, 
possibly functioning as a “second line” defence mechanism. In addition, novel 
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expression of Pgp, MRP1 and MRP2 was found in reactive astrocytes within the 
hippocampus in the CA1 and hilar regions. A recent post-mortem study showed 
Pgp overexpression in the sclerotic hippocampus of individuals with 
pharmacoresistant epilepsy, but not in post mortem seizure-free individuals or 
non-epileptogenic tissue with electrode-related injuries (Liu et al. 2012). 
Additionally, Pgp over expression has been studied in malformations of cortical 
development. Focal cortical dysplasia tissue removed from patients with 
pharmacoresistant epilepsy showed intralesional induction of MRP1 in 
dysplastic neurons, balloon cells and glial processes around blood vessels, 
whereas Pgp overexpression was observed primarily in the glial component and 
endothelial cells (Sisodiya, Lin et al. 2001). 
2.7.1 Clinical Imaging of Pgp function  
Pgp function at the BBB of healthy humans has been imaged and quantified 
using [11C]-verapamil and [11C]-N-desmethyl-loperamide (Kannan et al. 2009) . 
Recent studies have shown, however, that imaging of Pgp function at the BBB in 
humans may need to take into consideration a subject’s age and the genetic 
polymorphisms of Pgp. Bartels et al. (Bartels et al. 2009) studied the Pgp 
function using [11C]-verapamil PET in seventeen healthy volunteers with age 18-
86. Analysis with statistical parametric mapping showed significantly decreased 
Pgp function in older subjects than in younger subjects in the internal capsule 
and corona radiata white matter and in orbitofrontal regions; thereby suggesting 
that Pgp function declines with increasing age.  Furthermore, haplotypes of 
nucleotide polymorphisms at positions 1236, 2677 snf 3435 of the MDR1 gene 
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have been shown to alter Pgp activity in vivo and to alter substrate specificity in 
vitro. However, imaging studies with [11C]-verapamil show that pharmacokinetics 
were unaffected in healthy volunteers who expressed either the TTT or the CGC 
(wild-type) haplotype (Brunner et al. 2005; Takano et al. 2006). 
The promising concept of performing (R)-[11C]verapamil PET scans after 
blockade of Pgp was  recently translated into healthy human subjects (Wagner 
et al., 2009). Five healthy volunteers underwent paired (R)-[11C]verapamil PET 
scans before and after intravenous administration of tariquidar (2 mg/kg of body 
weight). TQD administration resulted in significant increases in K1, +49% +/- 
36% of (R)-[11C]verapamil across the BBB. The data from this first human study 
were re-analyzed region wise using an automated atlas approach to define 43 
different brain regions as well as parametric maps. No regional differences in 
TQD-induced Pgp inhibition were detected, suggesting that there were no 
regional differences in Pgp function in healthy human brain (Bauer et al., 
2010b). Shortly after, Eyal and co-workers confirmed the results in a study with 
[11C]-verapamil before and during infusion of CsA (2.5 mg x kg(-1) x h(-1)) (Eyal 
et al., 2010). Thereby K1 estimates were similar across gray-matter regions of 
the brain and the magnitude of Pgp inhibition was comparable across BBB-
protected brain structures.   
2.7.2 Clinical imaging of Pgp function in pharmacoresistant epilepsy 
The use of PET to determine Pgp function in epilepsy patients has only started 
recently. A pilot study by Langer et al. (Langer et al., 2007) used PET and the 
radiotracer (R)-[11C]verapamil to test for differences in Pgp activity between 
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epileptogenic and non-epileptogenic brain regions of patients with 
pharmacoresistant unilateral mTLE. Although statistical significance could not be 
reached it supported the hypothesis of Pgp overexpression. They observed 
increased influx rate constants from blood to brain, K1, and efflux rate constants 
from brain to blood, k2, in several temporal lobe regions that are known to be 
involved in seizure generation and propagation ipsilateral compared to 
contralateral. Additionally, parameter asymmetries were most prominent in 
parahippocampal and ambient gyrus, amygdala, medial anterior temporal lobe 
and lateral anterior temporal lobe. In contrast to temporal lobe volumes of 
interest asymmetries were minimal in regions not involved in epileptogenesis 
located outside the temporal lobe. A caveat of (R)-[11C]verapamil is that the 
peripheral metabolism of the radiotracer is significantly faster in epilepsy 
patients compared to healthy controls. This is most likely caused by hepatic 
cytochrome P450 enzyme induction of AEDs (Abrahim et al., 2008). The 
difficulty is that these radiometabolites which are generated from the (R)-
[11C]verapamil are also taken up into the brain tissue independent of Pgp 
function and compromise the quantitative measurement of Pgp function 
especially when comparing different study groups such as patient and healthy 
controls. A study in nine patients suffering from pharmacoresistant mTLE 
showed a reduction of [18F]MPPF for 5-HT1A receptors in the epileptogenic 
temporal lobe compared with control values, possibly indicating Pgp 
overexpression (Merlet et al., 2004;Didelot et al., 2008). At steady state, 
brain:blood, [11C]phenytoin activity was lower in the visual cortex, resulting in an 
average value of 1.32 (range 1.05.-1.66) in epilepsy patients compared to 1.61 
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(range 1.34-1.87) in non-epileptic patients (Baron et al., 1983). Whether 
[11C]phenytoin concentration were lower in the epileptogenic focus was not 
addressed in this study. 
Genetic polymorphism of Pgp might play a role pharmacoresistant mTLE. Only 
two imaging studies have been performed so far to investigate the role of Pgp 
and of its polymorphisms in pharmacoresistant mTLE. In a pilot study with seven 
patients with mTLE no apparent relationship between the ABCB1 genotype and 
the R-[11C]verapamil efflux rate constant k2 could be described but the sample 
size was small (Langer et al. 2007). On the other hand a SPECT study in 
patients with epilepsy the 3435CC genotype was associated with reduced brain 
uptake of (99mTc)sestamibi, which was correlated with drug resistance (Jensen 
et al. 2006). Furthermore, cerebrospinal fluid concentrations of phenobarbital 
were significantly lower in epilepsy patients with the 3435CC genotype (Basic et 
al. 2008).  
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CHAPTER III  OBJECTIVES OF THE PROJECT 
Our main objective is to validate radiotracers for Pgp activity as biomarkers for 
drug resistance using pharmacoresistant and seizure-free epilepsy as a 
biological model, the required proof-of-concept of a non-invasive molecular 
imaging-based tool. Epilepsy is the ideal condition for testing suitability of these 
imaging biomarkers, as either surgical specimens or whole brains are available 
for direct in-vivo / ex-vivo comparative analysis. 
1. To determine test-retest variability in pharmacoresistant and seizure-
free mTLE patients using PET and (R)-[11C]verapamil 
2. To determine the effects of chronic epilepsy and therapeutic AEDs on 
brain Pgp function 
3. To determine the effects of the Pgp inhibitor TQD on the cerebral 
uptake of (R)-[11C]verapamil  
3.1 HYPOTHESIS 
We hypothesise that: 
1. In pharmacoresistant mTLE patients, the uptake of the Pgp substrate 
VPM is reduced in the epileptogenic relative to contralateral regions 
and compared to seizure-free mTLE patients and healthy controls. 
2. Seizure activity worsens variability in pharmacoresistant mTLE 
patients compared to seizure-free mTLE patients and healthy controls. 
3. The third-generation Pgp inhibitor tariquidar increases  (R)-
[11C]verapamil uptake, but this increase is attenuated in epileptogenic 
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regions compared to contralateral regions of mTLE patients and to 
healthy controls 
4. This difference is expected to be correlated with the level of Pgp 
expression as measured independently using immunohistochemistry.  
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CHAPTER IV  COMMON METHODOLOGY 
4.1 POSITRON EMISSION TOMOGRAPHY IMAGING 
PET is a non-invasive quantitative imaging technique which can provide 
information about physiological and pharmacokinetic processes in vivo. These 
processes can be measured by intravenous injection of a radiotracer labelled 
with a positron emitter such as 15O, 13N, 11C and 18F. A positron is an electron 
with a positive electric charge. The positron travels at most a few millimetres (2-
5mm) in tissue before combining with an electron. These two particle then 
annihilate, resulting in the simultaneous emission of two 511 keV gamma 
photons in opposite directions. A PET scanner is equipped with a large number 
of scintillation detectors arranged in a ring surrounding the object of interest. 
When two opposing detectors register a photon simultaneously (coincidence 
detection), the line along which the annihilation took place (line of response, 
LOR) can be determined. A PET scan consists of the collection of large 
numbers of these coincidence events, which take place over time. Using 
mathematical reconstruction methods, the location of these coincidences, and 
thus the location or distribution of the compound can be calculated as a function 
over time (Cherry 2001). PET is a powerful diagnostic tool, particular in 
oncology, neurological disorders and cardiovascular disease. It is possible to 
acquire kinetic data with a time resolution of a few seconds. This offers the 
possibility to image relatively rapid physiological and pharmacological 
processes. Furthermore, PET is very sensitive, having the ability to detect 
picomolar or fetomolar concentrations of ligand in the tissue of interest. 
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Additionally, it is quantitative, providing the potential to measure physiological or 
pharmacological parameters in absolute units. 
4.1.1 PET data acquisition 
PET scans were performed at the Wolfson Molecular Imaging centre in 
Manchester on the High Resolution Research Tomograph (HRRT; CTI/Siemens 
Molecular Imaging, TN, USA) (Figure 3). This is a dedicated brain PET scanner 
comprising eight flat panel detectors, with transaxial and axial field of views of 
31.2. and 25.2cm, respectively. Depth-of interaction information is provided by a 
dual-layer scintillator (10mm LSO, 10 mm LYSO). Point source resolution varies 
across the field of view from approximately 2.3 to 3.2 mm (full-width-at-half 
maximum) in the transaxial direction and from 2.5 to 3.4 mm in the axial 
direction.  
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Figure 3: The HRRT PET scanner 
On the left hand side is the custom-built BGO detector. The HRRT PET scanner is 
located at the Wolfson Imaging Centre, University of Manchester. 
 
4.1.2 Head positing and transmission scans 
During scanning subjects’ heads were rested in the HRRT head holder.  An 
external position tracker (Polaris Vicra, Northern Digital Inc., Waterlook, 
Canada) monitored the head movement during emission and transmission 
scans by tracking the position with the reflective tool attached to the vertex of a 
customized neoprene swim cap. Head movement was reduced by the snug fit of 
the cap within the head holder and the use of Velcro forehead and chin straps. 
Attenuation and scatter correction was enabled by a six minute transmission 
scan at the end of the dynamic emission scan using a 1.1 gigabecquerel (GBq) 
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137 CS single photon emission source (662 kiloelectron volt (keV)), the energy 
window for the transmission scan is 550-800 keV. The delayed and prompt 
coincidence events were recorded using an energy window of 400-650keV. 
4.1.3 Arterial plasma input function 
Radiolabeled metabolites appear in plasma after a short delay following 
intravenous injection of the parent tracer. Arterial blood sampling is essential in 
order to determine the availability of the radiotracer in the brain. Therefore prior 
to scanning, a 22 gauge cannula was inserted into the radial artery after 
subcutaneous infiltration with 1-2% lidocaine and arterial blood was sampled for 
the duration of the PET scan. Radioactivity in arterial blood was assayed 
continuously for the first 15 minutes at a rate of 5ml minutes-1 using a custom-
built bismuth germanium oxide detector (Ranicar et al. 1991). These were 
combined with discrete blood samples at 5, 10, 15, 20, 30, 40, 50 and 60 
minutes to calibrate the on-line blood sampling system and to determine the 
partition of radioactivity between plasma and erythrocytes. The plasma samples 
except those at 15 and 50 minutes were also analysed to measure fractions of 
parent tracer and radiolabeled metabolites. The arterial plasma input function 
was generated by combining the continuous plasma (15 minutes) with the 
interpolated discrete plasma samples and corrected by the fractions of VPM to 
total radioactivity.  
Some radiolabelled metabolites of VPM are taken up into brain independently of 
Pgp-function and so compromise the quantitative estimation of VPM-K1. 
Increased VPM metabolism in epilepsy patients has previously been reported 
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and is most likely caused by AED-mediated hepatic cytochrome P450 enzyme 
induction (Abrahim et al. 2008). To limit the effect of radiolabeled metabolites, 
we performed kinetic analysis using a single-tissue compartment model on the 
first 10 minutes of dynamic PET data (Muzi et al. 2009). For the voxel-based 
analysis, weighted generalized linear least squares were employed to generate 
parametric maps of K1. 
4.1.4 Radiochemistry 
(R)-[11C]verapamil was produced based on the procedure reported by 
Luurtsema et al (Luurtsema et al. 2002). The total radiosynthesis time was 40-
45 minutes giving 2.4-5.9 GBq of formulated product at the end of the 
radiosynthesis. 
The average product characteristics at the end of synthesis were: radiochemical 
purity 98.37%, co-injected stable VPM 1.08ug/mL and the specific activity was 
156.71GBq/umol. 
4.1.5 Metabolite-corrected (R)-[11C]verapamil arterial input function 
Following administration of VPM a number of radio-metabolites are formed on 
the timescale of a 60 minute scan.  Luurtsema et al. (Luurtsema et al. 2002) 
referred to these as high-performance liquid chromatography metabolites 
(HPLC) and polar metabolites, reflecting their partition by a solid phase 
extraction cartridge.  The HPLC metabolites retained on the cartridge were 
eluted and analysed by HPLC (Shimadzu Prominence HPLC, instrument control 
and data acquisition Shimadzu Lab Solutions version 1.11 SP1). The polar 
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metabolites are not retained on the cartridge because of their polarity and they 
are therefore lost and not accounted for. We have developed an in-house 
method based on in-line solid phase extraction and HPLC that avoids sample 
acidification and exposure to atmosphere or vacuum where there is potential for 
loss of polar metabolites (assumed to be [11C]-formaldehyde [11C]-formate and 
[11C]-bicarbonate, all three possible polar metabolites are volatile at acidic pH). 
This in-house method ensures capture of these polar metabolites and allows for 
them to be accounted for. 
4.1.6 Scanning protocol 
The protocol aimed to scan subjects with VPM on the same day whenever 
possible with a two and a half hour break out of the camera between scans. In 
all subjects, a six minute [15O]H2O scan to measure regional cerebral blood flow 
(rCBF) was performed (reported in (Walker et al. 2012)), followed ten minutes 
later by a 60 minute VPM scan to assess Pgp function. For each scan [15O]H2O 
was administered as an intravenous bolus over 15 seconds and VPM was 
administered as an intravenous bolus over 20 seconds. The pharmacoresistant 
patients and healthy controls underwent a second set of [15O]H2O and VPM 
scans on the same day 60 minutes after a 30 minute intravenous infusion of 2 or 
3mg/kg TQD (Figure 4). The seizure-free mTLE patients also underwent a 
second set of [15O]H2O and VPM scans on the same day to assess test-retest 
reproducibility but did not receive TQD. The injection doses for the baseline 
scans in pharmacoresistant, seizure-free patients and healthy controls were 535 
± 37 MBq, 543 ± 41 MBq and 559 ± 23 MBq, respectively as well as 552 ± 48 
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MBq and 535 ± 63 MBq for pharmacoresistant patients and healthy controls for  
all the blocking scans. 
 
 
 
Figure 4: Scanning protocol of [15O]H2O and VPM PET scans 
 
Initially a dose of 2 mg/kg TQD was administered to pharmacoresistant patients 
based on previously published data (Wagner et al. 2009). To prove our basic 
assumption about partial Pgp inhibition increasing the difference between areas 
of Pgp overactivity and normality, we scanned a further seven 
pharmacoresistant patients and six healthy controls with 3 mg/kg TQD (Kuntner 
et al. 2010). Baseline- and inhibitor-scans were acquired in fixed order because 
of the long half- life of TQD (18-36 hours). 
The dynamic 3D acquisition in list mode lasted 60 minutes for the VPM-PET 
scan and was reconstructed into 28 frames, a variable background frame 
followed by 6 x 5 seconds, 5 x 10 seconds, 3 x 30 seconds, 3 x 60 seconds, 3 x 
120 seconds, 6 x 300 seconds and 2 x 600 seconds. 
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4.1.7 Image reconstruction 
4.1.7.1 Image reconstruction for regional analysis 
The images were reconstructed using ordinary Poisson (OP)-OSEM with 16 
subsets and ten iterations. The transmission scan, acquired after the emission 
scan, was segmented and co-registered to the first ten minutes of emission data 
in order to correct for head motion prior to use in attenuation and scatter 
corrections (Anton-Rodriguez et al. 2010). 
4.1.7.2 Image reconstruction with motion correction for parametric images 
The VPM-PET images for the voxel-based analysis were reconstructed using 
OP-OSEM with resolution modeling (RM-OP-OSEM) (Sureau et al. 2008) with 
16 subsets and 20 iterations. To correct for head motion a frame-by-frame 
motion correction approach was used (Anton-Rodriguez et al. 2010): 1) the 
transmission scan was co-registered to non-attenuation corrected VPM-PET 
image from the first 6 minutes of the dynamic scan using the software Vinci 
(version 2.55). 2) The whole dynamic scan was then reconstructed without 
attenuation correction into 28 frames. 3) Each frame was co-registered to the 
reference frame using the software Vinci and the individual transformation 
matrices were saved. 4) The transformation matrices were applied to co-
registered transmission scan (in reference frame space) to move the 
transmission scan in individual frame space. 5) The whole dynamic scan was 
reconstructed using the transmission scan in individual frame space with 
attenuation and scatter corrections. 6) The transformation matrices were then 
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applied to individual reconstructed dynamic frames to co-register individual 
frames into reference frame space. 
4.1.8 PET data correction  
4.1.8.1 Attenuation 
Attenuation is the loss of true coincidences detection events, due to photons 
being absorbed within the body or being scattered out of the detector field of 
view. Those photons may interact with the body; then the photons are scattered 
or/and absorbed by the body causing the true emission to be attenuated. Then 
any signal measured will be lower than expected. The loss of true coincidence 
event detection due to attenuation in PET imaging can range between 50 to 
95%, especially in a large person. The reconstructed image is affected 
increasing noise, artefacts and distortion. The most accurate attenuation 
correction methods are based on measured transmission scans acquired before, 
during or after the emission scan (Kuhl et al. 1966).  Alternatively, methods 
using segmented areas can compensate for photon attenuation in reconstructed 
images (Bailey 1998). In PET the correction for attenuation is exact, as 
attenuation is independent of the origin of the annihilation along a LOR. In other 
words, the probability of transmission for a pair of annihilation gamma rays 
travelling on a particular LOR, can be determines as the ratio of the number of 
gamma rays counted in the LOR from the transmission source with and with 
attenuation object in place. The main advantage of attenuation correction is an 
improved anatomic delineation and the ability to quantify tracer uptake. 
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4.1.8.2 Scatter  
The scatter event is originated from a single annihilation, but one (or both) 
photons change its trajectory while they are crossing the body or within the 
detector space. If the photon is registered by the detection system, the event 
collected does not have the information of the annihilation point. The problem is 
that the scatter events in some systems cannot be distinguished electronically 
from true events. The events together with the true events are used to 
reconstruct the PET image, resulting in a low contrast image with an 
overestimation of activity concentration. The sensivity to scattered coincidences 
is greater in 3D mode than in 2D mode and therefore accurate scatter 
corrections are required. The commonly used scatter correction method for 
modern PET estimates scatter events based on simulation, such as Watson 
(Watson 1997; Watson 2000). The algorithm uses the attenuation map obtained 
from a transmission scan together with the emission data and a model of the 
scanner geometry and detector systems to calculate the percentage of photons 
falling on each detector using the Klein-Nishina formula (Klein and Nishina 
1929). The Klein-Nishina formula gives the differential scattering cross-section 
as a function of scattering angle. Generally this methods are highly accurate but 
if the activity is outside the field of view these methods starts to fail and more 
complete treatments of scatter which are more time consuming can be used 
(Markiewicz et al. 2007). 
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4.1.8.3 Random correction 
Depending on the length of the timing window, there is a probability that two 
single photons originated from two different annihilation points can be measured 
in coincidence in a particular LOR. This event is referred as “random”. The 
created event does not include useful information about the radio tracer 
distribution within the body. The distribution of random coincidences is fairly 
uniform across the field of view, causing an incorrect isotope concentration if not 
corrected. Random events can be measured by introducing the delayed 
coincidence window (e.g. many times longer than the coincidence time window). 
The random coincidence events can be estimated using the coincidence events 
recorded during the delayed time window. After estimating the random events 
using the delayed time window, the random events can either be subtracted 
from the prompt events or more optimally be taken into account during image 
reconstruction (Yamamoto et al. 1986; Brasse et al. 2005).  
4.1.8.4 Normalisation correction 
Detectors in the PET scanner vary in their manufacture and performance. These 
variations lead to differences in the relative sensitivity between detectors and 
subsequently leading to different sensitivity for each LOR.  This difference in 
sensitivity is accounted for by scanner normalisation.  Normalisation coefficient 
can be measured by two methods: direct normalisation and component-based 
normalisation. The direct normalisation measures the normalisation coefficient 
by calculating the sensivity along each LOR. This is preformed by exposing the 
detectors to a rotating source. The difference between the expected count rate 
and detected count rate can represent the detector sensitivity. Component 
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based normalisation splits the normalisation coefficient into a few components. 
Each of the components is calculated as the final normalisation coefficient 
(Defrise et al. 1991; Oakes et al. 1997). 
4.2 MAGNETIC RESONANCE IMAGING 
PET allows the imaging of functional properties in the living tissue, whereas 
other modalities (CT/MRI) provide structural information at significantly higher 
resolution and better image quality (Turkheimer et al. 2008). Magnetic 
resonance imaging (MRI) is commonly used synergistically in PET studies to 
allow both anatomic and functional correlation. Fusion between functional and 
structural images is made practical by co-registering the two image modalities. 
MRI uses the magnetic properties of hydrogen and its interaction with both a 
large external magnetic field and radiowaves to produce highly detailed images 
of the human body. The human body primarily consists of fat and water which 
have many hydrogen atoms (approximately 63% of hydrogen atoms). The 
hydrogen atom has only one proton and consequently possesses a magnetic 
moment allowing its use for magnetic resonance imaging. The basis of MRI is 
the directional magnetic field, or moment, associated with charged particles in 
motion. Nuclei containing an odd number of protons and/or neutrons have a 
characteristic motion or precession. Because nuclei are charged particles, this 
precession produces a small magnetic moment. When a human body is placed 
in a large magnetic field, many of the free hydrogen nuclei align themselves with 
the direction of the magnetic field. To obtain an MR image of an object, the 
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object is placed in a uniform magnetic field of 0.5-3 Tesla. As results, the objects 
hydrogen nuclei align with the magnetic field and create a net magnetic Moment 
4.2.1 MRI acquisition 
For all subjects, a T1-weighted MRI brain scan was acquired on a 3 Tesla GE 
Excite II scanner (General Electric, Waukesha, Milwaukee, WI, USA). Standard 
imaging gradients with a maximum strength of 40mTm-1 and slew rate 150 Tm-
1s-1 were used. All data were acquired using an eight-channel array head coil for 
reception and the body coil for transmission. 
4.3 IMAGE ANALYSIS 
The dynamic image set, describing the uptake and subsequent wash-out of the 
tracer following intravenous injection, and the arterial plasma input function, 
describing the kinetic processes in the tissue, can be used to derive regional 
parameters such as the transport rate constant from blood to tissue, K1, the 
efflux rate constant k2 and the ratio of radioactivity concentration in tissue to that 
of plasma at equilibrium (Innis et al. 2007). These parameters are derived via 
modelling techniques. A tracer kinetic model provides the basis for operational 
equations for estimates of these physiological parameters form the acquired 
data (Gunn et al. 2001). The essential underlying assumption is that the 
observed time course of tissue radioactivity is the convolution of the arterial 
input and tissue response function which describes the physiological process 
under study at each voxel. 
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4.3.1 Compartment model 
Compartment models are the commonest form of a tracer kinetic model used in 
PET (Gunn et al. 2001). A compartment is a volume within which the tracer 
rapidly becomes uniformly distributed. In order to interpret the observed PET 
data over time, we assume there are physiologically separate pools of tracer 
substances as “compartments”.  A model which is too complex results in 
parameter estimates with large variances. In practice, simplified models and 
operational equations are developed in which the number of compartments are 
reduced by grouping them unto functional compartments that contain 
substructures for which no or only partial information is provided. The number, 
definition and interrelationship of compartments in a compartmental model are 
developed from knowledge of the biological properties of the radiotracer in 
question. 
4.3.1.1 Single tissue compartment model 
It has been shown that the single tissue compartment model adequately 
describes the kinetics of VPM (Lubberink et al. 2006). Hereby, the function of 
Pgp is measured as decrease in K1 as its entry into the brain is blocked (Kannan 
et al. 2009). Pgp is situated in the lipid bilayer (Figure 5) and captures 
substrates before they enter the intracellular compartment. Therefore, if Pgp 
captures all of the substrate while in transit through the membrane its effect is 
entirely on K1. However, if some of the substrate escapes and has time to 
interact with the intracellular milieu, and if there is an efflux from the cell later, 
Pgp will both decrease K1 and increase k2 (Kannan et al. 2009). 
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Figure 5: The single input, single tissue compartment model. 
K1 is the transport rate from blood to brain and k2 is the transport rate from brain to 
blood. The figure is from Kannan et al. (Kannan et al. 2009).  
The single tissue compartment model is the simplest compartment model and 
only has one tissue compartment. The first compartment is the arterial blood. 
From arterial blood, the radiotracer passes into the second compartment, known 
as the free compartment. Data obtained by PET camera are a summation of 
these compartments. The parameters can be estimated by fitting the model to 
measure PET data with arterial radioactivity concentrate as input function. The 
arterial radioactivity concentration must be measure separately from PET data 
acquisition (Watabe et al. 2006).  
4.3.2 Region of interest analysis 
Cerebral region of interests (ROIs) can be produced either manually or 
automatically. The manual delineation requires an experienced operator to draw 
the ROI on the raw T1 MR image. The procedure is time consuming, and gives 
rise to observer bias and partial volume effect. Alternatively, fully automatic ROI 
definition is reproducible and comparable with manual intervention. There are 
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currently a few fully automated methods for cerebral ROI definition. Babalola et 
al (Babalola et al. 2009) compared four different automated methods of 
segmenting subcortical brain structures and concluded that brain atlas based 
labelling and active appearance modelling are the most successful methods 
against the gold standard manual delineation. Predefined brain atlases are 
required for atlas based ROI labelling serving as prior anatomical knowledge of 
the brain. Typically a brain atlas is created in a template space (e.g. Montreal 
Neurological Institute (MNI) space). To register the brain atlas from template 
space to individual space MRI normalisation is necessary. A template MR image 
can be normalised into individual MR space and the non-linear transformation 
can be applied to the brain atlas to move the atlas into individual space. Three 
steps are usually required to create individual anatomical ROIs for the PET 
analysis: 
a. Segmentation of MR images to separate components of gray 
matter (GM), white matter (WM) and cerebrospinal fluid (CSF). 
b. Because the brain atlas is commonly generated in MNI space the 
brain atlas has to be registered into an individual MRI space to be 
used. The procedure involves non-rigid registration and is 
commonly referred to a normalisation. 
c. MRI-PET registration. After the ROI definition those ROIs should 
be moved into PET space for PET data analysis. This is performed 
through MRI-PET image co-registration. Since this is within subject 
registration, it is also an affine rigid body registration. 
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4.3.2.1 MR Image segmentation 
Normal MRI brain image without the skull can be generally classified into three 
main tissue components: GM, WM and CSF. The MR Image segmentation can 
be generally divided into two main categories: Structural segmentation and 
statistical segmentation. There are many structural based segmentation 
methods proposed in the literature, such as region growing and edge detection 
but they are generally not thought to be very robust. Statistical approaches 
classify tissue classes based on the intensity distribution of the image (i.e. 
histogram). The simplest method is to threshold the image to segment different 
tissue types. However, if a hard threshold is chosen, it is likely to be inaccurate. 
Several conditions can make the separation of statistical brain segmentation 
worse because the spatial information is not taken into account, which requires 
the brain image to be well defined with low noise level and higher spatial 
resolution. To achieve this efforts have been spent to correct for head motion 
artefact and non-uniformity of the image. 
4.3.2.2 MRI image normalisation 
MR image registration can be divided into within-subject registration and 
between–subject registration. Within-subject registration is simply applied to 
register MR images from the same subject but acquired under different 
conditions (e.g. different positions, scanner, MR sequences or image 
modalities). Usually rigid-body registration (three translations, three rotations) is 
performed to align two brain MR images because they are from the same brain. 
However, between-subject image registration will require non-rigid image 
registration which is often referred to as spatial normalisation. The aim of the 
125 
 
MR image normalisation is to map once space to another space. An affine 
transformation including 12 parameters is used (three rotations, three 
translations, three shears and three zooms). Rigid-body transformation (three 
rotation and three translations) can be seen as a simplified form of affine 
transformation. For the analysis we used statistical parametric mapping (SPM, 
http://www.fil.ion.ucl.ac.uk/spm/software/spm8, Wellcome Trust Centre for 
Neuroimaging, London, UK). This normalisation algorithm starts with a 12 
degree of freedom affine registration to initialise the normalisation process, 
followed by an iterative non-linear registration which estimates the non-linear 
warping field (or deformation field) from template MR image to target MR image. 
The affine transformation and non-linear deformation field define the mapping 
information from one MR space (i.e. brain atlas template MR) to another MR 
space (i.e. individual MR). 
4.3.2.3 Multi-modality Image Registration using MR images 
After generating the brain ROIs in individual MR space, the next step is to 
register those ROIs into PET space. Because this process is a within subject 
registration rigid body registration is appropriate. As PET and MR are images 
provide functional and anatomical information they are hugely different from 
each other. An accurate MRI-to-PET co-registration can be achieved by 
maximizing the normalized mutual information. The MRI-to-PET co-registration 
used in this study is discussed in the next chapter 4.3.2.4 for the ROI analysis 
and in chapter 4.3.3.2 for the voxel-based analysis. 
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4.3.2.4 Cerebral region of interest generation 
We used a maximum probability brain atlas (Hammers et al. 2003),  to define 
ROIs on the 3T T1-weighted MR images. First the brain was extracted from the 
MR image using the FMRIB Software Library (FSL)’s BET toolbox (Smith 2002). 
Secondly, the extracted brain was segmented in to GM, WM and CSF with 
correction for spatial intensity variations across the image (bias correction). 
Thirdly, the GM maps were thresholded at 50% to generate a GM mask. 
Fourthly, an MR template was normalised (using non-linear registration) to the 
bias corrected MR image using SPM 8 (Ashburner and Friston 1997). Finally, 
the normalised brain atlas was multiplied by the GM masks to generate GM 
ROIs. 
The co-registration from MRI space to VPM-PET space was performed via the 
[15O]H2O scan using SPM 8. First, the bias corrected MR image was co-
registered to a summation image of the whole dynamic [15O]H2O scan 
smoothed with a 4-mm Gaussian filter and the transformation was saved (TX1). 
Second, a summation image of the first ten minutes of the dynamic VPM-PET 
scan, assuming to have negligible head motion, was also smoothed with a 4-mm 
Gaussian filter. Third, the smoothed VPM-PET image was co-registered to the 
smoothed [15O]H2O scan and the transformation saved (TX2). Fourth, the 
transformation from the MRI space to VPM-PET space was calculated by 
combining the two transformations (TX=TX1xTX2-1). Finally, the GM ROIs were 
transferred into VPM-PET space by applying the combined transformation (TX) 
and nearest neighbour interpolation. 
127 
 
Tissue time-activity curves of each ROI were generated by overlaying these 
ROIs to the dynamic PET using Tacstats (in-house software). 
All GM ROIs excluding the ventricles were combined to generate the whole 
brain GM ROI. Eight additional ROIs were selected. Six different temporal lobe 
ROIs (lateral anterior temporal lobe, inferior temporal gyrus, occipitotemporal 
gyrus., parahippocampal and ambient gyrus, posterior temporal lobe, anterior 
superior temporal gyrus) and the extratemporal control ROI (superior parietal 
gyrus) as well as cerebellum and whole brain. The abbreviations for the ROIs 
are as follows: Ant TL lat, lateral anterior temporal lobe; Inf-Mid TL, inferior 
temporal gyrus; Occ TL, occipitotemporal gyrus.; ParaH, parahippocampal and 
ambient gyrus; Post TL, posterior temporal lobe; Sup TL ant, anterior superior 
temporal gyrus; Sup PL, superior parietal gyrus.  
4.3.3 Voxel based Analysis 
4.3.3.1 Statistical Parametric Mapping 
SPM is generally used to identify functionally specialised brain responses and is 
the most prevalent approach to characterising functional anatomy and disease-
related changes. It does this characterisation by treating each voxel separately 
and by performing voxel-wise statistical analysis in parallel creating an image of 
statistics. SPM refers to the construction of spatially extended statistical 
processes to test hypotheses about regionally specific effects. SPMs are image 
processes with voxel values that are, under the null hypothesis, distributed 
according to a known probability density function (usually Gaussian). These 
statistical parametric maps, are 3D projections of statistical functions that are 
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used to characterise significant regional brain differences in imaging 
parameters. Corrections for the implicit multiple comparisons, when making 
inferences based upon the statistical parametric map are confounded by spatial 
correlations. The theory of Gaussians fields is used to provide values that are 
corrected for the brain volume analysed (Friston 1997). 
4.3.3.2 Pre-processing for SPM Analysis 
All the image pre-processing steps were performed using the SPM 8 software 
(http://www.fil.ion.ucl.ac.uk/spm/software/spm8, Wellcome Trust Centre for 
Neuroimaging London, UK). First, the MR images from all subjects were 
segmented into GM, WM and CSF using the New Segmentation option 
(Ashburner and Friston 2005). During this segmentation fast diffeomorphic 
registration algorithm (DARTEL) parameters were also saved (Ashburner 2007). 
Second, a DARTEL template was created using the pharmacoresistant and 
seizure-free mTLE patients as well as the healthy controls. This DARTEL 
template was made symmetrical and centered following the method by Didelot 
et al. (Didelot et al. 2010) and normalized to MNI space. Third, summation VPM-
PET images were smoothed with a 4mm Gaussian filter and co-registered with 
the corresponding native space MR images which was skull stripped and 
smoothed with a 6-mm Gaussian filter. Fourth, the co-registered VPM-PET 
images and the individual gray matter probability maps (from the previous 
segmentation step) were right-left reversed, providing the flipped counterpart. 
Fifth, the unflipped and flipped gray matter probability maps were normalised to 
the symmetric and centered DARTEL template. The normalisation parameters 
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were saved and applied to the co-registered unflipped and flipped VPM-PET 
images, resulting in all VPM-K1 maps being in MNI space. Because of spill in 
from the CP into the neighbouring hippocampus (Figure 6), the CP, the region 
with the highest VPM uptake, was individually masked out of the VPM-K1 maps 
using individual threshold values (see for further details in following paragraph 
“Manual delineation of CP and generation of CP mask”). 
To normalize the effect of the different metabolism between the three groups, 
ratio images were created by first dividing the mean gray matter whole brain of 
the VPM-K1 of all patients and controls by the individual mean gray matter whole 
brain VPM-K1 and then multiplying the individual masked VPM-K1 parametric 
maps with this value. The masked VPM-K1 maps and ratio images were finally 
smoothed using an isotropic 8-mm Gaussian filter. These images were then 
used for the voxel-based SPM analysis which was restricted to voxels belonging 
to the gray matter by applying the gray matter probabilistic map thresholded at x 
> 0.3 to the symmetric and centered DARTEL template  (see generation of Gray 
matter mask in next paragraph). 
4.3.3.3 Generation of Gray matter mask 
The voxel-based SPM analysis was restricted to voxels belonging to gray matter 
by applying a mask obtained by thresholding at x > 0.5 the probabilistic map of 
GM within the SPM distribution (/spm8/apriori/gray.nii). This mask was then 
multiplied with the invert of the CP mask (creation of CP mask described in 
chapter below “Generation of CP”) to mask out voxel belonging to the CP 
contaminating into surrounding ROIs such as the hippocampus. This gray matter 
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mask was then applied to the SPM analysis, to sample the gray matter of the 
parametric images and remove the CP spill over into regions around it. 
4.3.3.4 Generation of choroid plexus mask 
The hippocampus cannot be correctly analyzed quantitatively in VPM-PET 
images due to a serious spill-over of activity (partial volume effects) from the 
adjacent CP, the region with by far the highest signal intensity (Figure 6).  
 
Figure 6: T1-weighted MR image and VPM-PET summation image 
The MR image is on the left and the PET summation image is on the right. The images 
show ROIs in the temporal lobe. The arrow indicates the spill in from the CP in the 
adjacent hippocampus. 
 
Therefore the ROI CP was masked out manually using the FMRIB Software 
Library (FSL, Release 5.0, 2012, The University of Oxford). We first created a 
binary mask of the CP applying individual thresholds to smoothed VPM-K1 maps 
using an isotropic 4 mm Gaussian filter (figure 7 b) and in a second step this 
binary mask was inverted and in a third step the inverted CP mask was 
multiplied to the original VPM-K1 maps (figure 7 c) so that the CP is masked out 
on the original VPM-K1 maps. 
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Figure 7: Generation of CP mask on VPM-PET Images 
Picture (a) shows the high VPM upatake in the CP on a VPM PET summation image. 
Picture (b) shows a binary CP mask. Picture (c) illustrates the CP mask on VPM PET 
summation image. 
4.4 STATISTICAL ANALYSIS 
4.4.1 Statistical Analysis for region of interest analysis 
The analyses were performed using SPSS 19.0 (SPSS Inc., Chicago). We used 
independent t-tests to compare the means between two groups. To compare 
multiple groups, we used analysis of variance (ANOVA), calculated Pearson 
correlation coefficients for normally distributed data, or Spearman's rank-order 
correlations otherwise. For pharmacoresistant mTLE patients only, we 
performed correlation analyses of VPM brain uptake at baseline with seizure 
frequency, for both whole brain and temporal lobe, the focus region for all mTLE 
patients. Differences were considered to reach statistical significance when p 
<0.05. 
a) b) 
c) 
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4.4.2 Statistical Analysis for voxel-based analysis 
We used independent t-tests to compare the means between two groups. To 
compare multiple groups, we used ANOVA, calculated Pearson correlation 
coefficients for normally distributed data, or Spearman's rank-order correlations 
otherwise. For pharmacoresistant patients only, we performed correlation 
analyses of VPM brain uptake at baseline with seizure frequency, for both whole 
brain and ipsilateral hippocampus, the focus region for all mTLE patients. The 
analyses were performed using SPSS 19.0. All comparisons were 2-tailed 
unless otherwise specified. Differences were considered to reach statistical 
significance when p <0.05. We compared voxel-by-voxel parametric VPM-PET 
images of pharmacoresistant to seizure-free mTLE patients and healthy controls 
using factorial design analysis within SPM 8, considering age and gender as 
confounders and we used group and laterality as between-subjects factors 
assuming unequal variances between groups. The analysis was restricted to 
voxels belonging to grey matter by applying an additional probabilistic map with 
a threshold of 30% grey matter probability. Significance for activations in whole 
brain for areas without a-priori hypothesis was set at p<0.001. Based on a-priori 
hypothesis that P-glycoprotein is altered in the temporal lobes, activations within 
temporal lobe regions are considered significant for p<0.01 (uncorrected). In 
view of the smaller size of the hippocampus, we report changes for this region at 
p<0.05. 
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4.5 RECRUITMENT 
4.5.1 MTLE Patients 
We recruited 16 pharmacoresistant (PR, six male, median age 39.5 years, range 
18-56) and eight seizure-free (SF) mTLE patients (three male, median age 45 
years, range 23-53) with unilateral hippocampus sclerosis as well as three 
pharmacoresistant epilepsy patients with focal cortical dysplasia (two male, 
median age 37, range 24-62) between October 2008 and November 2011, from 
consultant-led outpatient clinics at the National Hospital for Neurology and 
Neurosurgery, a tertiary, nation-wide referral centre with an additional local 
catchment area of three million people in North London. Pharmacoresistance 
was defined as on-going seizures despite two tolerated and appropriately 
prescribed AEDs (Kwan et al. 2010). Seizure-free mTLE patients had active 
epilepsy for at least three years, but were free of all seizures on AEDs for at 
least one year prior to PET scanning. Seizure semiology and onset was 
concordant with side of HS, as verified with prolonged and repeated EEG 
recordings when epilepsy was active. Pharmacoresistant mTLE patients were 
matched to seizure-free mTLE patients according to gender, age and 
antiepileptic drugs. The numbers of patients needed for the study were based on 
power calculations using standard formulae (Dupont and Plummer Jr 1990). Six 
patients are usually required to allow a detailed analysis of the validity and 
reproducibility of radiotracers (Hammers et al. 2007a). The published test-retest 
variability of (R)-[11C]verapamil brain uptake is 5% (Lubberink et al. 2006). For 
comparisons of groups with assumed unequal variance, group sizes of 13 
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patients with pharmacoresistant mTLE and six seizure-free mTLE control 
patients are sufficient to detect a moderate effect size (dt=0.7, at a=0.05, two-
tailed and b=0.08). Assuming a failure rate of 20%, we aimed to recruit at least 
16 pharmacoresistant and eight seizure-free mTLE patients, and 16 healthy 
controls for inclusion in our study (Figure 8). 
4.5.1.1 MTLE Patients’ inclusion/exclusion criteria  
The inclusion criteria included, males and females aged 18−60, diagnosis of 
temporal lobe epilepsy (from history, clinical examination, EEG and imaging 
data and other data if available, e.g. video−EEG with ictal recordings, 
neuropsychology), currently treated with AEDs known to be a substrate for Pgp 
or multidrug resistance protein-1 (MRP1), willing and able to give informed 
consent. Exclusion criteria included relevant medical, particularly neurological, 
condition other than temporal lobe epilepsy (e.g. subjects with a history of stroke 
will have abnormal brain anatomy which would interfere with analyses), notably 
history of alcohol or benzodiazepine abuse, high-quality volumetric MRI 
identified structural abnormalities other than hippocampal sclerosis or prolonged 
EEG recordings (ictal video-EEG telemetry for pharmacoresistant mTLE) 
identified other than mesio-temporal seizure-onset, standard MRI exclusion 
criteria, participation in another trial involving medicinal products in the last three 
months or in another procedure involving ionising radiation in the past year, 
inability to give informed consent or pregnancy.  
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4.5.2 Healthy controls 
Seventeen healthy controls (eight male, median age 45 years, range 35-55) 
were recruited locally by newspaper advertisement and posters displayed in the 
community. Males and females were included aged 35−55 (age limits were 
chosen in order not to expose younger persons to the radiation dose, Figure 8). 
4.5.2.1 Healthy controls inclusion/exclusion criteria 
Subjects were required to be in good health on the basis of medical history, vital 
signs, physical examination and laboratory investigations. Exclusion criteria 
included relevant medical, particularly neurological, condition, notably history of 
alcohol or benzodiazepine abuse, regular or recent intake of medication known 
to be a substrate (e.g.: amiodaron, digoxin, steroids, loperamide, colchicine, 
amytriptyline, b-blockers, erythromycin, rifampicin) or inhibitor (e.g.: CsA, 
quinidine, ketoconalzole) for Pgp or MPR1, standard MRI exclusion criteria, 
participation in another trial involving medicinal products in the last three months 
or in another procedure involving ionising radiation in the past year, inability to 
give informed consent, or pregnancy. Controls were matched for age and 
gender with the patients. Prior to PET scanning, subjects were asked to refrain 
from using alcohol with the preceding 24 hours. 
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Figure 8: Flowchart of subjects’ recruitment and selection process
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The study was approved by the London – City Road and Hampstead Ethic 
Committee previously known as Moorfields and Whittington Research Ethics 
Committee then East Central London REC 1 and by the United Kingdom 
Administration of Radioactive Substances Advisory Committee (ARSAC).  All 
subjects provided written informed consent after receiving written and verbal 
explanation of the study. 
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CHAPTER V  (R)-[11C]VERAPAMIL PET AT 
BASELINE IN PHARMACORESISTANT AND SEIZURE-
FREE MTLE PATIENTS VERSUS HEALTHY CONTROLS 
– REGION OF INTEREST ANALYSIS  
5.1 BACKGROUND 
 Pgp has been shown to contribute to pharmacoresistance in rodent epilepsy 
models: (i) pharmacoresistant rats exhibit higher endothelial Pgp-expression in 
limbic regions ipsilateral to the seizure focus compared to seizure-free rat (Volk 
and Loescher 2005), (ii) seizures transiently increase Pgp-expression at the 
BBB (Bankstahl and Löscher 2008),  (iii) increased Pgp-expression is 
associated with decreased brain concentration of Pgp-substrate AEDs (van Vliet 
et al. 2007) and (iv) Pgp-inhibition enhances AED efficacy (Brandt et al. 2006). 
Human studies showed increased Pgp-expression at the BBB, ex-vivo in 
epileptogenic tissues removed at surgery from patients with pharmacoresistant 
epilepsy (Tishler et al. 1995; Sisodiya et al. 2002; Aronica et al. 2004) or post-
mortem (Liu et al. 2012). The functional relevance of this increased expression 
in humans cannot be assessed ex-vivo. Using in-vivo positron emission 
tomography (PET) experiments with the Pgp-substrate (R)-[11C]verapamil 
(VPM), we studied  pharmacoresistant and seizure-free patients with mesial 
temporal lobe epilepsy (mTLE) due to unilateral hippocampal sclerosis (HS) as 
well as healthy controls, testing the hypotheses that Pgp-activity is higher in 
pharmacoresistant than seizure-free mTLE patients and healthy controls, and 
that Pgp overactivity is most pronounced in the epileptic focus. 
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5.2 METHODS 
The common methods are described in Chapter 4, and the specific methods for 
this study are described here. 
5.2.1 Subjects 
Seventeen healthy controls and 16 pharmacoresistant and eight seizure-free 
mTLE patients with unilateral HS were included in this study.  Data from four 
healthy controls and two pharmacoresistant mTLE patients were excluded due 
to technical problems: failure to sample arterial blood for input function (n=2); 
hardware failure (n=2), excessive head motion (n=1), claustrophobia (n=1). 
Therefore, 14 pharmacoresistant mTLE patients, eight seizure-free mTLE 
patients and 13 healthy controls were included in the data analysis (Figure 7).  
5.2.2 Radiochemistry  
(R)-[11C]verapamil was synthesised as previously described (refer to section 
4.1.4). 
5.2.3 PET Image acquisition 
The PET scans were performed at the Wolfson Molecular Imaging Centre, 
Manchester, UK, on the High Resolution Research Tomograph (CTI/Siemens, 
TN, USA). A 60 minute VPM-PET scan was acquired following intravenous 
bolus injection over 20 sec of 555 MBq of VPM. Arterial blood was sampled 
continuously for the first 15 minutes and discrete blood samples taken thereafter 
to measure the plasma radioactivity concentrations due to unmetabolised VPM 
for use as the input function in the kinetic modeling of the dynamic PET data 
(Lubberink et al. 2006). Seizure-free mTLE patients also underwent a second 
140 
 
scan on the same day in order to assess test-retest reproducibility (calculated as 
the absolute difference between test and re-test scans, divided by the average 
of the two scans). A 6 minute transmission scan was acquired at the end of the 
dynamic VPM scan using a 1.1-GBq 137Cs single photon (662 keV) point 
source for attenuation and scatter corrections. 
5.2.4 MRI data acquisition 
For all subjects, a T1-weighted MRI brain scan was acquired on a 3-Tesla GE 
Excite II scanner (General Electric, Milwaukee, WI, USA) for co-registration with 
the PET images, as previously described in section 4.2.1. 
5.2.5 PET data analysis  
The dynamic VPM-PET data were reconstructed and corrected for head motion 
as described in section 4.1.7 and 4.1.8 (Anton-Rodriguez et al. 2010). For the 
ROI analysis, regions were defined automatically using a maximum probability 
brain atlas as previously described in section 4.3.2. 
Ratios of VPM-K1 values were calculated between a reference region (parietal 
cortex) and target regions.  
The asymmetry index (AI) was calculated as: 
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All image processing steps were performed in SPM 8, Wellcome Trust Centre 
for Neuroimaging London, UK as previously described in section 4.3.2.  
5.2.6 Statistical Analysis 
The statistical analyses were performed using SPSS 19.0 as previously 
described in section 4.4.1 and the level of significance was set at p<0.05.  
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5.3 RESULTS 
Fourteen pharmacoresistant mTLE patients (six men, median age 38 years, 
range 18-56), eight seizure-free mTLE patients (three male, median age 45 
years, range 23-53) and 13 healthy controls (seven men, median age 45 years, 
range 35-55) were studied for comparison. The pharmacoresistant mTLE 
patients had seizures (median: nine focal seizures with impaired 
awareness/month; range: 1-30) despite current treatment with a median of two 
AEDs (range: 1-4) and trials of a median of five AEDs (range 2-12) in the past. 
The eight seizure-free mTLE patients had been seizure-free for at least 12 
months (median: 3.5 years; range: 1-12) and were taking a median of two AEDs 
(range: 2-3) at the time of scanning, with a median of three AEDs (range: 1-6 
AEDs) tried previously. Patients’ characteristics are summarized in Table 2. 
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Table 2: Clinical data of pharmacoresistant and seizure-free mTLE patients 
Pat 
No 
Gender/ 
Age  
(yrs) 
Age at 
onset of 
epilepsy  
(yrs) 
Interval 
last CPS  
(PR:days 
SF:yrs) 
Duration 
of  
epilepsy 
(yrs) 
Seizure 
frequency 
/month 
Current AEDs  
(dose: mg/day) 
Hippo 
volume 
(Ratio) / 
laterality) 
Pharmacoresistant patients 2mg/kg TQD 
1 M/43 5 21 38 2 PHT(325),CLB(20), 47 /L 
2 F/38 18 12 20 12 
VPA(1500),LEV(2000) 
CBZ(1000) 
ZON(150),CLB(10) 69 / R 
3* F/56 11 2 45 18 LTG(200),PGB(300), 76 / R 
4 M/30 19 6 11 15 
LEV(750),OXC(600) 
CLB(20) 63 / L 
5 M/56 1 3 55 2 
VPA(1600),CBZ(1200) 
TPM(150), CBZ (400) 65 / L 
6* F/50 12 4 38 8 PHT(350),LTG(100) 82 / R 
7* F/18 2 6 16 10 LEV(3000),TPM(200)  70 / L 
Pharmacoresistant patients 3mg/kg TQD 
8 F/52 4 2 48 8 LTG(500),PHT(225)  74 / R 
9 F/27 8 6 19 10 CLB(20)  63 / L 
10* M/51 35 60 16 2 LEV(3000),CBZ(1600) 83 / R 
11* F/20 15 4 5 10 
LEV(2250),CBZ(400), 
LTG(275)  76 / L 
12 M/38 2 28 36 1 VPA(1000),LTG(200)  63 / L 
13 F/37 33 1 4 30 LEV(2000),LTG(250)  58 / L 
14 M/24 11 3 13 4 LEV(2000),CBZ(1200)  78 / L 
Seizure-free patients 
1 F/50 25 3 22 n.a. LTG(400),LEV(2000) 73/R 
2 M/39 23 2 14 n.a. CBZ(800),LEV(2000) 90/L 
3 F/42 18 7 17 n.a. CBZ(1600),CLB(40) 72/L 
4 F/40 17 12 11 n.a. VGB(500),CBZ(1400) 70/L 
5 F/48 5 1 42 n.a. 
PHT(450),CNZ(2), 
VPA(2000) 60/L 
6 M/53 19 4 30 n.a. 
PHT(300),LEV(1000), 
LTG(300) 79/R 
7 M/50 35 10 5 n.a. CBZ (1400),VGB(1500) 58/L 
8 F/23 1 2 20 n.a. 
LTG(50),LEV(3000), 
CLB(10) 58/R 
M, male; F, female; R, right; L, left; CPS, complex partial seizure; PR, 
pharmacoresistant patients; SF, seizure-free patients; AED, antiepileptic drug; hippo, 
hippocampus; LEV, levetiracetam; LTG, lamotrigine; OXC, oxcarbazepine; CBZ, 
carbamazepine; VPA, valproic acid; PHT, phenytoin; CLB, clobazam; PGB, pregabalin; 
TPM, topiramate; ZON, zonisamide; VGB, vigabatrin, CNZ, clonazepam;*patients who 
underwent epilepsy surgery. 
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There was no difference in age (p=0.290) and weight (p=0.319) between the two 
mTLE patient groups and the healthy controls. There was no difference in 
injected doses of VPM/kg body weight between the three groups at baseline 
(pharmacoresistant mTLE patients: 540 ± 37 MBq, seizure-free mTLE patients: 
536 ± 43 MBq, healthy controls: 558 ± 21 MBq; p=0.292). 
5.3.1 Test-retest variability 
The test-retest reproducibility (calculated as mean absolute difference) of VPM-
K1 in temporal lobe of epilepsy patients was 5.6% (n=6) for the seizure-free 
mTLE patients who underwent paired PET scans with VPM at baseline on the 
same day. There was no order effect of the time of day when the scans are 
performed, as indicated by the mean difference between test-retest scans of -
0.8% in the temporal lobe. 
5.3.2 Differences in VPM metabolism between mTLE patients and 
healthy controls  
The function of Pgp can be quantified in-vivo using standard compartmental 
models (Lubberink et al. 2006). As we administer the Pgp substrate PET tracer 
VPM intravenously, its entry into the brain is limited, and this is measured as a 
decrease in K1, the influx rate of the radiolabelled Pgp substrate. Thus, reduced 
VPM-K1 equates to higher Pgp brain-to-blood transport (Abrahim et al. 2008; 
Muzi et al. 2009). 
Metabolites of VPM are taken up into brain tissue independent of Pgp function 
(Abrahim et al. 2008) and so compromise the quantitative measurement of 
VPM-K1. To limit the effect of radiolabeled metabolites, kinetic analysis of PET 
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data was performed using a single-tissue compartment model on the first ten 
minutes of dynamic data after VPM radiotracer injection as described in section  
4.1.3  (Muzi et al. 2009).  
Ten minutes after tracer injection, the fraction of unmetabolised VPM was 
indeed higher for healthy controls (mean±s.d.: 0.69±0.08) than for both mTLE 
patient groups (p<0.001), but not different between pharmacoresistant 
(0.49±0.11) and seizure-free (0.47±0.13) mTLE patients (p=0.680, Figure 9). 
Increased VPM metabolism in epilepsy patients has previously been reported 
and this is most likely caused by AED-mediated hepatic cytochrome P450 
enzyme induction (Abrahim et al. 2008).  
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Figure 9:  Differences of VPM metabolism between the three groups 
VPM fraction in plasma is shown over 60 minutes for 13 healthy controls (HV), 8 seizure-free mTLE patients (DS) and 14 
pharmacoresistant (DR) mTLE patients before and after tariquidar (TQD). Error bars represent SEM.
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Despite minimising the effect of different VPM metabolism between controls and 
patients by only using the first ten minutes of data, we found a significant 
difference in VPM-K1 globally across all analysed brain regions. VPM-K1 values 
in whole brain were lower in healthy controls (mean ± SEM, 0.036±0.003 
ml/min/cm3) compared to pharmacoresistant mTLE patients (0.049±0.004 
ml/min/cm3; p=0.012) but not different compared to seizure-free mTLE patients 
(0.045±0.004 ml/min/cm3; p=0.138). There was no difference between seizure-
free and pharmacoresistant mTLE patients (p=0.441, Figure 10). 
 
 
 
 
 
 
 
 
Figure 10: VPM-K1 across eight brain regions and whole brain 
VPM-K1 is shown at baseline for 13 healthy controls (HC), 14 pharmacoresistant (PR) 
and eight seizure-free (SF) mTLE patients in six temporal lobe regions of interests 
(ROI) and the extratemporal ROI (superior parietal gyrus) as well as cerebellum and 
whole brain. Ant TL lat, lateral anterior temporal lobe; OccTL, occipitotemporal gyrus; 
ParaH, parahippocampal and ambient gyrus; Sup TL ant, anterior superior temporal 
gyrus; Inf-mid TL, inferior temporal gyrus; Post TL, posterior temporal lobe; Sup PL, 
superior parietal gyrus; Cer, cerebellum. Error bars represent SEM. 
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5.3.3 Differences in asymmetry index in pharmacoresistant mTLE 
At baseline seizure-free mTLE patients had significantly different AI in anterior 
temporal lobe compared to healthy controls (p= 0.30) but AI was not significantly 
different compared to pharmacoresistant mTLE patients (p=0.69). There was no 
significant difference in the AI index for any of the other brain regions for 
pharmacoresistant, seizure-free mTLE patients or healthy controls (p>0.111, 
Figure 11).  
 
 
 
 
 
 
 
 
 
Figure 11: Differences in asymmetry index of VPM-K1 at baseline 
Asymmetry index is shown at baseline for 13 healthy controls (HC), 14 
pharmacoresistant (PR) and eight seizure-free (SF) mTLE patients in six temporal lobe 
ROIs and the extratemporal ROI (superior parietal gyrus) as well as cerebellum and 
whole brain. Ant TL lat, lateral anterior temporal lobe; OccTL, occipitotemporal gyrus; 
ParaH, parahippocampal and ambient gyrus; Sup TL ant, anterior superior temporal 
gyrus; Inf-mid TL, inferior temporal gyrus; Post TL, posterior temporal lobe; Sup PL, 
superior parietal gyrus; Cer, cerebellum. Error bars represent SEM. 
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5.3.4 Frequent seizures increase Pgp activity  
In pharmacoresistant mTLE patients, VPM-K1 correlated inversely with average 
monthly seizure frequency, measured at the time of the baseline PET scan 
(correlation for whole brain: r =-0.535, p= 0.030; temporal lobe: r =-0.588, p= 
0.017; Figure 12 and 13).  There was no correlation of VPM-K1 with the interval 
of seizures before the PET scan in the pharmacoresistant mTLE patients 
(correlation for whole brain: r =0.119., p= 0.349; temporal lobe: r =0.056, p= 
0.428), duration of epilepsy (correlation for whole brain: r =-0.138, p= 0.327; 
temporal lobe: r =-0.103, p= 0.368) or age at first onset of epilepsy (correlation 
for whole brain: r =0.085., p= 0.391; temporal lobe: r =0.054, p= 0.431).  
 
 
 
 
 
 
 
 
 
 
Figure 12: Correlation of seizure frequency and VPM-K1 for whole brain 
Monthly seizure frequency is shown for the 14 pharmacoresistant mTLE patients. 
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Figure 13: Correlation of seizure frequency and VPM-K1 for temporal lobe 
Monthly seizure frequency is shown for the 14 pharmacoresistant mTLE patients. 
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5.3.5 Shorter interval of seizures to PET scan increases Pgp activity  
In seizure-free mTLE patients a shorter interval of last seizure to PET scan 
correlates with lower VPM-K1 (correlation for whole brain: r =0.627, p= 0.048; 
temporal lobe: r =0.590, p= 0.062, figure 14). No correlations were found for 
seizure-free mTLE patients with duration of epilepsy (correlation for whole brain: 
r =-0.285, p= 0.247; temporal lobe: r =-0.367, p= 0.185), or age of onset of 
epilepsy (correlation for whole brain: r =0.285, p= 0.247; temporal lobe: r =-0.22, 
p= 0.480). 
 
 
 
 
 
 
 
 
Figure 14: Correlation of interval of last seizure to PET scan and VPM-K1 
for whole brain 
Interval of last seizure to PET scan is shown for the eight seizure-free mTLE patients. 
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5.3.6 Ratios of VPM-K1 lessens dependency on VPM parent fractions 
Because of the significant difference in VPM metabolism between mTLE 
patients and controls, we calculated ratios of VPM-K1 values between a 
reference region (parietal cortex and for whole brain) and target regions. By 
taking the VPM-K1 ratios the VPM-K1 dependency on VPM fraction in plasma 
lessens (Figure 15, 16 and 17). 
 
 
 
 
 
 
 
 
 
Figure 15: Correlation of VPM-K1 with VPM fraction in plasma 
Correlation of VPM-K1 values with VPM fraction in plasma at ten minutes is shown for 
13 healthy controls (HC), 14 pharmacoresistant (PR) mTLE patients and eight seizure-
free (SF) mTLE patients. 
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Figure 16: Correlation of ratios of VPM-K1 (parietal cortex) with VPM 
fraction in plasma 
Correlation of VPM-K1 ratios (parietal cortex) with VPM fraction in plasma at ten 
minutes is shown for 13 healthy controls (HC), 14 pharmacoresistant (PR) mTLE 
patients and eight seizure-free (SF) mTLE patients. 
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Figure 17: Correlation of ratios of VPM-K1 (whole brain) with VPM fraction 
in plasma 
Correlation of VPM-K1 ratios (whole brain) with VPM fraction in plasma at ten minutes is 
shown for 13 healthy controls (HC), 14 pharmacoresistant (PR) mTLE patients and 
eight seizure-free (SF) mTLE patients. 
 
5.3.7 Baseline ratios of VPM-K1 are not different between groups 
For multiple regions of interest, there was no difference between VPM-K1 ratios 
at baseline for healthy controls and seizure-free mTLE patients (p=0.673) or 
between pharmacoresistant mTLE patients and healthy controls (p=0.308) or 
between pharmacoresistant and seizure-free mTLE patients (p=0.190, Figure 
18). 
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Figure 18: Ratios of VPM-K1 between target regions and reference region 
(superior parietal gyrus) 
Ratios between reference region (superior parietal gyrus) and target regions (6 different 
temporal lobe ROIs as well as cerebellum) are shown at baseline for 13 healthy 
controls (HC), 14 pharmacoresistant (PR) mTLE patients and eight seizure-free (SF) 
mTLE patients. Ant TL lat, lateral anterior temporal lobe; OccTL, occipitotemporal 
gyrus; ParaH, parahippocampal and ambient gyrus; Sup TL ant, anterior superior 
temporal gyrus; Inf-mid TL, inferior and middle temporal gyrus; Post TL, posterior 
temporal lobe; Cer, cerebellum. Error bars represent SEM. 
 
 
Additionally, there was no difference between VPM-K1 ratios at baseline 
normalised for global whole brain differences for healthy controls and seizure-
free mTLE patients (p=0.068) or between pharmacoresistant mTLE patients and 
healthy controls (p=0.685) or between pharmacoresistant and seizure-free 
mTLE patients (p=0.134, Figure 19). 
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Figure 19: Ratios of VPM-K1 between target regions and reference region 
(whole brain) 
Ratios between reference region (whole brain) and target regions (6 different temporal 
lobe ROIs as well as superior parietal lobe and cerebellum) are shown at baseline for 
13 healthy controls (HC), 14 pharmacoresistant (PR) mTLE patients and eight seizure-
free (SF) mTLE patients. Ant TL lat, lateral anterior temporal lobe; OccTL, 
occipitotemporal gyrus; ParaH, parahippocampal and ambient gyrus; Sup TL ant, 
anterior superior temporal gyrus; Inf-mid TL, inferior and middle temporal gyrus; Post 
TL, posterior temporal lobe; Sup PL, superior parietal gyrus; Cer, cerebellum. Error bars 
represent SEM. 
5.4 DISCUSSION 
Despite minimising the effect of different VPM metabolism between healthy 
controls and patients by using only the first ten minutes of data, we found a 
significant difference in the fraction of unmetabolised VPM, which was higher for 
healthy controls than for both mTLE patient groups, but not different between 
pharmacoresistant and seizure-free mTLE patients. Whole brain VPM-K₁ was 
lower in controls than in pharmacoresistant mTLE patients and seizure-free 
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mTLE patients but there was no difference between seizure-free and 
pharmacoresistant mTLE patients. VPM undergoes extensive metabolism and 
the peripherally-generated VPM radiometabolites pass into the brain 
independently of Pgp activity compromise quantitative VPM-K1 measurement; 
levels of such metabolites are higher in patients than controls. This is most likely 
caused by antiepileptic drug-mediated hepatic cytochrome P450 enzyme 
induction (Abrahim et al. 2008). We therefore we created individual VPM-K1 
ratios, which were normalized for global whole brain differences and to a 
reference region (parietal cortex).  These normalised ratios were then used for 
further analysis to detect regional differences between healthy controls and the 
two patient groups. However, at baseline by using the ROI analysis we could not 
detect a difference of VPM-K1 ratios between healthy controls or between 
pharmacoresistant and seizure-free mTLE patients. The difficulty is that VPM is 
a high-affinity substrate of Pgp and is therefore very effectively transported by 
Pgp at the BBB. This results in low brain uptake of this radiotracer thus making it 
difficult to elicit regional differences in cerebral Pgp function. To overcome this 
limitation, dynamic PET scans after partial blockade by Pgp modulating drugs 
such as cyclosporine A (CsA) or tariquidar (TQD) can be undertaken (Löscher 
and Langer 2010). Here, it is important that Pgp is only partially blocked as 
complete blockade results in radiotracer uptake which is only caused by passive 
diffusion and is independent of Pgp function. Furthermore, we may not have 
detected differences between the three groups because the ROI analysis is less 
sensitive than voxel-based analysis for this radiotracer with low brain uptake and 
small differences between groups. By employing voxel-based SPM analysis we 
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may improve sensitivity of statistical analysis, and elicit differences between 
pharmacoresistant, seizure-free mTLE patients and healthy controls. 
At baseline we observed an association between Pgp activity and seizure 
frequency. Pharmacoresistant mTLE patients who had frequent seizures had 
higher Pgp activity. Similarly, seizure-free mTLE patients who had shorter 
intervals of their last seizure to their PET scan had higher Pgp activity. In rodent 
models of TLE, Pgp expression increases significantly as early as 24 hours after 
experimentally induced status epilepticus (Rizzi et al. 2002; Seegers et al. 2002; 
Bankstahl and Löscher 2008). The excitatory neurotransmitter glutamate, which 
is excessively released by seizures, upregulates Pgp expression in brain 
capillary endothelial cells, astrocytes and neurons in the dentate gyrus, 
amygdala, hippocampus, piriform and parietal gyrus (Zhang et al. 1999; Seegers 
et al. 2002; Zhu and Liu 2004; Bankstahl et al. 2008a; Bankstahl et al. 2011). A 
recent post-mortem study showed Pgp overexpression in the sclerotic 
hippocampus of individuals with pharmacoresistant epilepsy, but not in post 
mortem tissue of seizure-free individuals or non-epileptogenic tissue with 
electrode-related injuries (Liu et al. 2012) indicating that seizures are necessary, 
but not sufficient, for increased Pgp expression. These findings suggest that (i) 
there is measurable, localized Pgp overactivity in pharmacoresistant mTLE 
which is related to seizure activity; (ii) Pgp overexpression is not seen in seizure-
freedom. Pgp overactivity might thus explain why pre-treatment seizure density 
is one factor predicting poor response to AEDs.  
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5.5 CONCLUSION 
At baseline apparent VPM-K1 values were lower in healthy controls compared to 
mTLE patients but pharmacoresistant and seizure-free mTLE patients were not 
different. There are differences in VPM metabolism between mTLE patients and 
healthy controls which are caused by AED-mediated hepatic cytochrome P450 
enzyme induction in mTLE patients requiring images to be normalised for 
differences (either to the global whole brain or to a target region, for example the 
parietal lobe) when comparing mTLE patients with healthy controls.  We 
observed an association between Pgp activity and seizure frequency in mTLE 
patients. At baseline using the ROI VPM analysis there was no difference in 
VPM-K1 ratios in pharmacoresistant compared to seizure-free mTLE patients or 
healthy controls. However, the differences between groups could be 
accentuated by using a Pgp inhibitor such as TQD and employing voxel-based 
SPM analysis.  
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CHAPTER VI  (R)-[11C]VERAPAMIL PET AFTER 
PARTIAL PGP INHIBITION WITH TARIQUIDAR IN 
PHARMACORESISTANT MTLE PATIENTS COMPARED 
TO HEALTHY CONTROLS – REGION OF INTEREST 
ANALYSIS 
6.1 BACKGROUND 
Verapamil (VPM) is a high-affinity substrate of Pgp and is therefore very 
effectively transported by Pgp at the blood-brain barrier (BBB).  This results in 
low brain uptake of this radiotracer thus making it difficult to elicit regional 
differences in cerebral Pgp function. A possible strategy to overcome this 
limitation of low brain uptake of Pgp substrate radiotracers is to perform dynamic 
PET scans after partial blockade by Pgp modulating drugs such as Cyclosporin 
A (CsA) or Tariquidar (TQD) (Löscher and Langer 2010). Blocking Pgp with an 
inhibitor allows the radiotracer VPM to enter the BBB and hence increases its 
uptake and signal in the brain. To test the functional relevance of the VPM 
baseline difference, we performed experiments with the third-generation Pgp 
inhibitor TQD.  We determined whether there were regional variations in Pgp 
activity as assessed by differences in VPM-K1 before and after partial TQD 
inhibition in pharmacoresistant mTLE patients and healthy controls. We 
hypothesize that the uptake of VPM is reduced after Pgp inhibition with TQD in 
pharmacoresistant mTLE patients in the epileptogenic relative to contralateral 
regions and compared to healthy controls. 
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6.2 METHODS 
The common methods are described in Chapter 4, and the specific methods for 
this study are described here. 
6.2.1 Subjects 
Pharmacoresistant mTLE patients and healthy controls were recruited as 
previously described in section 4.5. Thirteen healthy controls (from the age 
range 35-55 years) and 14 pharmacoresistant mTLE patients (from the age 
range 18-60 years) with unilateral hippocampal sclerosis (HS) were included in 
this part of the study.  Clinical details of the pharmacoresistant mTLE patients 
are in table 2.  
6.2.2 Radiochemistry  
(R)-[11C]verapamil was synthesized as previously described in section 4.1.4. 
6.2.3 PET Image acquisition 
The PET scans were performed at the Wolfson Molecular Imaging Centre, 
Manchester, UK, on the High Resolution Research Tomograph (CTI/Siemens, 
TN, USA) as previously described in section 4.1.1. The protocol aimed to study 
subjects twice with VPM PET on the same day whenever possible with a two 
and a half hour break out of the PET camera between scans. In all subjects, a 
60 minute VPM PET scan was performed to assess Pgp function. The 
pharmacoresistant mTLE patients and healthy controls underwent a second set 
of VPM-PET scans on the same day starting 60 minute after the end of a 30 
minute intravenous infusion of 2 or 3 mg/kg TQD. Baseline and inhibitor scans 
were acquired in fixed order because of the long half-life of tariquidar (18-36 
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hours). Seizure-free patients did not receive TD because of the remote 
possibility that the interaction of TQD with AEDs could lead to seizure 
recurrence (Giacomini et al. 2010). The injection doses of VPM for the baseline 
scans in pharmacoresistant and healthy controls were 540 ± 37 MBq and 558 ± 
21 MBq, respectively, and 533 ± 55 MBq, 551 ± 41 MBq for pharmacoresistant 
mTLE patients and healthy controls for the inhibitor scans after administration of 
TQD (Figure 4).  
For 27 subjects, it was possible to perform both scans on the same day with a 
standardized protocol for lunch in-between. However, due to technical 
(scanner/hardware failure), we had to re-schedule the inhibitor scan on a 
different visit, but also at the same time of the day for two healthy controls. TQD 
plasma levels were measured at 95, 110 and 170 minutes after start of TQD 
infusion. 
6.2.4 MRI data acquisition 
For all subjects, a T1-weighted MRI brain scan was acquired on a 3-Tesla GE 
Excite II scanner (General Electric, Milwaukee, WI, USA) for co-registration with 
the PET images, as previously described in section 4.2.1. 
6.2.5 PET data analysis  
As shown recently in rodent models of Pgp-overactivity (Bankstahl et al. 2011), 
partial Pgp-inhibition increases VPM-K1, but this increase is attenuated in areas 
of high Pgp-activity, since a fixed dose of Pgp-inhibitor (2 or 3mg/kg) inhibits a 
lower proportion of Pgp binding sites in areas of high Pgp-activity. It has 
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previously been reported in healthy controls (Bankstahl et al. 2011) that TQD did 
not alter VPM peripheral metabolism in pharmacoresistant  mTLE patients. 
Subjects served as their own control, which eliminated the need for ratio images. 
The asymmetry index (AI) was calculated as: 
 
 
All image processing steps were performed in SPM8, Wellcome Trust Centre for 
Neuroimaging London, UK as previously described in section 4.3.2. 
6.2.6 Statistical Analysis 
The statistical analyses were performed using SPSS 19.0 as previously 
described in section 4.4.1 and the level of significance was set at p<0.05.  
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6.3 RESULTS 
6.3.1 Pgp overactivity in pharmacoresistant mTLE compared to 
healthy controls 
After 2mg/kg TQD, pharmacoresistant mTLE patients had significantly reduced 
increases in VPM-K1 globally (26%, n=6) compared to healthy controls (52%, 
n=7, p<0.001). A recent study showed a sigmoidal relationship between TQD 
inhibition and VPM-K1 in healthy controls with a half-maximum effect of about 
3mg/kgTQD (Bauer, Zeitlinger et al. 2012).  To further support our basic 
assumption that partial Pgp-inhibition increases the difference between areas of 
Pgp overactivity and normality, we scanned an additional seven 
pharmacoresistant mTLE patients and six healthy controls with the higher dose 
of 3 mg/kg TQD. Increases of VPM-K1 were also significantly different after 
3mg/kg TQD globally between both groups (48% for pharmacoresistant mTLE 
patients (n=7), compared to 70% in healthy controls (n=6), p=0.001, Figure 20 
and 21) suggesting Pgp overactivity in pharmacoresistant mTLE. 
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Figure 20: Change in VPM-K1 after TQD 
% change in VPM-K1 is shown after 2 and 3mg/kg tariquidar for six different temporal 
lobe ROIs as well as cerebellum and whole brain for 13 healthy controls (HC), 14 
pharmacoresistant (PR) mTLE patients. Ant TL lat, lateral anterior temporal lobe; 
OccTL, occipitotemporal gyrus; ParaH, parahippocampal and ambient gyrus; Sup TL 
ant, anterior superior temporal gyrus; Inf-mid TL, inferior temporal gyrus; Post TL, 
posterior temporal lobe; Sup PL, superior parietal gyrus; Cer, cerebellum. Error bars 
represent SEM. 
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Figure 21: Change in VPM-K1 for whole brain after TQD 
% change in VPM-K1 is shown after 2 and 3mg/kg tariquidar for the whole brain as well 
as the mean for 13 healthy controls (HC), 14 pharmacoresistant (PR) mTLE patients.  
 
6.3.2 Tariquidar plasma levels not different between mTLE patients 
and healthy controls 
Average TQD plasma levels were not significantly different between healthy 
controls and pharmacoresistant mTLE patients after 2mg/kg TQD (360 vs. 226 
ng/ml, respectively, p=0.080) or 3mg/kg TQD (418 vs. 324 ng/ml, respectively, 
p=0.115). As in healthy controls, TQD did not alter the peripheral metabolism of 
VPM (Figure 22). Average TQD plasma levels for healthy controls and 
pharmacoresistant mTLE patients are shown in table 3. 
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Figure 22: Correlation of TQD plasma level with change in VPM-K1 for 
whole brain after TQD  
% change in VPM-K1 is shown after 2 and 3mg/kg tariquidar for the whole brain as well 
as the mean for 13 healthy controls (HC), 14 pharmacoresistant (PR) mTLE patients.  
 
6.3.3 Differences in asymmetry index after Pgp inhibition with 
Tariquidar 
After Pgp inhibition with 2mg/kg TQD pharmacoresistant mTLE patients had a 
significantly reduced asymmetry index (i.e. increases of VPM-K1 
contralateral>ipsilateral hence Pgp activity > ipsilateral) in the posterior temporal 
lobe (p=0.019). There was no significant difference in the AI index in any of the 
other brain regions either after 2 or 3 mg/TQD (p>0.159, Figure 23). 
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Figure 23: Differences in asymmetry index of VPM-K1 after TQD 
Asymmetry indedx is shown after 2 and 3mg/kg tariquidar for six different temporal lobe 
ROIs as well as cerebellum and whole brain for 13 healthy controls (HC), 14 
pharmacoresistant (PR) mTLE patients. Ant TL lat, lateral anterior temporal lobe; 
OccTL, occipitotemporal gyrus; ParaH, parahippocampal and ambient gyrus; Sup TL 
ant, anterior superior temporal gyrus; Inf-mid TL, inferior temporal gyrus; Post TL, 
posterior temporal lobe; Sup PL, superior parietal gyrus; Cer, cerebellum. Error bars 
represent SEM. 
 
6.3.4 Tariquidar induced AED side-effects 
Five controls and six pharmacoresistant mTLE patients experienced mild 
adverse events possibly related to TQD such as phlebitis (two controls, two 
patients), hypotension (two controls, one patient) and nausea (one control, three 
patients); one control also reported a metallic taste. One pharmacoresistant 
mTLE patient (PR 2, table 2) developed AED-related side-effects starting 24 
hours after the end of the TQD infusion: blurred vision, nausea and ataxia, with 
increasing severity over the following 24 hours during which the patient 
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continued taking regular AEDs before reporting the effects to the investigators. 
These symptoms were typical of concentration-dependent AED side-effects and 
subsided once AEDs were stopped for 24 hours, about 60 hours after TQD 
infusion. Following the TQD administration, the patient was seizure-free for four 
weeks, compared to seizure-frequency over the preceding six months of at least 
12 seizures per month. This is a significant improvement as determined by the 
„rule of three-to-six” (Westover et al. 2012 ), which accounts for expected 
variation in seizure-frequency in individuals who a priori are known to probably 
respond or not respond to AED changes: if an individual goes without seizures 
for 6 times the average pre-intervention inter-seizure interval that is statistically 
unlikely to have happened by chance. 
6.4 DISCUSSION 
We provide the first direct, in-vivo evidence for Pgp overactivity in human 
pharmacoresistant mTLE, as pharmacoresistant mTLE patients have two-fold 
lower increases in VPM-K1 after TQD compared to healthy controls. As shown in 
rodent models of Pgp overactivity (Bankstahl et al. 2011),   partial Pgp inhibition 
increases VPM- K₁, but this increase is attenuated in areas of high Pgp activity, 
since a fixed dose of  the Pgp-inhibitor TQD (2 or 3 mg/kg) inhibits a lower 
proportion of binding sites in areas of high Pgp activity than in areas of low 
activity. Hereby, it is important that Pgp activity is only partially inhibited. In the 
case of full Pgp inhibition, VPM-K1 would be driven entirely by passive diffusion, 
and, thus, would not delineate regional differences in Pgp function (Löscher and 
Langer 2010).  So far only studies in healthy volunteers with paired VPM-PET 
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scans, before and after TQD have been performed (Wagner et al. 2009; Bauer 
et al. 2010). So far two Pgp inhibitors have been used in human PET studies, 
CsA (Sasongko et al. 2005; Eyal et al. 2010) and TQD (Wagner et al. 2009). 
The third-generation Pgp inhibitor TQD is safer than the non-selective CsA (Fox 
and Bates 2007). More importantly TQD has no effect on VPM metabolism or 
plasma protein binding (Bankstahl et al. 2008b; Wagner et al. 2009). 
Accordingly, the average TQD plasma levels were not significantly different 
between healthy controls and pharmacoresistant mTLE patients after 2 or mg/kg 
TQD. One of 16 pharmacoresistant patients showed signs of AED-intoxication 
after Pgp-inhibitor TQD (PR 2, table 2). The timeline of side-effects in this 
patient was in keeping with the known half-life of TQD (18-36 hours). In-vitro 
experiments have shown that Pgp can undergo long-lasting conformational 
change with functional consequences after molecular modulation, which could 
be a molecular explanation for this observation (Kimchi-Sarfaty et al. 2007). We 
hypothesise that significant Pgp-inhibition following TQD led to higher 
intracellular AED brain concentrations resulting in an unusually long period of 
seizure freedom. However, only one of 16 patients suffered from AED-
concentration-related side-effects, which reflects that Pgp and its inhibition might 
not be as relevant in humans, as in rodent models. TQD had 10 times greater 
effect sizes in rats than in humans, with similar doses resulting in half-maximum 
blockade (Kuntner et al. 2010).. 
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6.5 CONCLUSION 
In conclusion, our findings provide direct in-vivo evidence for Pgp overactivity in 
pharmacoresistant mTLE with VPM-PET showing attenuated increases of VPM 
brain uptake after partial Pgp-inhibition by TQD globally in pharmacoresistant 
mTLE patients compared to healthy controls. However, differences in VPM brain 
uptake were reduced globally and voxel-based analysis may elicit regional 
differences. 
 
 
 
 
 
 
 
 
 
 
172 
 
CHAPTER VII  (R)-[11C]VERAPAMIL PET AT 
BASELINE IN PHARMACORESISTANT AND –SENSITIVE 
MTLE PATIENTS VERSUS HEALTHY CONTROLS – 
VOXEL-BASED ANALYSIS 
7.1 BACKGROUND 
At baseline by using the regional VPM analysis we failed to detect a difference 
of VPM-K1 between healthy controls or between pharmacoresistant and seizure-
free mTLE patients in brain ROIs. VPM is a high-affinity Pgp substrate and its 
brain uptake is very low, so that small differences in regional Pgp activity cannot 
easily be measured (Kuntner et al. 2010). On the other hand, we may not have 
detected differences between the three groups because the ROI analysis is less 
sensitive for this radiotracer with low brain uptake and small differences between 
groups. ROI analysis is used with either manually delineated, anatomically 
defined ROIs within the brain or by using a probability atlas of the brain 
(Hammers et al. 2003). ROI refers to selecting a cluster of voxels or brain region 
a priori when investigating a region for effects. The ROI method has many 
strengths, namely anatomical validity. However, it also has limitations, including 
the time-consuming nature of manual ROI drawings, both in delineating a priori-
defined regions and in the rigorous training needed to ensure reliability, which 
does not easily allow for comparison of many brain regions or large subject 
groups (Kubicki et al. 2002). Additionally, it is generally the case that regions 
specified in this approach will be relatively large and that even if the region is 
significantly active, this activation may only occur in a small proportion of voxels 
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in the ROI. This suggests that simply averaging across the entire region could 
swamp the signal from this small number of voxels with noise from the 
remaining non-activated voxels. Another approach to analyse PET data is to 
employ voxel-based analysis by using SPM (Friston et al. 1995), Using voxel-
based SPM analysis, has several benefits compared with traditional ROI 
analysis. The central idea of SPM analysis is that no a priori hypotheses are 
required, enabling the analysis of the entire brain volume. Thus, changes also 
outside of a priori specified regions can be detected. Furthermore, SPM 
explores every voxel, provides improved sensitivity of statistical analysis, and is 
more objective than manual ROI analysis (Kemppainen et al. 2006). In chapter 5 
we based our VPM data analysis on the traditional ROI analysis of selected 
brain regions. Here we used voxel-based SPM analysis exploring the whole 
brain without any a priori hypothesis of involved brain regions. Group differences 
in VPM uptake were explored between pharmacoresistant and seizure-free 
mTLE patients and healthy controls. We hypothesise that VPM uptake is 
reduced in pharmacoresistant mTLE compared to seizure-free mTLE and 
healthy control. Additionally, we hypothesise that voxel-based SPM analysis 
further improves the diagnostic yield of our VPM-PET data and that voxel-based 
SPM analysis of this same data set would complement and extend the ROI 
findings. 
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7.2 METHODS 
The common methods are described in Chapter 4, and the specific methods for 
this study are described here. 
7.2.1 Subjects 
Thirteen healthy controls (from the age range 35-55 years) and 14 
pharmacoresistant and eight seizure-free mTLE patients (from the age range 
18-60 years) with unilateral hippocampal sclerosis (HS) were included in this 
study as previously described in section 4.5.  Clinical details of the 
pharmacoresistant and seizure-free patients are in table 2.  
7.2.2 Radiochemistry  
(R)-[11C]verapamil was synthesised as previously described in section 4.1.4.  
7.2.3 PET Image acquisition 
The PET scans were performed at the Wolfson Molecular Imaging Centre, 
Manchester, UK, on the High Resolution Research Tomograph (CTI/Siemens, 
TN, USA) and the PET data was acquired as previously described in section 
4.1.1. 
7.2.4 MRI data acquisition 
For all subjects, a T1-weighted MRI brain scan was acquired on a 3-Tesla GE 
Excite II scanner (General Electric, Milwaukee, WI, USA) for co-registration with 
the PET images as previously described in section 4.2.1.  
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7.2.5 PET data analysis  
For the voxel-based SPM analysis, we generated parametric VPM-K1 maps as 
previously described in section 4.3.3.   
All image processing steps were performed in SPM 8, Wellcome Trust Centre 
for Neuroimaging London, UK. MRI and co-registered VPM-K1 maps were 
spatially normalized using a symmetrical and centered gray matter DARTEL 
template.  To determine changes ipsi- and contralateral to the sclerotic 
hippocampus, VPM-K1 maps were also right-left reversed and normalised to the 
same DARTEL template as previously described in section 4.3.3.2. 
To normalise for differences in peripheral metabolism of VPM, we created PET 
images corrected for differences in whole brain radiotracer uptake; we first 
calculated the mean whole brain gray matter VPM K1 for patients and controls 
separately, and then normalised to the mean of the two. We used these globally 
normalised images when comparing patients with healthy controls. For 
differences between pharmacoresistant and seizure free mTLE patients we used 
the original VPM K1 maps which were not normalised for whole brain differences 
as there was no difference in metabolism between the two patient groups as 
described in section 5.3.2. 
Since the CP has the highest VPM uptake resulting in spill-over of radioactivity 
into the neighbouring hippocampus, the CP was individually masked out as 
described in section 4.3.3.4. The masked VPM-K1 maps and globally normalised 
images were finally smoothed using an isotropic 8-mm Gaussian filter. 
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7.2.6 Statistical Analysis 
The statistical analysis of voxel-based PET analysis was performed as 
previously described in section 4.4.2.  
7.3 RESULTS  
7.3.1 Pgp overactivity in pharmacoresistant compared to seizure-free 
mTLE patients 
The voxel-based SPM analysis showed that at baseline, compared to seizure-
free patients, pharmacoresistant mTLE patients had significantly lower regional 
VPM-K1, which corresponds to increased Pgp activity, in the ipsilateral 
amygdala (15.5%, VPM-K1- PR 0.031; VPM-K1-SF 0.036, p=0.014), and bilateral 
parahippocampal (16.7%, VPM-K1-PR 0.032; VPM-K1-SF 0.037;  <0.0001), 
fusiform (16.3%, VPM-K1-PR 0.036; VPM-K1-SF 0.041; p<0.0001), inferior (ITG) 
(15.4%, ITG; VPM-K1-PR 0.035; VPM-K1-SF 0.041; p<0.0001) and middle 
temporal gyri (MTG) (15.3%, MTG; VPM-K1-PR 0.038; VPM-K1-SF 0.044; 
p<0.0001; Figure 24a). When comparing pharmacoresistant to seizure-free 
patients, no area of significant increase in VPM-K1 was detected. 
7.3.2 Pgp overactivity correlates with seizure frequency  
In pharmacoresistant mTLE patients, VPM-K1 correlated inversely with average 
monthly seizure frequency, measured at the time of the baseline PET scan 
(correlation for whole brain: r =-0.651, p= 0.016; hippocampus: r =-0.604, 
p=0.029; Figure24b).  
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Figure 24: Differences in VPM-K₁ uptake between pharmacoresistant and seizure-free mTLE patients 
VPM-K₁ brain uptake at baseline is lower bilaterally in the temporal lobe in the 14 pharmacoresistant compared to the eight seizure-
free mTLE patients (a). Areas of significantly reduced K₁ in pharmacoresistant and seizure-free mTLE patients are superimposed in 
yellow on a coronal T1-weighted MRI template image. Seizure frequency per month inversely correlates with VPM-K₁ in the 
hippocampus of pharmacoresistant mTLE patients  (b).
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7.3.3 Pgp overactivity in pharmacoresistant mTLE patients compared 
to healthy controls  
Because of differences in VPM metabolism between mTLE patients and healthy 
controls we created individual VPM-K1 images, which were normalised for global 
whole brain differences in VPM-K1 arisen from this measure being a composite 
of parent VPM and its metabolites. These globally normalized images were then 
used for further analysis to detect regional differences between healthy controls 
(HC) and the two mTLE patient groups.  
Voxel-based comparison of globally normalised images revealed 12.6% lower 
VPM-K1 in pharmacoresistant mTLE patients (VPM-K1-PR 0.038) compared to 
healthy controls in MTG (VPM-K1-HC 0.043; p<0.0001) and 14.2% lower VPM-K1 
in superior temporal gyrus (STG) (VPM-K1-PR 0·037; VPM-K1-HC 0.042, 
p<0·.0001) bilaterally. There was no area of significant difference between 
seizure-free patients and healthy controls. 
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7.4 DISCUSSION 
Our voxel-based SPM analysis revealed that at baseline the VPM brain uptake 
is lower in the temporal lobes of patients with pharmacoresistant mTLE 
compared to seizure-free patients and healthy controls. We translated findings 
from animal rodent studies (Bankstahl et al. 2011) and our in-vivo PET 
measurements of Pgp activity are in keeping with the hypothesis that there is 
localized Pgp overactivity in pharmacoresistant mTLE. Additionally, in 
agreement with our ROI analysis we found an association between Pgp activity 
and seizure frequency. Since Pgp overexpression in the epileptic focus region is 
an important mechanism of pharmacoresistance in epilepsy patients (Löscher 
and Potschka 2005a), a validated method for in vivo detection of regionally 
increased Pgp activity would be a valuable tool for predicting the individual risk 
of an epilepsy patient not responding to pharmacological treatment with 
antiepileptic drugs that are Pgp substrates. In contrast to the traditional ROI 
analysis we were able to detect differences between pharmacoresistant and 
seizure-free mTLE patients and healthy controls by using voxel-based SPM 
analysis. Employing voxel-based SPM analysis to the VPM data compared to 
ROI analyses appears to have several potential advantages. For example, 
voxel-based SPM analysis enables regional comparisons throughout the whole 
brain without restriction to a few selected areas in the typical ROI methodology. 
Traditionally, statistical analyses of PET data are derived from ROI analysis or 
voxel-by-voxel approaches. ROI analyses are used to test hypotheses about 
specific regions. In this type of analysis, functional or anatomical regions are 
drawn for each individual subject based on his or her PET or structural image or 
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a probability brain atlas/template is applied. The alternative, a voxel-by-voxel 
approach, requires that all images be spatially transformed to a template space. 
This process, known as stereotaxic normalization, assumes that each voxel 
corresponds to the same anatomical region across subjects. Statistical analyses 
are therefore performed for every voxel across all subjects. This approach to 
analyzing PET data is more exploratory than the ROI approach because it 
requires no prior hypothesis about the expected location of the effect. Indeed by 
using voxel-based SPM analysis we found differences in regions not examined 
in our ROI study and the reduction in VPM brain uptake is not restricted to 
ipsilateral epileptogenic regions but also extends to contralateral temporal lobe 
regions, implying a wider area of Pgp overexpression than the epileptogenic 
focus. Furthermore it also raises the question whether epilepsy, uncontrolled 
seizures or chronic AED treatment stimulate a global rather than regional 
response of Pgp function. 
7.5 Conclusion 
By using voxel-based SPM analysis we provide direct in-vivo evidence for Pgp 
overactivity in pharmacoresistant mTLE, with VPM-PET showing lower focal 
VPM uptake in pharmacoresistant compared to seizure-free mTLE patients and 
healthy controls. Furthermore, Pgp overactivity in the ipsilateral hippocampus of 
pharmacoresistant mTLE patients correlates with seizure frequency.   
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CHAPTER VIII   (R)-[11C]VERAPAMIL PET 
AFTER PGP INHIBITION WITH TARIQUIDAR IN 
PHARMACORESISTANT MTLE PATIENTS COMPARED 
TO HEALTHY CONTROLS – VOXEL-BASED ANALYSIS  
8.1 BACKGROUND 
Our ROI analysis provided in-vivo evidence for Pgp overactivity in 
pharmacoresistant mTLE with VPM-PET showing attenuated increases of VPM-
uptake after partial Pgp-inhibition by TQD in temporal lobe regions in 
pharmacoresistant mTLE patients compared to healthy controls (chapter 6).  
However, the differences in reduced VPM uptake were observed globally rather 
than regionally in all temporal regions and the whole brain. By applying voxel-
based SPM analysis to the VPM-PET data at baseline compared to ROI 
analysis we were able to detect differences between pharmacoresistant and 
seizure-free mTLE patients and controls (chapter 7). Voxel-based analysis 
allows for comparisons throughout the whole brain without restriction to a few 
selected areas in the typical ROI methodology. Here, we performed PET scans 
with the Pgp substrate VPM in pharmacoresistant mTLE patients and healthy 
controls before and after partial Pgp inhibition with TQD and employed voxel-
based SPM analysis to the VPM-PET data to assess specific regional changes. 
We hypothesize that voxel-based SPM analysis of the same data would 
complement the ROI findings and elicit regional differences in VPM-K1 brain 
uptake before and after partial TQD inhibition in pharmacoresistant mTLE 
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patients and healthy controls and that the brain uptake of VPM is reduced in the 
epileptogenic relative to contralateral regions and compared to healthy controls. 
8.2 METHODS  
The common methods are described in Chapter 4, and the specific methods for 
this study are described here. 
8.2.1 Subjects 
Pharmacoresistant patients and healthy controls were recruited as previously 
described in section 4.5. Thirteen healthy controls (from the age range 35-55 
years) and 14 pharmacoresistant mTLE patients (from the age range 18-60 
years) with unilateral hippocampal sclerosis (HS) were included in this study.  
Clinical details of the pharmacoresistant are in table 2.  
8.2.2 Radiochemistry  
(R)-[11C]verapamil was synthesised as previously described in section 4.1.4.  
8.2.3 PET Image acquisition 
The PET scans were performed at the Wolfson Molecular Imaging Centre, 
Manchester, UK, on the High Resolution Research Tomograph (CTI/Siemens, 
TN, USA) and the PET data was acquired as previously described in section 
4.1.1. The pharmacoresistant mTLE patients and healthy controls underwent a 
second set of VPM-PET scans on the same day starting 60 minutes after the 
end of a 30 minute intravenous infusion of 2 or 3 mg/kg TQD (Figure 4). 
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8.2.4 MRI data acquisition 
For all subjects, a T1-weighted MRI brain scan was acquired on a 3-Tesla GE 
Excite II scanner (General Electric, Milwaukee, WI, USA) for co-registration with 
the PET images, as previously described in section 4.2.1. 
8.2.5 PET data analysis  
For the voxel-based SPM analysis, we generated parametric VPM-K1 maps as 
previously described in section 4.3.3. All image processing steps were 
performed in SPM 8, Wellcome Trust Centre for Neuroimaging London, UK. MRI 
and co-registered VPM-K1 maps were spatially normalized using a symmetrical 
and centered gray matter DARTEL template.  To determine changes ipsi- and 
contralateral to the sclerotic hippocampus, VPM-K1 maps were also right-left 
reversed and normalised to the same DARTEL template as previously described 
in section 4.3.3.2. Since the CP has the highest VPM uptake resulting in spill-
over of radioactivity into the neighbouring hippocampus, the CP was individually 
masked out as described in section 4.3.3.4. The masked VPM-K1 maps and 
globally normalised images were finally smoothed using an isotropic 8-mm 
Gaussian filter. Subjects served as their own control, which eliminated the need 
for ratio images. 
8.2.6 Statistical Analysis 
The statistical analysis of voxel-based PET analysis was performed as 
previously described in section 4.4.2.  
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8.3 RESULTS 
8.3.1 Maximum Pgp overactivity in hippocampus 
Our voxel-based SPM analysis showed that in pharmacoresistant mTLE patients 
TQD-induced increase in VPM-K1 was globally attenuated following 2mg/kg 
TQD, pointing to increased Pgp activity (21.9%; VPM-K1-PR-baseline 0.047; VPM-
K1-PR-TQD 0.057) compared to controls (56.8%; VPM-K1-HC-baseline 0.030; VPM-
K1-HC-TQD 0.047; p<0.0001). 
There were no differences at baseline between the two groups of 
pharmacoresistant mTLE patients scanned either after 2 or 3mg/kg TQD, but 
VPM-K1 increases after 3 mg/kg TQD were globally higher (42.6%; VPM-K1-PR-
baseline 0.051; VPM-K1-PR-TQD 0.074) than after 2 mg/kg TQD (21.9%; VPM-K1-PR-
baseline 0.047; VPM-K1-PR-TQD 0.057; p=0.016). VPM-K1 in healthy controls did not 
increase significantly more with 3mg/kg TQD (57.9%; VPM-K1-HC-baseline 0.036; 
VPM-K1-HC-TQD 0.056) compared to 2mg/kg TQD (p=0.874). Voxel-based SPM 
analysis before and after TQD showed significant differences in increases of 
VPM-K1 between pharmacoresistant mTLE patients and healthy controls, 
suggestive of increased Pgp activity in TLE patients, only in the ipsilateral 
hippocampus (Figure 25) .  
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Figure 25: Differential effects of Pgp inhibition with TQD on VPM-K1 in pharmacoresistant mTLE patients 
VPM-K₁ brain uptake after 2 and 3 mg/kg tariquidar is reduced in the epileptogenic hippocampus in the 14 pharmacoresistant 
compared to 13 healthy controls (a). Area of significantly reduced VPM-K₁ brain in pharmacoresistant mTLE patients is superimposed 
in yellow on a coronal T1-weighted MRI template image. Increases in VPM-K₁ brain uptake after 2 and 3 mg/kg tariquidar in the 
hippocampus are shown for the ipsi and contralateral side for the pharmacoresistant mTLE patients and healthy controls (b). The bold 
line indicates the mean for each group. Pharmacoresistant patient 2, who became temporarily seizure-free and had side-effects 
associated with antiepileptic drug use after tariquidar, is indicated by a red line. TQD=tariquidar. 
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The difference between mTLE patients and healthy controls was more 
pronounced after 2 mg/kg TQD (+16.5%; VPM-K1-PR-baseline 0.038; VPM-K1-PR-TQD 
0.042; versus +63.5%; VPM-K1-HC-baseline 0.023; VPM-K1-HC-TQD 0.038; p<0.0001) 
than after 3 mg/kg TQD, (+32.4% (VPM-K1-PR-baseline 0.041; VPM-K1-PR-TQD 0.056) 
versus +66.8% (VPM-K1-HC-baseline 0.025; VPM-K1-HC-TQD 0.041); p=0.002). 
Differences in TQD-induced increase in VPM-K1 between patients and controls 
could not be explained by differences in TQD plasma levels between groups 
(Table 3, Figure 22). 
The maximum difference between pharmacoresistant mTLE patients and 
healthy controls was in the hippocampus, suggesting that there is regionally 
specific Pgp overactivity for the epileptogenic hippocampus which is functionally 
relevant.  
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Table 3: VPM-K₁ and % change in VPM-K1 in pharmacoresistant mTLE 
patients and healthy controls after TQD 
Pat 
No 
TQD 
level 
(ng/ml) 
Ipsilateral 
hippocampus 
K1-baseline/ K1-TQD  
(% change) 
Ipsilateral middle 
temporal gyrus 
K1-baseline/ K1-TQD  
(% change) 
Ipsilateral inferior 
temporal gyrus 
K1-baseline/ K1-TQD  
(% change) 
Whole brain 
K1-baseline/ K1-TQD  
(% change) 
Pharmacoresistant (PR) patients 2mg/kg TQD 
1 384 0.020/0.024 (21.8) 0.026/0.034 (33.2) 0.025/0.030 (19.3) 0.025/0.033 (32.6) 
2 140 0.054/0.055 (1.4) 0.061/0.063 (3.2) 0.052/0.053 (1.1) 0.058/0.063 (9.1) 
3 348 0.029/0.034 (17.4) 0.041/0.047 (14.9) 0.032/0.041 (27.4) 0.035/0.044 (26.2) 
4 160 0.034/0.036 (7.4) 0.040/0.053 (34.4) 0.035/0.044 (25.5) 0.041/0.053 (28.5) 
5 130 0.044/0.044 (0.1) 0.052/0.056 (7.2) 0.045/0.050 (11.7) 0.051/0.056 (10.9) 
6 113 0.042/0.059 (41.2) 0.067/0.071 (5.4) 0.057/0.063 (9.9) 0.066/0.072 (8.8) 
7 312 0.041/0.052 (26.6) 0.051/0.074 (44.6) 0.049/0.073 (49.8) 0.057/0.078 (37.3) 
Pharmacoresistant (PR) patients 3mg/kg TQD 
8 212 0.027/0.039 (42.7) 0.042/0.065 (54.5) 0037/0.058 (56.2) 0.040/0.059 (46.8) 
9 491 0.042/0.051 (20.6) 0.040/0.071 (79.4) 0.035/0.065 (86.6) 0.040/0.069 (71.0) 
10 269 0.057/0.067 (17.3) 0.064/0.078 (22.4) 0.058/0.079 (36.2) 0.059/0.076 (29.3) 
11 326 0.038/0.058 (50.4) 0.057/0.073 (27.7) 0.047/0.065 (36.9) 0.058/0.075( 27.6) 
12 287 0.040/0.050 (25.1) 0.059/0.084 (41.8) 0.051/0.079 (53.8) 0.056/0.078 (40.2) 
13 396 0.027/0.036 (34.4) 0.034/0.050 (46.0) 0.030/0.053 (76.4) 0.034/0.052 (51.8) 
14 291 0.055/0.075 (36.6) 0.067/0.099 (48.3) 0.059/0.088 (47.9) 0.071/0.093 (31.6) 
Healthy controls (HC)  2mg/kg TQD 
1 661 0.020/0.033 (67.4) 0.024/0.041 (70.8) 0.024/0.035 (46.7) 0.024/0.038 (55.1) 
2 349 0.017/0.028 (61.4) 0.030/0.046 (53.1) 0.028/0.047 (64.4) 0.029/0.047 (63.4) 
3 246 0.026/0.052 (98.7) 0.039/0.056 (42.5) 0.036/0.050 (38.6) 0.035/0.054 (52.6) 
4 225 0.026/0.045 (74.1) 0.033/0.058 (76.3) 0.031/0.050 (61.9) 0.034/0.054 (60.1) 
5 453 0.025/0.039 (54.1) 0.033/0.051 (51.9) 0.030/0.042 (39.4) 0.032/0.048 (49.3) 
6 380 0.027/0.037 (36.8) 0.030/0.049 (62.6) 0.027/0.045 (68.4) 0.027/0.045 (66.8) 
7 328 0.022/0.033 (52.2) 0.031/0.044 (41.9) 0.026/0.043 (62.3) 0.030/0.044 (50.6) 
Healthy controls (HC)   3mg/kg TQD 
8 332 0.030/0.054 (79.6) 0.053/0.077 (45.6) 0.049/0.071 (42.8) 0.050/0.074 (48.3) 
9 449 0.019/0.028 (48.7) 0.023/0.038 (65.7) 0.018/0.032 (80.2) 0.023/0.036 (58.9) 
10 388 0.028/0.052 (83.2) 0.052/0.076 (46.5) 0.043/0.063 (45.1) 0.048/0.074 (53.5) 
11 590 0.024/0.040 (67.7) 0.029/0.047 (61.3) 0.025/0.050(100.7) 0.030/0.049 (64.5) 
12 323 0.015/0.027 (83.0) 0.021/0.042 (95.0) 0.017/0.034(100.1) 0.022/0.042 (86.3) 
13 303 0.033/0.046 (38.5) 0.047/0.064 (36.4) 0.040/0.058 (44.6) 0.046/0.062 (36.3)  
Data are baseline K₁/ K₁ (mL/min/cm³) after tariquidar (% change from 
baseline), unless otherwise stated. Mean tariquidar plasma concentrations 
(ng/mL) calculated from two samples taken 15 min and 60 min after injection of 
VPM. 
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8.3.2 Different response to Tariquidar in pharmacoresistant mTLE 
patients taking carbamazepine 
The observed whole brain increases in VPM-K1 in response to TQD 
administration showed a relatively large spread of values amongst 
pharmacoresistant mTLE patients when using the voxel-based analysis, ranging 
from +8.8 to 37.3% following 2 mg/kg (VPM-K1-PR-baseline range: 0.025; to 0.066; 
VPM-K1-PR-TQD range: 0.033; to 0·.78) and +27.6 to 71% after 3 mg/kg (VPM-K1-
PR-baseline range; 0.034; to 0.071; VPM-K1-PR-TQD range: 0.052; to 0.093). Those 
pharmacoresistant mTLE patients who had lower increases in VPM-K1 following 
TQD than any of the healthy controls, suggestive of highest Pgp activity, were all 
taking the AED carbamazepine (n=6), in different combinations with other AEDs. 
None of the other patients were taking carbamazepine. There was no difference 
in age of onset of epilepsy, duration of epilepsy, average monthly seizure 
frequency, time since last seizure before PET scan, or TQD plasma 
concentrations between patients taking carbamazepine and the other patients.  
8.4 DISCUSSION 
Our voxel-based analysis complements results from the ROI analysis and 
provides in-vivo evidence for Pgp overactivity in human pharmacoresistant 
mTLE, manifesting as attenuated TQD-induced increases in VPM brain uptake. 
Differences between pharmacoresistant mTLE patients and healthy controls 
became more pronounced after partial Pgp-inhibition: increased VPM-K1 in 
pharmacoresistant mTLE patients were less than half of that seen in healthy 
controls, with the maximum difference between patients and controls found in 
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the ipsilateral hippocampus. The response to TQD was not uniform in our 
cohort, in keeping with the suggestion that Pgp-overactivity is only a relevant 
mechanism of pharmacoresistance in a subset of patients. Six of our 14 
pharmacoresistant patients showed whole brain increases of VPM-K1, which 
was below the lowest TQD-induced increase in healthy controls. All those six 
patients were taking carbamazepine, which was not being taken by any of the 
other patients. We cannot determine if this is a causal relationship. Studies with 
fewer AED combinations are required to address the effect of specific AEDs. A 
central question of the transporter hypothesis is whether AEDs are meaningful 
substrates for Pgp. There is general agreement that phenytoin, phenobarbital, 
lamotrigine, levetiracetam, topiramate, and carbamazepine-epoxide are 
substrates of human Pgp, but not valproic acid and carbamazepine (Baltes et al. 
2007a; Zhang et al. 2011). One possible explanation for the observed 
association of high Pgp-activity and carbamazepine usage in our cohort is that 
carbamazepine might be better tolerated in those patients because the toxic 
metabolite, carbamazepine-epoxide, is transported out by Pgp (Zhang et al. 
2011). Pgp induction by carbamazepine (Lombardo et al. 2008) does not explain 
the observed intra-subject regional variation, with the maximum difference 
between pharmacoresistant patients and healthy controls found in the 
epileptogenic hippocampus. The variation in response across the 
pharmacoresistant mTLE patient group is likely to be multifactorial.  
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8.5 CONCLUSION 
In conclusion, our findings provide direct in-vivo evidence for Pgp overactivity in 
pharmacoresistant mTLE with VPM-PET showing attenuated increases of VPM 
uptake after partial Pgp-inhibition by TQD in pharmacoresistant mTLE patients 
compared to healthy controls. TQD being least effective in increasing VPM 
uptake in the epileptogenic hippocampus in pharmacoresistant mTLE patients 
compared to healthy controls suggests that Pgp overactivity is pronounced in 
the region of the focus and thus, potentially functionally relevant. 
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CHAPTER IX  EX-VIVO ANALYSIS OF PGP AND 
COMPARISON WITH (R)-[11C]VERAPAMIL PET  
9.1 BACKGROUND 
The direct evidence for increased expression of Pgp in humans at the blood- 
brain barrier (BBB) is limited to studies from post-mortem and from epileptic 
tissues removed during epilepsy surgery from patients with pharmacoresistant 
epilepsy (Tishler et al. 1995; Dombrowski et al. 2001; Sisodiya et al. 2002; 
Aronica et al. 2004; Liu et al. 2012), which have substantiated assumptions 
implicit in the transporter hypothesis that Pgp is likely to be the most important 
transporter in pharmacoresistant epilepsy at a structural level. However, the 
functional relevance of this increased expression in humans cannot be assessed 
ex vivo. Using in vivo PET with the Pgp substrate radiotracer (R)-[11C]verapamil 
(VPM) before and after Pgp inhibition with Tariquidar (TQD), we studied 
pharmacoresistant patients with mesial temporal lobe epilepsy (mTLE) due to 
unilateral hippocampal sclerosis (HS) and compared the results of their VPM-
PET scans with their epileptic tissues removed during epilepsy surgery, testing 
the hypotheses that Pgp overactivity demonstrated with VPM-PET correlates 
with Pgp expression established in surgically-resected brain tissue.  
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9.2 METHODS 
This study was approved by the Joint Research Ethics Committee of the 
National Hospital for Neurology and Neurosurgery (NHNN)/University College 
London (UCL) Institute of Neurology; use of tissue was in accordance with UK 
Human Tissue Authority guidelines. Written informed consent was obtained from 
surgical patients. We studied surgically-resected brain tissue from patients with 
pharmacoresistant mTLE, who had pre-surgical VPM-PET scans, to measure 
Pgp function, before and after Pgp inhibition with TQD. Five of the 14 
pharmacoresistant mTLE patients had anterior temporal lobe resection 5.7±4.7 
months later at the NHNN. The recruitment of the pharmacoresistant mTLE 
patients was as previously described in section 4.5.1. In the interval between 
PET scanning and resection, no patient had any drug changes or episodes of 
status.  
9.2.1 Tissue Sampling 
Drs Joan Liu and Maria Thom from the Institute of Neurology, University College 
London, helped with this analysis. A 5mm-thick block of the surgically-resected 
hippocampus (mid-level) and temporal cortex (posterior-level) of each case was 
removed and stored in a -80ºC freezer. The remaining specimens were then 
fixed in 10% neutral-buffered formalin overnight. Fixed tissue was dissected 
anteroposteriorly into 5mm-thick blocks. Blocks were processed and embedded 
in paraffin wax within a week following sampling. 5μm sections were cut from 
each region and mounted on to adhesive microscopic slides (Superfrost, VWR 
International, UK).  
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9.2.2 Immunohistochemistry 
The surgically-resected brain tissue was analysed by immunohistochemistry 
using antibodies against Pgp (JSB-1, C219 and C494) as previously described 
in Liu et al., 2012 (Liu et al. 2012).  
9.2.3 Qualitative and quantitative assessments 
All immunolabelled sections were qualitatively examined under a light 
microscope (Nikon Eclipse 80i) using 10x, 20x and 60x objective lenses.  
Quantitative studies were performed as previously described in Liu et al., 2012 
(Liu et al. 2012) for anti-Pgp and anti-BCRP antibodies. In brief, the head of the 
hippocampus (inclusive of dentate gyrus and all cornu Ammonis subfields), and 
the grey matter of the temporal pole, middle temporal gyrus (MTG) and inferior 
temporal gyrus (ITG) were outlined using image analysis software (ImagePro 
Plus, Media cybernetics, UK) under 2.5x objective. Images were acquired in a 
random systematic sequence within the ROI under 20 x objectives using a CCD 
camera (JVC, USA). Positive immunolabelling was segmented (thresholded) 
using the ColorCube module of the ImagePro Plus software (Media Cybernetics, 
Inc. USA): positive labelling was manually selected by centering a 5x5 pixel 
selection grid on the darkest pixel in the image with the highest sensitivity option 
selected. The final results for each region of each case were expressed as the 
percentage area of the region of interest that was positively immunolabelled per 
case per marker. 
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9.2.4 Statistical Analysis 
For the correlation of voxel-based analysis with immunohistochemistry 
Spearman rank tests were applied. The results are shown as mean ± SD and he 
level of significance was set at p<0.05. 
9.3 RESULTS 
The histological diagnosis for cases with pharmacoresistant mTLE is 
summarised in Table 4. In summary, all five cases with epilepsy from UCL 
showed a loss of NeuN-immunopositive cells in the CA1, 3, and 4 of the 
hippocampus, which is consistent with classical HS. 3/5 cases additionally 
showed neuronal cell loss, or increased numbers of ectopic white matter 
neurons in the temporal cortex. Regions of neuronal cell loss were accompanied 
by gliosis and an infiltration of CD68-immunopositive microglial cells. 
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Table 4: Histological diagnosis for cases with pharmacoresistant mTLE who underwent epilepsy surgery 
 
 
Pat No Resected regions Histological diagnosis 
PR 3 
Hippocampus, 
Temporal cortex 
FCD IIIA. Classical HS and temporal lobe sclerosis. Severe neuronal cell loss was observed 
in CA1,3, and 4 of the hippocampus and the superficial layers of the temporal cortex 
(particularly MTG and ITG).    
PR 6 
Hippocampus, 
Temporal cortex 
Classical HS and mild malformation of cortical development (MCD type II). Neuronal cell 
loss was observed in the CA1, 3, and 4 of the hippocampus. An increase in the number of 
single neurons in the white matter, leading to mild dysplasia or mild MCD were observed.    
PR 7 
Hippocampus, 
Temporal cortex 
FCD IIIA. Classical HS and temporal lobe sclerosis. Severe neuronal cell loss was observed 
in CA1,(3), and 4 of the hippocampus and the superficial layers of the temporal cortex. 
PR 10 
Hippocampus, 
Temporal cortex 
Classical HS. Neuronal cell loss was observed in the CA1, 3, and 4 of the hippocampus. 
PR 11 
Hippocampus, 
Temporal cortex 
Classical HS. Neuronal cell loss was observed in the CA1, 3, and 4 of the hippocampus. 
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9.3.1 Pgp expression in post-surgical pharmacoresistant mTLE 
specimens 
Pgp immunoreactivity was observed in the blood vessels, glia and neurons in 
the hippocampus and temporal cortex of all pharmacoresistant mTLE cases. No 
evidence of ‘double-cuff’ or type 2 blood vessels was noted. Results from the 
quantification analysis are shown in Table 5. 
Table 5: Percentage area of Pgp immunopositive labelling 
   PR 3 PR 6 PR 7 PR 10 PR 11 
Region Level 
Percentage area of Pgp immunopositive 
labelling 
Hippocampus Pole 0.41 0.69 0.74 0.82 0.66 
 Anterior 0.26 0.58 0.57 0.78 0.50 
 Middle 0.53 0.48 0.71 0.65 0.54 
 Posterior 0.93 0.52 0.86 0.88 0.71 
  Average 0.57 0.57 0.72 0.78 0.60 
Temporal 
lobe Pole 0.35 0.81 0.87 0.68 0.59 
Middle 
temporal lobe Anterior 0.58 0.84 0.54 0.55 0.59 
 Middle 0.54 0.86 0.62 0.83 0.73 
 Posterior 0.39 0.81 0.6 1.03 0.71 
  Average 0.50 0.84 0.59 0.80 0.68 
Inferior 
temporal lobe Anterior 0.55 0.6 n/a 0.49 0.56 
 Middle 0.3 0.67 n/a 0.62 0.55 
  Posterior 0.36 0.8 n/a 0.82 0.71 
  Average 0.40 0.69 0.00 0.64 0.61 
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9.3.2 Pgp expression in post-surgical specimens correlate with in-
vivo PET measurements of Pgp activity in pharmacoresistant mTLE 
Pgp immunoreactivity was observed in the blood vessels, glia, and neurons in 
the hippocampus and temporal cortex of the five PET-scanned 
pharmacoresistant mTLE patients who underwent surgery. In three 
pharmacoresistant mTLE patients (PR 3,7 and 10, table 2), increases in VPM-K1 
after TQD were less pronounced, suggesting relatively higher Pgp activity, in the 
ipsilateral (sclerotic) hippocampus (20.4% ±5.3) than the ipsilateral temporal 
neocortex (combined inferior, middle, and superior temporal gyrus 31.7% ±11.6; 
figure 26). In accordance with this observation, the same three 
pharmacoresistant mTLE patients also showed a higher percentage area of Pgp 
immunopositive labelling in the sclerotic hippocampus (0.68% ±0.10) compared 
with the ipsilateral neocortex (0.59% ±0.13). The remaining two 
pharmacoresistant mTLE patients (PR 6 and 11, table 2), had less pronounced 
increases of VPM-K1 in the ipsilateral neocortex (+20% ±6.5) than in the 
hippocampus (+45.8% ±14.8), and correspondingly higher Pgp immunopositive 
labelling in the neocortex (+0.70% ±0.08) compared with the hippocampus 
(+0.56% ±0.04; Spearman, r=−0.900, p=0.034; figure 26C). 
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Figure 26: In-vivo and ex-vivo correlation of Pgp activity 
Immunolabelling of ipsilateral hippocampus (a) and temporal neocortex (b; defined as combined inferior, middle, and superior 
temporal gyrus) from one of the five patients with pharmacoresistant mTLE who underwent surgery with anterior temporal lobe 
resection. Immunolabelling P-glycoprotein (brown) of ipsilateral hippocampus and temporal neocortex (defined for corresponding PET 
analysis as combined inferior, middle, and superior temporal gyrus). (c) Negative correlation in patients with pharmacoresistant mTLE 
who underwent epilepsy surgery (n=5), and differences in VPM-K₁ after tariquidar compared with areas of Pgp immunopositive 
labelling in the hippocampus as a percentage of that in the neocortex. This correlation shows less increase or greater Pgp activity for 
hippocampus than neocortex (i.e. negative values) and greater hippocampal than neocortical Pgp expression (i.e. positive values) in 
three of five patients (left upper quadrant). 
a 
b 
c 
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9.4 DISCUSSION 
Our in-vivo PET measurements of Pgp activity correlated with ex-vivo Pgp 
expression in the surgical temporal lobe specimens of those patients who had 
undergone surgery, in keeping with the hypothesis that there is localized Pgp 
overactivity in pharmacoresistant mTLE. This is the first study to date comparing 
in-vivo Pgp activity by using VPM-PET before and after Pgp inhibition with ex-
vivo Pgp expression from pharmacoresistant mTLE patients who underwent 
temporal lobe resections. Recently Bauer et al. (Bauer et al. 2014) examined 
seven patients with mTLE in a longitudinal study using VPM-PET before and 
after temporal lobe resections to assess whether postoperative changes in 
seizure frequency and AED load are associated with changes in Pgp function 
and correlated their in-vivo VPM-PET measurements of Pgp function with ex -
vivo immunohistochemistry from surgical temporal lobe specimens.  However, 
they only performed VPM-PET scans at baseline and did not perform PET scans 
after Pgp inhibition. The seven patients were followed up for a median of six 
years (range 4–7) after epilepsy surgery. They found that pharmacoresistant 
mTLE patients who became seizure-free after surgery had lower VPM-K1 values, 
hence increased temporal lobe Pgp activity before surgery, increased Pgp 
expression in their surgically resected hippocampal specimens, and reduced 
global Pgp activity postoperatively, i.e. higher VPM-K1 values postoperatively, 
compared with patients who continued to have seizures postoperatively and had 
a poorer surgical outcome.  Their results are consistent with our findings in 
seizure-free mTLE patients who have higher VPM-K1 values, i.e. reduced Pgp 
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activity, compared to pharmacoresistant mTLE patients. In line with this a 
immunohistochemistry study in postmortem brain tissue also showing almost no 
Pgp overexpression in the sclerotic hippocampus of patients with epilepsy who 
had entered terminal remission before death (Liu et al. 2012). Several other 
previous studies have demonstrated Pgp expression in surgically resected 
specimens from patients with pharmacoresistant epilepsy with a variety of 
structural abnormalities, including hippocampal sclerosis (Tishler et al. 1995) 
(Tishler et al. 1995; Dombrowski et al. 2001; Sisodiya et al. 2002; Aronica et al. 
2004; Liu et al. 2012). Investigating Pgp expression in the surgically resected 
tissue of our pharmacoresistant mTLE patients we could also observe Pgp 
immunoreactivity in the blood vessels, glia and neurons in the hippocampus. In 
particular, our study is the first study to assess whether this Pgp overexpression 
in pharmacoresistant mTLE is functionally relevant by combining in-vivo VPM-
PET investigated Pgp activity with ex-vivo analysis of Pgp expression in 
surgically resected tissue.  
9.5 Conclusion 
The pre-operative results showed that the hippocampus of pharmacoresistant 
mTLE patients has a smaller percentage difference in Pgp function between the 
VPM-K1 pre- and post-TQD, suggesting that the Pgp activity or expression might 
be higher in the hippocampus than temporal cortex of patients with 
pharmacoresistant mTLE patients. This was confirmed with the 
immunohistochemistry data where we observed a higher percentage area of 
Pgp in the hippocampus than temporal cortex in three of five cases 
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demonstrating that the Pgp overexpression in the epileptic focus of 
pharmacoresistant mTLE patients is functionally relevant. 
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CHAPTER X  PERIPHERAL BIOMARKERS OF PGP 
EXPRESSION, BLOOD-BRAIN BARRIER DAMAGE AND 
ABCB1 GENETIC ANALYSIS 
10.1 BACKGROUND 
In human pharmacoresistant epileptic brain tissue (Tishler et al. 1995; Sisodiya 
et al. 2002; Aronica et al. 2004), as well as in the epileptic rat brain (Volk and 
Loescher 2005; van Vliet et al. 2007), Pgp is overexpressed in endothelial cells, 
neurons, and glial cells and this overexpression  may lead to increased 
extrusion of AEDs from the brain to the blood, preventing the attainment of 
appropriate AED concentrations at therapeutic targets (Van Vliet et al. 2006). In 
addition to brain cells Pgp is also expressed by peripheral blood mononuclear 
cells (PBMCs). Ban et al. (Ban et al. 2012) and Kumar et al. (Kumar et al. 2014) 
have observed higher Pgp expression in PBMCs in pharmacoresistant epilepsy 
patients.  
Pgp is the product of the ABCB1 (MDR-1) gene. As an indirect evidence of 
enhanced Pgp expression, several studies studied the ABCB1 gene 
polymorphism in human subjects with pharmacoresistant epilepsy. It has been 
speculated that the common SNP C3435T in the MDR 1 gene, specifically the 
3435CC genotype, is associated with pharmacoresistance to AEDs. The first 
phamacogenetic study on this matter suggested a significant association 
between the C/C genotype than the T/T genotype in the ABCB1 C3435T 
polymorphism and pharmacoresistant epilepsy (Siddiqui et al. 2003). Although 
several association studies on the MDR 1 gene with drug disposition and 
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disease susceptibility have been completed to date, the data remain unclear and 
incongruous. 
Dysfunction of the BBB is a hallmark of epileptogenic brain injuries, regardless 
of their aetiology (Loescher et al. 2013). S100B is a calcium binding protein and 
is a biomarker for BBB dysfunction (Kapural et al. 2002). Although it is found in a 
wide variety of vertebrates with very little structural variation, its biological 
function is not fully known. S100B protein is present in and secreted from both 
normal and transformed glial cells in the brain. Structural damage to the glial 
cells causes leakage of S100B protein into the extracellular compartment and 
then into CSF, eventually entering the blood stream (Heizmann et al. 2013).  
Studies suggest that the concentration of S100B protein in CSF and serum 
could be a useful marker for damage to the nervous system. High CSF and 
serum levels of S100B have been reported in Alzheimer’s disease, stroke, 
traumatic brain injury and acute subarachnoid haemorrhage (Chaves et al. 
2010; Wunderlich et al. 1999; Kleindienst et al. 2007). Central nervous system 
dysfunction and injury occur in patients sustaining generalized seizures. As a 
marker of epilepsy S100B protein has been studied in a few studies which have 
reported controversial results (Lu et al. 2010; Calik et al. 2013).  
Here, we evaluate Pgp activity measuring PBMC ABCB1 mRNA levels as well 
as the ABCB1 polymorphism and S100B level in pharmacoresistant compared 
to seizure-free mTLE patients and healthy controls. We hypothesise that 
patients with pharmacoresistant mTLE have higher PBMC ABCB1 mRNA levels, 
present the haplotype CC and have higher Protein S100B levels. 
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10.2 METHODS 
The common methods are described in Chapter 4, and the specific methods for 
this study are described here. 
Professor Joan Abbott and colleagues at Kings College performed the S100 
protein analysis. Drs Joan Liu and Maria Thom from the Institute of Neurology, 
University College London, did the genotypic analysis and Dr Dickens and 
Professor Pirmohamed from University of Liverpool helped with the PBMC 
analysis.  
10.2.1 PBMC isolation and analysis of ABCB1 mRNA expression 
Seventeen healthy controls, 16 patients with pharmacoresistant mTLE and eight 
seizure-free mTLE patients had PBMC isolation and analysis of ABCB1 mRNA 
expression. The recruitment of the mTLE patients and healthy controls was as 
previously described in section 4.5. The isolation of PBMCs using Ficoll-Paque 
was performed according to the manufacturer’s instructions. 
10.2.2 RNA extraction and quantitative RT-PCR 
PBMCs were resuspended in Hank’s Balanced Salt Solution (HBSS) and 
centrifuged at 250× g for 5 minutes. The resultant cell pellet was resuspended in 
Tri reagent (1 mL) for subsequent RNA extraction as described in the 
manufacturer’s instructions. Following RNA extraction, reverse transcription 
utilising TaqMan® Reverse Transcription Reagents (Applied Biosystems, 
Paisley, UK) was performed. The samples were prepared for real-time 
polymerase chain reaction (qPCR); 80 ng cDNA was combined with universal 
master mix, sense and antisense primers (0.4 µM each) and oligonucleotide 
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probe (0.2 µM). Assays on demand primer and probe mixes for ABCB1 and 
glyceraldehyde 3-phophate dehydrogenase (GAPDH, 4310884) were purchased 
from Applied Biosystems. GAPDH was included as a housekeeping gene. 
Thermal cycling conditions for all assays consisted of 15 minutes at 95°C 
followed by 50 cycles of 15 s at 95°C and 60 s at 60°C. Quantification of PCR 
products occurred in real time and was analysed using a Bio-Rad Chromo4 real-
time qPCR machine. Expression data were normalized to GAPDH expression 
using the Δ Ct method to determine expression of ABCB1 mRNA (Pfaffl 2001).  
10.2.3 Genotyping Analysis 
Blood samples were collected from 17 healthy controls, 16 patients with 
pharmacoresistant mTLE and eight seizure-free mTLE patients. DNA was 
extracted from blood samples of all cases. The recruitment of the mTLE patients 
and healthy controls was as previously described in section 4.5. DNA from 
patients with epilepsy were typed using the Illumina Infinium 550K/ Illumina 
Human 610-Quad genome-wide genotyping array chip, and DNA from healthy 
controls were typed at ABCB1. Written informed consent was obtained from all 
participants. 
10.2.4 Protein S100B  
Ten healthy controls, ten pharmacoresistant mTLE patients and one seizure-free 
mTLE patient had Protein S100 levels. The recruitment of the mTLE patients 
and healthy controls was as previously described in section 4.5. The S100B kit 
was distributed by Diasorin, Charles House, Toutley Road, Wokingham, 
Berkshire. This kit is run on the Liaison chemiluminescence analyser.  
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This assay is a two-site chemiluminescence immunoassay for the measurement 
of S100B in human serum. It utilises paramagnetic particles coated with two 
mouse monoclonal antibodies to human S100B and one mouse monoclonal 
antibody labelled with an isoluminol derivative. S100B is sandwiched between 
these antibodies. The formation of a soluble sandwich complex occurs only in 
the presence of S100B molecules, which bridge the two antibodies. Therefore, 
only peptides that bridge these two antibodies can be quantitated. See figure 27 
below. 
 
 
 
 
 
 
Figure 27: Principle of the S100 assay 
The figure was kindly provided by Prof Roy Sherwood, Professor of Clinical, 
Biochemistry, King's College London. 
 
10.2.4.1 Sensitivity 
The minimal detectable dose is 0.02 µg/L. 
10.2.4.2 Reference range 
The normal range for S100B protein is 0.02 - 0.2 µg/L. 
Pgp 
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10.2.5 Radiochemistry  
(R)-[11C]verapamil was synthesised as previously described in section 4.1.4.  
10.2.6 PET Image acquisition 
The PET scans were performed at the Wolfson Molecular Imaging Centre, 
Manchester, UK, on the High Resolution Research Tomograph (CTI/Siemens, 
TN, USA) and the PET data was acquired as previously described in section 
4.1.1. 
10.2.7 MRI data acquisition 
For all subjects, a T1-weighted MRI brain scan was acquired on a 3-Tesla GE 
Excite II scanner (General Electric, Milwaukee, WI, USA) for co-registration with 
the PET images as previously described in section 4.2.1.  
10.2.8 PET data analysis  
For the voxel-based SPM analysis, we generated parametric VPM-K1 maps as 
previously described in section 4.3.3.   
All image processing steps were performed in SPM 8, Wellcome Trust Centre 
for Neuroimaging London, UK. MRI and co-registered VPM-K1 maps were 
spatially normalized using a symmetrical and centered gray matter DARTEL 
template.  To determine changes ipsi- and contralateral to the sclerotic 
hippocampus, VPM-K1 maps were also right-left reversed and normalised to the 
same DARTEL template as previously described in section 4.3.3.2.  To 
normalize for differences in peripheral metabolism of VPM, we created PET 
images corrected for differences in global means; first we calculated the mean 
whole brain gray matter concentrations for patients and controls separately, and 
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then normalized to the average of the two. Since the CP has the highest VPM 
uptake resulting in spill-over of radioactivity into the neighbouring hippocampus, 
the CP was individually masked out as described in section 4.3.3.4. The masked 
VPM-K1 maps and globally normalised images were finally smoothed using an 
isotropic 8-mm Gaussian filter. 
10.2.9 Statistical Analysis 
The analyses were performed using SPSS 19.0 (SPSS Inc., Chicago). We used 
independent t-tests to compare the means between two groups. To compare 
multiple groups, we used analysis of variance (ANOVA), calculated Pearson 
correlation coefficients for normally distributed data, or Spearman's rank-order 
correlations otherwise. For the genotyping data allele frequencies were 
compared between groups with use of chi-square tests and the level of 
significance was set at p<0.05. 
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10.3 RESULTS 
10.3.1 No correlation with PBMC ABCB1 mRNA expression and Pgp 
activity  
The level of PBMC ABCB1 mRNA expression was not different for healthy 
controls (mean±SD.: 4.6±5.9, n=17) from pharmacoresistant (9.2±12.8, p=0.222, 
n=16) and seizure-free (7.9±12.7, p=0.476, n=8) mTLE patients and the level of 
PBMC ABCB1 mRNA expression was not different between both patient groups 
(p=0.777, Figure 28). 
 
 
 
 
 
 
 
 
Figure 28: PBMC ABCB1 mRNA expression level for the three groups 
PBMC ABCB1 mRNA expression data is shown for 17 healthy controls (HC), 16 
pharmacoresistant (PR) and eight seizure-free (SF) mTLE patients. The cross 
represents the mean for each group. 
 
 
The level of PBMC ABCB1 mRNA expression did not correlate with VPM-K1 or 
its increase after TQD for either the regional analysis (whole brain VPM-K1 at 
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baseline r=0.253, p=0.405; whole brain VPM-K1 after blocking with TQD 
r=0.247, p=0.415; whole brain increase after TQD r=-0.112, p=0.729, n=14) or 
voxel based analysis in pharmacoresistant mTLE patients (whole brain VPM-K1 
at baseline r=0.350, p=0.241; whole brain VPM-K1 after blocking with TQD 
r=0.377, p=0.204; whole brain increase after TQD r=-0.286, p=0.344, n=14). 
The level of PBMC ABCB1 mRNA expression did not correlate with clinical 
parameters of pharmacoresistant mTLE such as duration of epilepsy 
(Spearman, r= 0.250, p= 0.409, n=16), time of last seizure before PET scan 
(r=0.456, p=0.118, n=16), seizure frequency (r=-0.211, p=0.490, n=16) or age at 
onset of mTLE (r=-0.365, p=0.222, n=16). There was no difference in the level 
of PBMC ABCB1 mRNA expression in pharmacoresistant mTLE patients who 
were taking Carbamazepine (4.2±5.1, n=5) and pharmacoresistant mTLE 
patients who were taking other AEDs (12.19±3.9, n=11, p=0.237). 
10.3.2 No difference in genotyping data between the three groups 
The frequency of the three different alleles did not differ significantly between 
pharmacoresistant, seizure free mTLE patients and healthy controls (χ2= 1.56, 
p=0.816; Table 6, Figure 29).  
Table 6: Frequency of genotyping data for the three different groups 
Phenotype Number of  
cases  
genotyped 
 
CC 
No. % 
CT 
No. % 
TT 
No. % 
Pharmacoresistant mTLE 14 3 (21) 6 (43) 5 (36) 
Seizure-free mTLE 8 2 (25) 5(63) 1(13) 
Healthy controls 13 3 (23) 7 (54) 3 (23) 
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Figure 29: Differences in Pgp genotyping data between the three groups 
The genotyping data is shown for 13 healthy controls (HC), 14 pharmacoresistant (PR) 
and eight seizure-free mTLE patients for the three Pgp genotypes CT, TT and CC.  
 
 
The genotyping data did not correlate with VPM-K1 or increase after TQD for 
either the regional analysis (Spearman, whole brain VPM-K1 at baseline r=-
0.254, p=0.380; whole brain VPM-K1 after blocking with TQD r=-0.071, p=0.810; 
whole brain increase after TQD r=0.048, p=0.877, n=14) or voxel based analysis 
in pharmacoresistant mTLE patients (whole brain VPM-K1 at baseline r=-0.210 
p=0.471; whole brain VPM-K1 after blocking with TQD r=-0.486, p=0.078; whole 
brain increase after TQD r=-0.191, p=0.513, n=14 increase in ipsilateral 
hippocampus after TQD r=-0.090, p=0.761, n=14). 
The genotyping data did not correlate with clinical parameters of 
pharmacoresistant mTLE such as duration of epilepsy (Spearman, r= 0.491, p= 
212 
 
0.075, n=14), time of last seizure before PET scan (r=-0.174, p=0.553, n=14), 
seizure frequency (r=-0.069, p=0.815, n=14) or age at onset of mTLE (r=0.211, 
p=0.468, n=14). 
10.3.3 Protein S100B does not correlate with blood-brain barrier 
damage in pharmacoresistant mTLE 
All results for S100B were below the normality threshold of 0.2 µg/L for 
pharmacoresistant, seizure-free mTLE patients as well as healthy controls and 
therefore did not show an increase in Protein S100B in any of the three groups. 
For pharmacoresistant mTLE patients the blood samples for protein S100B 
samples were taken on average 11 days (range 1-60 days) after the last CPS. 
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10.4 DISCUSSION 
We compared the PBMC ABCB1 mRNA expression between 
pharmacoresistant, seizure-free mTLE and healthy controls and analysed the 
data with clinical parameters as well as compared it to the Pgp function 
measured with (R)-[11C]verapamil PET. We could not find a difference between 
the PBMC ABCB1 mRNA expression between the three groups and there was 
no correlation of the PBMC ABCB1 mRNA expression with clinical parameters 
or Pgp function measured with (R)-[11C]verapamil PET. Very few studies have 
investigated the Pgp expression on peripheral blood mononuclear cells in 
patients with refractory epilepsy.  Kumar et al. (Kumar et al. 2014) used 
peripheral blood mononuclear cells to evaluate the Pgp expression and function 
in 29 children with Lennox-Gastaut syndrome, a well-defined refractory 
childhood epilepsy syndrome, and compared  the expression/function of Pgp on 
PBMCs to 23 children with other epilepsies, and 19 healthy children. The 
authors found a higher Pgp expression/function in Lennox-Gastaut syndrome, a 
higher percent positive cells as compared to children with other epilepsy (p< 
0.001) and to healthy controls (p = 0.012), higher Pgp expression as compared 
to healthy controls (p = 0.003), a higher total Pgp expression as compared to 
children with other epilepsies (p < 0.001) and healthy controls (p < 0.001), and a 
higher Pgp function as compared to children with other epilepsies (p = 0.001) 
and healthy controls (p = 0.002). Similarly, Ban et al. (Ban et al.) collected MDR-
1 data on PBMcs from 140 patients with epilepsy, 30 healthy volunteers, and 20 
control patients taking antiepileptic  drugs. MDR1 profiles were also analyzed 
according to various clinical parameters, including seizure frequency and 
214 
 
number of medications used in epilepsy patients. Epilepsy patients had a higher 
basal MDR1 level than non-epilepsy groups (p=0.01). Among epilepsy patients, 
there was a tendency for the higher seizure frequency group to have higher 
basal MDR1 levels (p = 0.059). Additionally, the MDR1 conformational change 
level was significantly higher in the high-medication-use group than the low-use 
group (p = 0.028). Basal MDR1 (OR = 1.16 [95% CI: 1.060–1.268]) and 
conformational change level (OR = 1.11 [95% CI: 1.02–1.20]) were independent 
predictors for seizure frequency and number of medications, respectively. They 
concluded that the MDR1 profile of PBMNCs is associated with high seizure 
frequency and medication conditions in patients with epilepsy. However, both 
studies did not correlate the Pgp expression/function on peripheral blood 
mononuclear cells with other tissues including brain cells. 
Our genotype analyses for ABCB1 polymorphism did not show a difference in 
frequency of the CT, TT or CC alleles between pharmacoresistant, seizure-free 
mTLE patients and healthy controls. The single nucleotide polymorphism 
C3435T in exon 26 is one of more than 100 polymorphic variants of this gene 
that have been discovered to date. This polymorphism correlates with altered 
expression levels of Pgp, range of drug response and clinical conditions. 
However, the nature of this relationship is still unclear (Sterjev et al. 2012). 
Siddiqui et al. (Siddiqui et al. 2003) were the first to compare the frequencies of 
the ABCB1 C3435T variant in 315 patients with epilepsy and classified 200 
patients as pharmacoresistant and 115 as drug-responsive patients and 
compared them to 200 controls without epilepsy. They found that 
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pharmacoresistant patients were more likely to have the CC genotype as 
ABCB1 3435 than the TT genotype (odds ratio, 2.66; 95% confidence interval, 
1.32 to 5.38; p=0.006). However, 22 replication studies were conducted to 
evaluate this hypothesis but only nine found significant association in which 
three reported that the T/T genotype was more frequent in pharmacoresistant 
patients (Haerian et al. 2010). In addition, four meta-analyses, the first involving 
1073 Caucasian patients (Leschziner et al. 2007), the second 3371 (Bournissen 
et al. 2009), the third 3996 (Nurmohamed et al. 2010), and the fourth 6755 Asian 
and Caucasian patients (Haerian et al. 2010) did not confirm this association in 
the total study population or in the ethnic subgroups (Haerian et al. 2011). It is 
unclear why these reports have found such contradictory results and how such 
conflicting results can be interpreted. 
Furthermore the peripheral marker of BBB permeability Protein S100B was not 
elevated in pharmacoresistant, seizure-free mTLE patients or healthy controls. 
Astrocytosis may be an etiology for mTLE. Reactive astrocytosis could generate 
local synaptic dysfunction and lead to deficits in neuronal inhibition. An 
imbalance between excitatory and inhibitory synapses may lead to epileptiform 
firing in epilepsy. S100B is a cytokine produced and released predominantly by 
astrocytes in the CNS. S100B is involved in the regulation of astrocyte 
proliferation and the differentiation or apoptosis of neurons. Elevated S100B 
concentration has been detected in epilepsy animal models or post surgery 
specimens from epilepsy patients. Here the overexpression of S100B by 
reactive astrocytosis was detected in sections and homogenates of resected 
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hippocampus of pharmacoresistant mTLE compared with controls. Additionally, 
cerebral spinal fluid S100B levels were elevated in pharmacoresistant mTLE. 
But only a few studies have examined peripheral blood S100B level in–vivo in 
epilepsy patients. Lu et al. (Lu et al. 2010) investigated S100B levels in 28 
patients with mTLE and compared them to 28 healthy controls. They found that 
patients showed significantly elevated S100B levels compared to healthy 
controls (p=0.018). Moreover, S100B levels were significantly higher in female 
patients than those in male patients (p=0.027). On the other hand Portela et al. 
(Portela et al. 2003) found normal Serum S100B level in 19  patients with focal 
epilepsy and in 20 patients with epilepsy secondary to neurocysticercosis (p > 
0.39). Additionally, serum S100B levels were not affected by antiepileptic drugs, 
frequency and type of seizures. However, significantly higher levels of S100B 
were observed in patients with bilateral EEG findings than in patients with 
unilateral and normal EEG findings (p < 0. 05). Furthermore, Atici et al. (Atici et 
al. 2012) investigated whether  S100B level were elevated in children with febrile 
seizures (FS), the most common convulsive disorder during childhood. Although 
the prognosis associated with FS is generally considered good, the long-term 
effects of FS on brain development have not yet been clearly identified, 
particularly its effects associated with neuronal damage and neurocognitive 
functions. The relationship between FS and mesial temporal sclerosis (MTS) 
has been one of the most contentious issues in epileptology. For instance, some 
evidence suggests that prolonged FS directly damages the hippocampus and 
surrounding structures, while other authors contend that an independent 
underlying pathology may be responsible for FS and development of MTS (Atici 
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et al. 2012). In this study S100B level of 39 children with FS were compared to 
age-matched and sex-matched controls including 30 patients with fever and 30 
healthy subjects. Two serum samples were obtained for S100B from the study 
group at 0–1 hours and 6–24 hours following seizures. No significant differences 
were detected in serum S100B levels of children with FS at 0–1 hours or 6–24 
hours when compared to the control groups.  
S100B has been used as a marker for the extent of glial cell damage in a variety 
of other neurological conditions: strokes, traumatic head injury, sub-arachnoid 
haemorrhage, encephalitis and hypoxic brain damage. The cut-off for serum 
S100B that gives the best negative and positive predictive values for poor 
outcome varies depending on the neurological condition being investigated, but 
falls in the range 0.2-0.6 mg/L. Serum S100B concentrations above 0.6 mg/L 
are almost invariably associated with residual cognitive dysfunction, persistent 
vegetative state or death.  Peak S100B levels have been reported within the first 
24 h in hypoxic brain damage after traumatic brain injury (Sandler et al. 2010). 
Additionally, de Oliveira et al. (De Oliveira et al. 2008) showed elevated CSF 
S100B levels 24 hours after pilocarpine induced status epilepticus in rats. In our 
study, analysis for protein S100B was limited as blood samples for 
pharmacoresistant epilepsy patients were taken on average 11 days (range 1-60 
days) after the last CPS. An association of elevated Protein S100B levels in 
pharmacoresistant mTLE patients and Pgp overactivity/expression may be 
found when blood samples are taken 24 hours after the last seizure. However, in 
the present study, a sensitive method was employed, which detected S100B in 
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serum of controls and patients with epilepsy. We postulated that patients with 
pharmacoresistant mTLE would increase peripheral S100B levels. But our 
results do not support this hypothesis, as no differences in S100B levels 
between controls, pharmacoresistant or seizure-free mTLE patients were found. 
Overall, a limitation of our study was small numbers and larger studies would be 
needed to investigate a correlation between Pgp activity/expression and 
peripheral markers of Pgp. 
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CHAPTER XI  (R)-[11C]VERAPAMIL PET BEFORE 
AND AFTER PGP INHIBITION WITH TARIQUIDAR IN 
PATIENTS WITH FOCAL CORTICAL DYSPLASIA 
COMPARED TO HEALTHY CONTROLS 
11.1 BACKGROUND  
Focal cortical dysplasia (FCD) is not only a congenital maldevelopment of the 
cortical tissue but also one of the most common causes of refractory epilepsy. 
Several studies demonstrating the overexpression of Pgp in brain tissues of 
patients with mTLE have been reported, however; studies to the neuronal 
expression and function of Pgp in patients with FCD are scarce (Ak et al. 2007). 
We assessed Pgp activity in vivo in patients with mTLE by using PET and the 
Pgp substrate VPM together with the Pgp inhibitor TQD (Feldmann et al. 2013). 
When using voxel-based analysis we detected that pharmacoresistant patients 
had lower baseline VPM-K₁, corresponding to higher baseline Pgp activity, than 
seizure-free patients and healthy controls (p<0.0001). Additionally, there were 
lower increases of VPM- K₁ after TQD in patients with pharmacoresistant mesial 
temporal lobe epilepsy compared to healthy controls and this difference in TQD 
response was most pronounced in the sclerotic hippocampus (p<0.0001). 
One of the major drawbacks of performing PET studies using Pgp substrate 
radiotracers in patients with mTLE is that the region of most interest, the 
hippocampus, is difficult to quantify due to a spillover from the adjacent CP into 
the hippocampus. In our voxel-based analysis we individually masked out the 
CP using individual thresholds in order to assess the hippocampus. This is a 
220 
 
time consuming and complex task (see section 4.3.3.4). Therefore other 
epilepsy forms such as FCD, where the seizure focus is far away from the CP 
thereby avoiding partial volume effects into the region of interest, may possibly 
be better suited for direct analysis of epileptogenic brain regions to further 
elucidate the role of Pgp in pharmacoresistant epilepsy. 
Here, we report the application of our methodology to three patients with FCD 
and pharmacoresistant epilepsy and performed PET scans with the Pgp 
substrate radiotracer VPM together with the Pgp inhibitor TQD. 
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11.2 METHODS 
The common methods are described in Chapter 4, and the specific methods for 
this study are described here. 
11.2.1 Subjects 
Pharmacoresistant patients and healthy controls were recruited as previously 
described in section 4.5. Three pharmacoresistant patients (two male) with 
quantitative MRI findings of FCD were recruited. Pharmacoresistance was 
defined as on-going seizure activity despite trials with at least two AEDs given in 
sufficient doses. In one pharmacoresistant patient (case 2) the inhibitor scan 
could not be acquired due to radiochemistry failure. 
Thirteen healthy controls (seven male, median age 45, range 35-55years), free 
of relevant, particularly neurological, condition and no regular or recent intake of 
medication known to be a substrate or inhibitor for Pgp or MPR1 were included 
in this study.  Patients’ and control characteristics summarized in Table 7. 
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Table 7: Clinical data of FCD patients and healthy controls 
M, male; F, female; LEV, levetiracetam; OXC, oxcarbazepine; CBZ, carbamazepine; CLOB, 
clobazam; ZON, zonisamide; TPM, topiramate; TLE, temporal lobe epilepsy, FLE, frontal lobe 
epilepsy; FCD, focal cortical dysplasia; PR, pharmacoresistant FCD patients; HC, healthy 
controls, yrs, years. Case 2 is highlighted in red as the inhibitor scan could not be performed due 
to radiochemistry failure and only the baseline scan is available for analysis. 
 
Subjects  
 
Gender 
Age 
(yrs) 
Weight 
(kg) 
Epilepsy 
Syndrome 
MRI 
Onset of 
epilepsy 
(age in 
yrs) 
Duration 
seizures 
(yrs) 
 
Medication 
Case 1 M 62 85 Left TLE 
FCD left 
inferior 
temporal 
gyrus 
17 45 
ZON, LEV, 
CLB, OXC 
Case 2 F 37 58 FLE 
FCD 
posterior 
part of 
right  
calloso-
marginal 
sulcus 
19 18 CBZ, TPM 
Case 3 M 24 96 
Left 
posterior 
central 
seizures 
FCD left 
posterior 
central 
gyrus 
5 19 CBZ, LEV 
Mean  
2M/1F 
41 80 
 
 
11 35 
  
SD  19 20   7 15   
Control 1 M 47 110 n/a n/a n/a  n/a  n/a 
Control 2 F 35 133 n/a n/a n/a  n/a  n/a 
Control 3 F 42 74 n/a n/a n/a  n/a  n/a 
Control 4 F 37 63 n/a n/a n/a  n/a  n/a 
Control 5 M 36 93 n/a n/a n/a  n/a  n/a 
Control 6 M 47 89 n/a n/a n/a  n/a  n/a 
Control 7 M 51 89 n/a n/a n/a  n/a  n/a 
Control 8 F 42 57 n/a n/a n/a  n/a  n/a 
Control 9 M 44 80 n/a n/a n/a  n/a  n/a 
Control 10 F 53 60 n/a n/a n/a  n/a  n/a 
Control 11 M 45 90 n/a n/a n/a  n/a  n/a 
Control 12 M 48 89 n/a n/a n/a  n/a  n/a 
Control 13 F 35 71 n/a n/a n/a  n/a  n/a 
Mean  
7M/6F 
43 84   
      
SD  6 21         
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11.2.2 Radiochemistry  
(R)-[11C]verapamil was synthesised as previously described in section 4.1.4.  
11.2.3 PET Image acquisition 
The PET scans were performed at the Wolfson Molecular Imaging Centre, 
Manchester, UK, on the High Resolution Research Tomograph (CTI/Siemens, 
TN, USA) and the PET data was acquired as previously described in section 
4.1.1. The pharmacoresistant FCD patients and healthy controls underwent a 
second set of VPM-PET scans on the same day starting 60 minutes after the 
end of a 30 minute intravenous infusion of 2 or 3 mg/kg TQD (Figure 4). The 
transfer rate constant from plasma to brain, K1, was estimated using a single-
tissue compartment model with a VPM-in-plasma arterial input function. Analysis 
was performed as previously described in section 4.1.3 on the first ten minutes 
of dynamic data containing limited radiolabeled metabolites (Muzi et al. 2009). 
Since we administer the Pgp substrate PET tracer VPM intravenously, its entry 
into the brain is limited by Pgp activity, and the net effect is measured as K₁, the 
transport rate constant from plasma to brain; a low net influx from plasma to 
brain, indicated by a low VPM-K₁ value, therefore indicates high efflux from the 
brain and, thus, high Pgp activity. As shown in rodent models of Pgp 
overactivity, (Bankstahl et al. 2011) partial Pgp inhibition increases VPM-K₁, but 
this increase is attenuated in areas of high Pgp activity, since a fixed dose of 
Pgp inhibitor inhibits a lower proportion of binding sites in areas of high Pgp 
activity than in areas of low activity. 
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11.2.4 MRI data acquisition 
For all subjects, a T1-weighted MRI brain scan was acquired on a 3-Tesla GE 
Excite II scanner (General Electric, Milwaukee, WI, USA) for co-registration with 
the PET images, as previously described in section 4.2.1.  
11.2.5 PET data analysis  
For the voxel-based analysis, we generated parametric VPM-K1 maps as 
previously described in section 4.3.3. Parametric VPM-PET images of 
pharmacoresistant FCD patients were compared to healthy controls (n=13; 
“one-against-all-analysis”) using the factorial analysis of the SPM8 software 
package, Wellcome Trust Centre for Neuroimaging London, UK, with equal 
variance between groups and with overall grand mean scaling. The analysis was 
restricted to voxels belonging to gray matter by applying a gray matter mask 
(generation of gray mask explained above). Activations are shown in the figures 
as p< 0.01, uncorrected with clusters > 10 voxels. 
11.2.6 Statistical Analysis 
Statistical Analysis was performed using SPSS 19.0 and results are shown as 
mean ± sd. As numbers were small in the FCD group we used independent non-
parametric-tests to compare the means between the two groups. The level of 
significance was set at p <0.05.  
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11.3 RESULTS 
There was no statistically significant difference in age, weight or injected doses 
of (R)-[11C]verapamil between the FCD patients and the healthy controls 
(p>0.05). 
11.3.1 Case 1 
At baseline there was a significantly reduced uptake of VPM corresponding to 
the area of FCD in the left inferior temporal gyrus (Figure 30) implying Pgp 
overexpression in this epileptic region. This was not only restricted to the area of 
FCD but also spread to other areas within the ipsilateral temporal lobe such as 
there was reduced VPM uptake in the ipsilateral middle temporal gyrus, superior 
temporal pole and rolandic operculum (p<0.01) implying the Pgp overactivity 
extended further than the area of FCD identified by MRI. 
 
 
 
 
 
 
Figure 30: Parametric map of VPM-K1 for FCD case 1 at baseline  
Parametric map of VPM-K1 for FCD case 1 at baseline is shown compared to 13 
healthy controls. There is reduced VPM-K1 uptake in the area of FCD inferior temporal 
gyrus, as well as in the ipsilateral medial temporal gyrus and rolandic operculum. 
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After Pgp inhibition with TQD the uptake of VPM was increased but this increase 
was significantly attenuated in the corresponding area of FCD the inferior 
temporal gyrus as well as the ipsi lateral hippocampus. There was also a 
reduced uptake of VPM in the contralateral amygdala (p<0.01; (Figure 31). 
 
 
 
   
 
 
Figure 31: Parametric map of VPM-K1 for FCD case 1 after TQD 
Parametric map of VPM-K1 for FCD case 1 after blocking with the Pgp inhibitor 
tariquidar compared to 13 healthy controls. There are reduced increases of VPM-K1 
uptake in the area of FCD in the inferior temporal gyrus, as well as ipsilateral 
hippocampus and contralateral amygdala. 
 
 
There were no areas of significantly increased VPM uptake in case 1 compared 
to healthy controls. 
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11.3.2 Case 2 
At baseline case 2 had significantly reduced uptake of VPM in areas adjacent to 
the area of FCD (posterior part of right callosomarginal sulcus) in the ipsilateral 
post central gyrus, precuneus, frontal superior gyrus as well as superior motor 
area ((p<0.01;  Figure 32) implying Pgp overactivity in these epileptic regions.  
 
  
 
 
 
 
 
Figure 32: Parametric map of VPM-K1 for FCD case 2 at baseline 
Parametric map of VPM-K1 for FCD case 2 at baseline compared to 13 healthy controls. 
There is reduced VPM-K1 uptake in areas adjacent to the area of FCD in the ipsilateral 
postcentral gyrus, precuneus, frontal superior gyrus and superior motor area. 
 
 
Unfortunately, the inhibitor scan could not be performed for this subject due to 
radiochemistry failure. 
There were no areas of significantly increased VPM uptake in case 2 compared 
to healthy controls. 
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11.3.3 Case 3 
At baseline there was significantly reduced uptake of VPM corresponding to the 
area of focal cortical dysplasia in the ipsilateral post central gyrus (Figure 33) 
implying Pgp overactivity in this epileptic region. There were additional areas of 
reduced VPM uptake on the ipsilateral occipital lobe as well as the contralateral 
occipital lobe and cuneus (p<0.01). 
 
 
 
 
 
 
 
Figure 33: Parametric map of VPM-K1 for FCD case 3 at baseline 
Parametric map of VPM-K1 for FCD case 3 at baseline compared to 13 healthy controls. 
Lower VPM-K1 uptake in the area of FCD is observed in the ipsilateral postcentral 
gyrus, as well as bilateral occipital lobe and contralateral cuneus. 
 
 
After inhibition with TQD the VPM uptake increased but this increase was 
significantly attenuated in the corresponding area of focal cortical dysplasia in 
the ipsilateral post central gyrus but also extended further to the inferior parietal 
gyrus, insula, superior temporal lobe and Heschl gyrus. There were also 
contralateral reduced uptake in the precuneus and inferior temporal lobe (Figure 
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34). There were no areas of significantly increased VPM uptake in case 3 
compared to healthy controls. 
 
 
 
 
 
 
Figure 34: Parametric map of VPM-K1 for FCD case 3 after TQD 
Parametric map of VPM-K1 for FCD case 3 after inhibition with the Pgp inhibitor 
tariquidar compared to 13 healthy controls. There are reduced increases of VPM-K1 
uptake in the area of FCD in the ipsilateral postcentral gyrus but it also extends further 
to the ipsilateral inferior parietal gyrus, superior temporal lobe, insula and to the 
contralateral precuneus and inferior gyrus. 
 
11.4 DISCUSSION 
This is the first in-vivo human PET study investigating Pgp function in patients 
with FCD compared to healthy controls. We showed that pharmacoresistant 
FCD patients have reduced uptake of VPM in close proximity to the area of FCD 
identified in the MRI implying that there is Pgp overexpression in the 
epileptogenic seizure onset-zone.  Previous PET experiments were restricted to 
investigating Pgp function in TLE (Langer et al. 2007; Feldmann et al. 2013; 
Bauer et al. 2014). Evidence for Pg expression in FCD has mainly been 
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performed in epileptogenic human brain tissue resected during epilepsy surgery. 
Sisodiya et al. (Sisodiya et al. 2001) were the first to show an overexpression of 
Pgp in FCD. They studied four samples of surgically resected FCD and 
compared the findings with normal necropsy brain tissue. They showed an 
overexpression of Pgp in abnormal giant dysplastic neurons, glial cells, and in 
perivascular distribution in epileptogenic tissue. The authors extended their work 
by increasing the number of patients and included 14 patients with FCD in their 
study (Sisodiya et al. 2002). Their findings confirmed their previous work 
demonstrating an overexpression of Pgp also in astrocytes, dysmorphic neurons 
and balloon cells of patients with FCD. These findings have since been 
confirmed in several other studies (Aronica et al. 2003; Aronica et al. 2005; Ak et 
al. 2007; Oh et al. 2008). Ak et al. included a higher number of patients than the 
previously reported and studied the expression of Pgp in the epileptic tissues 
resected surgically in 28 patients with FCD and compared the results with 10 
normal necropsy brain tissues (Ak et al. 2007). Normal brain showed no Pgp 
expression in neurons and astrocytes. In contrast to normal brain Pgp is 
intensely expressed in both neurons and reactive astrocytes in the vast majority 
of dysplastic tissues and endothelial cells of patients with FCD. These findings 
supported the ‘transporter hypothesis’ that overexpression of multidrug efflux 
transporters in epileptogenic brain regions may lower drug concentrations and 
thereby reducing their antiepileptic effects, which may explain the refractoriness 
to AEDs in FCD. However, although increased multidrug efflux transporter 
expression has been demonstrated in human tissue of patients with FCD that 
had been resected in surgery it may not be functionally relevant. Therefore non 
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invasive brain imaging of multidrug efflux transporter function in 
pharmacoresistant epilepsy patients are a strategy to evaluate whether the 
overexpression of multidrug efflux transporters at the BBB as postulated in the 
‘transporter hypothesis’ have any functional consequences that underlie 
pharmacoresistance in epilepsy. Additionally, PET tracers for multidrug efflux 
transporters could be useful to identify epilepsy patients with increased 
multidrug efflux transporter activity who will benefit from treatment with drug 
transporter modulation drugs and therefore hold great promises for 
individualized medicine (Ak et al. 2007; Sisodiya 2003). We observed that the 
reduced uptake of VPM extends further to other ipsilateral regions implying that 
the distribution of Pgp overexpression is spread across to other cortical regions. 
One possible mechanism could be that seizures induce Pgp overexpression and 
hence the Pgp expression follows the seizure spread through neuronal network 
connections. In rodent models of mTLE, experimentally induced seizures have 
been shown to increase the expression of Pgp in brain capillary endothelial 
cells, astrocytes and neurons in the dentate gyrus, amygdala, hippocampus, 
piriform and parietal gyrus (Zhang et al. 1999; Seegers et al. 2002; Löscher and 
Potschka 2005b). Furthermore, FCD has a relative poor surgical outcome 
compared with TLE with hippocampal sclerosis. Whereas approximately 80% of 
patients became seizure free after surgical treatment for mesial TLE related to 
HS (Jeong et al. 2005) the efficacy of surgical treatment for FCD was 
consistently less favourable, with approximately 33–75% of individuals 
becoming seizure free (Tassi et al. 2002). The relative poor prognosis can be 
explained by that FCD is often invisible on MRI which leads to the difficulty to 
232 
 
define epileptogenic zone. The other factor affecting the relative poor surgical 
outcome is that even after the removal of all visible lesions on MRI, residual 
microscopic lesion can still be epileptogenic, which means that dysplastic 
tissues tend to be more extensive than is apparent on MRI and we therefore 
may elicit epileptogenic lesions with Pgp overactivity with our VPM PET study 
(Sisodiya et al. 1995; Aaron et al. 2004; Lee and Kim 2013).  
Our study is limited by the small number of patients studied to date and a larger 
group is needed. Because of the small number of patients, no further subgroup 
analysis was possible to take into account genetic information (ie, 
polymorphisms) or correlations with seizure frequency or duration of epilepsy.  
11.5 CONCLUSION 
This is the first study demonstrating Pgp overactivity in pharmacoresistant 
epilepsy patients due to FCD in-vivo by using VPM PET showing that VPM 
uptake is reduced in the area of FCD and also extends further to other ipsilateral 
regions suggesting widespread abnormalities in FCD. We provide support for 
the ‘transporter hypothesis’ that there is overexpression of Pgp which may 
contribute to the pharmacoresistance of epilepsy caused by focal cortical 
dysplasia. 
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CHAPTER XII  OVERALL CONCLUSION 
12.1 INTRODUCTION 
This thesis aimed to evaluate Pgp activity and expression in pharmacoresistant 
mTLE. We assessed Pgp activity in vivo by using the imaging technique PET 
and performed PET scans with the Pgp substrate VPM in pharmacoresistant 
and seizure-free mesial temporal lobe epilepsy patients and healthy controls 
before and after the Pgp inhibitor TQD. We compared the results of the in vivo 
VPM-PET scans with ex vivo epileptic tissues removed during epilepsy surgery 
correlating Pgp activity measured with VPM-PET with Pgp expression 
established in surgically-resected brain tissue. Furthermore, we evaluated Pgp 
activity by measuring additional peripheral markers of Pgp function: PBMC 
ABCB1 mRNA level as well as the ABCB1 polymorphism and S100B level in 
pharmacoresistant mTLE and compared them to seizure-free mTLE patients 
and healthy controls. Finally, we extended our study to other epilepsy 
syndromes by applying the methodology of measuring in-vivo Pgp activity with 
PET using the Pgp substrate VPM together with the Pgp inhibitor TQD to three 
patients with FCD and pharmacoresistant epilepsy.  
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12.2 SUMMARY OF THE MAIN FINDINGS 
 Using ROI analysis we showed that there are differences in VPM 
metabolism between mTLE patients and healthy controls which is caused 
by AED-mediated hepatic cytochrome P450 enzyme induction in mTLE 
patients requiring images to be normalised for global brain differences.  
 
 ROI analysis at baseline showed no difference of VPM K1 ratios in 
pharmacoresistant compared to seizure-free mTLE patients or healthy 
controls.  
 
 ROI analysis after partial Pgp-inhibition with TQD showed attenuated 
global increases of VPM brain uptake in pharmacoresistant mTLE 
patients compared to healthy controls but there where no regional 
differences. 
 
 Voxel-based SPM analysis at baseline, showed that pharmacoresistant 
mTLE patients have significantly reduced VPM uptake compared to 
seizure free mTLE patients and healthy controls in the temporal lobes. 
However, the reduction is not restricted to ipsilateral epileptogenic 
regions but also extends to contralateral temporal lobe regions, implying 
a wider area of Pgp overexpression than the epileptogenic focus.  
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 Pharmacoresistant mTLE patients who have frequent seizures have the 
lowest VPM uptake, substantiating the contribution of seizures to the 
induction of Pgp overexpression in epilepsy. 
 
 Voxel-based SPM analysis after partial blockade of Pgp with TQD, 
pharmacoresistant mTLE patients have attenuated increases of VPM 
uptake in the whole brain and more so in the ipsilateral epileptogenic area 
of the hippocampus compared to healthy controls, implicating functionally 
elevated Pgp function primarily in the epileptogenic hippocampus in 
pharmacoresistant epilepsy. 
 
 A case-by-case comparison of epilepsy patients with focal cortical 
dysplasia against a group of healthy controls revealed that VPM uptake is 
reduced not only in close proximity to the area of FCD identified by MRI 
but also that the reduction extends further to other ipsilateral regions, 
supplementing the findings in mTLE patients that Pgp overexpression is 
not limited to the epileptogenic seizure-onset zone but also spreads 
across to other cortical regions.  
 
 The difference in percentage change in VPM uptake after Pgp inhibition 
with tariquidar in the hippocampus compared to a reference temporal 
lobe region is inversely correlated with the corresponding difference in 
percentage area of Pgp immunopositive labelling in pharmacoresistant 
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mTLE patients who underwent anterior temporal lobe resection for 
surgical treatment, demonstrating that imaging with PET and a 
radiolabeled Pgp substrate is a suitable tool to assess Pgp function in 
vivo in humans. 
 
  There was no difference in peripheral markers of Pgp activity measured 
by PBMC ABCB1 mRNA level expression and S100B level as well as 
with the ABCB1 genetic polymorphism in pharmacoresistant compared to 
seizure-free mTLE patients and healthy controls.  
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12.3 NEUROBIOLOGICAL AND CLINICAL IMPLICATIONS 
We provide the first direct in-vivo evidence for Pgp overactivity in human 
pharmacoresistant temporal lobe epilepsy manifesting as attenuated tariquidar-
induced increases in VPM brain uptake in six of our 14 patients.  We directly 
translated findings of Pgp overexpression from rodent studies (Rizzi et al. 2002; 
Seegers et al. 2002; Van Vliet et al. 2006; Bankstahl et al. 2008b) and ex-vivo 
studies in epileptogenic tissues removed during surgery from patients with 
pharmacoresistant epilepsy and post-mortem tissue (Sisodiya et al. 2002; 
Aronica et al. 2004; Liu et al. 2012)  in-vivo and showed that Pgp is a 
functionally relevant mechanism in pharmacoresistant temporal lobe epilepsy. 
Using this imaging technique we can identify individual patients where 
pharmacoresistance is caused by Pgp overactivity and potentially individualise 
treatment. Moreover, comparative studies between pharmacoresistant and 
seizure-free epilepsy patients can enable testing for a correlation between Pgp 
function and the pharmacoresponse. This imaging technique can also guide 
patient selection for future clinical studies. In particular, PET imaging of Pgp 
function may allow individualized application of approaches to overcome Pgp–
associated pharmacoresistance. Our study provides useful information for future 
combined imaging and clinical trials of novel treatment strategies, such as Pgp 
inhibitors or modulators of overexpression in patients who have Pgp overactivity 
on VPM-PET. Targeting Pgp by modulators can enhance the efficacy of 
antiepileptic drugs. The compound verapamil is a substrate for Pgp at low 
concentrations (which is used in PET), but, like many substrates, verapamil is 
also an inhibitor for Pgp at high concentrations (Kannan et al. 2009). Verapamil 
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was among the first identified inhibitors of Pgp and it may function to block Pgp–
modulated efflux of AEDs in the brain, thereby raising the intracellular 
concentration of AEDs (Summers et al. 2004). The third-generation modulator 
TQD increased the efficacy of phenytoin in a chronic rat epilepsy model and 
helped to overcome pharmacoresistance to phenobarbital in chronic rat epilepsy 
models (Van Vliet et al. 2006). On the other hand, first- and second-generation 
inhibitors are not specific for Pgp alone and can exert additional 
pharmacodynamic and pharmacokinetic effects. Third-generation inhibitors are 
considered fairly specific.  But there is recent evidence for the third-generation 
inhibitor TQD that it can also affect the efflux transporter BCRP/ABCG2. 
Moreover, long-term inhibition of this transporter needs to take into account that 
Pgp serves as a protective mechanism and gatekeeper in several blood tissue 
barriers as well as hematopoietic cells (Huls et al. 2009). In addition to limiting 
access of harmful xenobiotics to sensitive tissues or cells, Pgp also accelerates 
extrusion of xenobiotics based on its efflux function in the liver and kidneys. 
Therefore, alternate approaches that leave basal transporter expression and 
function unaffected might offer advantages for tolerability and safety issues. 
Preventing seizure-associated transporter upregulation might offer an intriguing 
alternate approach to overcoming transporter associated pharmacoresistance 
(Potschka). In addition our study provides further support for an association 
between Pgp activity and seizure frequency.  As already stated, experimental 
data indicate that seizure activity is the main factor upregulating Pgp in the 
epileptic brain. In rodent models of mTLE, Pgp expression increases 
significantly as early as 24 hours after experimentally induced SE (Rizzi et al. 
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2002; Seegers et al. 2002; Bankstahl et al. 2008a). The excitatory 
neurotransmitter glutamate, which is excessively released by seizures, 
upregulates Pgp expression in brain capillary endothelial cells, astrocytes and 
neurons in the dentate gyrus, amygdala, hippocampus, piriform and parietal 
gyrus  (Zhang et al. 1999; Seegers et al. 2002; Zhu and Liu 2004; Bankstahl et 
al. 2008a; Bankstahl et al. 2011). In a recent study published by our department 
in post-mortem tissue, we showed Pgp overexpression in the sclerotic 
hippocampus in all eight individuals with pharmacoresistant epilepsy, but not in 
post-mortem tissue from a seizure-free individual, eight of eight post-mortem 
controls, or non-epileptogenic tissue from 14 of 14 patients with epilepsy with 
electrode-related injuries, indicating that the occurrence of seizures appear 
central to Pgp overexpression (Liu et al. 2012). These findings suggest that 
there is measurable, localised Pgp overactivity in pharmacoresistant temporal 
lobe epilepsy which is related to seizure activity; Pgp overexpression was not 
seen in the patient who was seizure free. Pgp overactivity might thus explain 
why pre-treatment seizure density is one factor predicting poor response to 
antiepileptic drugs. 
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12.4 LIMITATIONS OF THE STUDY 
Although our study was relatively large for a PET study and sufficiently 
statistically powered, all studies in this thesis contain relatively small numbers of 
patients and our findings will have to be confirmed in other and larger 
populations of patients with epilepsy.  
A further limitation of our study is that only five of our pharmacoresistant patients 
have undergone epilepsy surgery so far, and the correlation between in-vivo and 
ex-vivo measures of Pgp activity needs to be investigated in larger studies.  
Our aim was to show a difference between groups of pharmacoresistant and 
seizure-free patients with temporal lobe epilepsy. Because of the small number 
of patients, no further subgroup analysis was possible to take into account 
genetic information (ie, polymorphisms), psychiatric co-morbidities, or potential 
differences in Pgp activity due to race or previous drug use. Association 
genetics requires large cohort sizes and to further refine the multidrug resistant 
phenotype a sufficient number of patients will have to be included.  
Direct labelling of antiepileptic drugs is possible than could represent an 
alternative strategy for directly probing the clinical relevance in patients showing 
resistance to individual antiepileptic drugs. PET scans performed with the weak 
Pgp substrate [¹¹C]diphenylhydantoin long before the transporter hypothesis was 
formulated did not show any difference in binding between pharmacoresistant 
patients and non-epileptic patients. The greater affinity of (R)-[¹¹C]verapamil and 
[¹¹C]diphenylhydantoin for Pgp might explain why we were able to detect not 
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only whole brain but also regional differences in Pgp activity at baseline. 
Experiments with a Pgp inhibitor and ¹¹C]diphenylhydantoin have not been done, 
but will be important to increase the sensitivity to detect group differences 
between patients and controls.  
The manual delineation of the CP is a time-consuming, potentially error-prone 
and subjective task. Since the CP has the highest VPM uptake resulting in spill-
over of radioactivity into the neighbouring hippocampus, the CP has to be 
masked out when assessing mTLE patients. An erroneous CP mask effects the 
results of the hippocampus therefore developing automated segmentation 
methods for the partial volume correction of the CP would be useful so that the 
hippocampus can be accurately assessed in a timely-manner. 
Finally, currently the clinical application of VPM PET is limited by the need for a 
cyclotron on-site, the significant expense, the injection of a radiolabeled tracer 
thus limiting the number of studies that can be performed in a particular subject 
and the invasive arterial line. In the future a fluorine-18 VPM PET tracer with a 
longer half-life without the need for an on-site cyclotron as well as the 
development of image derived input functions would improve the clinical 
application of VPM PET. 
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12.5 FUTURE WORK 
Clinically it is what happens to individual patients that is important and the next 
step in the validation of these techniques will involve similar studies with larger 
numbers of patients. These should include also other epilepsy syndromes. 
Furthermore, the correlation between in-vivo and ex-vivo measures of Pgp 
activity by comparing VPM-PET scans with surgical tissue of pharmacoresistant 
patients undergone epilepsy surgery as well as the genotyping analysis will 
need to be extended to larger studies. In the future larger studies are needed to 
assess the effect of age and gender on Pgp activity and expression in 
pharmacoresistant epilepsy. 
The next step in the future will be to combine imaging and clinical trials of novel 
treatment strategies, with Pgp inhibitors or modulators in patients who have Pgp 
overactivity on VPM-PET aimed at reversing drug resistance with selection of 
optimal patients and assessment of molecular targets. But further development 
of the approach needs to also consider tolerability issues specific to the different 
targets (Potschka 2010). In particular more evaluation is needed in view of the 
controversial findings which AEDs are Pgp substrates and, thus, determine the 
penetration of which particular AEDs are affected by Pgp. Of course, evidence 
that some antiepileptic drugs are affected by the human Pgp isoform and that 
others are not substrates, needs to be considered when drawing conclusions 
about the future promises of any approach to modulate Pgp expression or 
function. Modulating Pgp might, therefore, only help to overcome resistance to 
selected antiepileptic drugs, but might not help to overcome multidrug 
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resistance. More precise knowledge about substrate specificities is, therefore, 
crucial to guide the putative future application of respective diagnostics as well 
as therapeutic strategies to selected patients.  
Finally, although here we provide the proof of concept for the transporter 
hypothesis and show that there is functionally relevant Pgp overactivity in 
pharmacoresistant mTLE, the critical question remains whether it sufficient to 
overcome Pgp overexpression as one putative mechanism of a multifactorial 
problem or that other mechanisms such as intrinsic disease severity, alterations 
in targets, different gene variants or network alterations need to be taken into 
account and in the future further investigated. Given the complexity of epilepsy, 
it is unlikely that pharmacoresistant epilepsy is caused by a single mechanism 
but instead is due to several mechanisms which may even occur in the same 
patient. Overcoming pharmacoresistance in epilepsy represents a challenge and 
will necessitate a multifactorial approach and the combined efforts of basic and 
clinical epilepsy researchers (Loescher et al. 2013). 
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